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ABSTRACT

Palmitoylation refers to the covalent attachment of fatty acids, such as palmitate,
onto the cysteine residues of proteins. This process may subsequently alter their
localization and function. Nearly all of the enzymes that catalyze palmitoylation,
zDHHC protein acyl transferases (PATs), are implicated in neurological
disorders, infectious diseases, and cancer in humans. Of particular interest to
those who study palmitoylation are Ras family GTPas and zDHHC9-GCP16, the
zDHHC PAT that palmitoylates Ras proteins. Erf2-Erf4 is the zDHHC PAT that
palmitoylates Ras proteins in Saccharomyces cerevisiae. Currently, there are no
methods to therapeutically target palmitoylation for the treatment of disease.
One of the barriers to identifying a modulator of palmitoylation is the lack of a
reliable high-throughput screening system. To date, few assay systems have
been developed to examine the kinetics and mechanism of that palmitoylation
reaction. This lab has developed a fluorescence-based coupled assay to gain
insight into the enzymology, biochemical mechanism, and kinetics of the
palmitoylation reaction. This assay may be used to identify specific inhibitors of
autopalmitoylation. In the first step of this reaction, the palmitoyl-moiety from
palmitoyl-CoA is transferred to the zDHHC9 PAT cysteine side chain to form a
palmitoyl:enzyme intermediate.

The second step of palmitoylation is the

subsequent transfer of the palmitoyl-moiety from the palmitoyl:enzyme
viii

intermediate to the cysteine residue of the substrate protein. This fluorescencebased coupled assay was utilized to screen a natural products library and a
unique synthetic compound library for inhibitors of Erf2 autopalmitoylation.
These screens led to the identification of fungal metabolite extracts and ten biscyclic piperazine compounds that inhibit Erf2 autopalmitoylation in the low
micromolar range. This effect is similar to known inhibitors of palmitoylation that
lack specificity for the palmitoylation reaction itself.
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CHAPTER 1
Protein Lipidation and the Function of Ras Oncogene Proteins

1.1

Key Words and Abbreviations

Enzymology; Inhibitor; Mechanism; Palmitoylation; Ras; zDHHC.
Aβ, β-amyloid protein; AD, Alzheimer’s Disease; APP, Amyloid Precursor
Protein; BACE1, β-secretase 1; CDKL5, Cyclin-Dependent Kinase-Like 5; CRD,
Cysteine Rich Domain; eNOS, Endothelial Nitric Oxide Synthase; ER,
Endoplasmic Reticulum; ER α , Estrogen Receptor α ; ERF, Effect on Ras
Function; FTase, Farnesyl Transferase; GAP, GTPase activating protein;
GCP16, 16 kDa Golgi Complex Protein; GEF, Guanine Nucleotide Exchange
Factors; GGTase, Geranylgeranyl Prenyltransferase; HD, Huntington’s Disease;
HIP-14, Huntingtin Interacting Protein 14; htt, Huntingtin; HVR, Hyper Variable
Region; ICMT, Isoprenylcysteine Carboxyl Methyltransferase; MAPK, MitogenActivated Protein Kinase; mBOAT, Membrane Bound O-acyltransferases; NSF,
N-ethymaleimide-sensitive factor attachment protein receptor; PAT, Protein Acyl
Transferase; PM, Plasma Membrane; PTM, Post-translational Modification;
RCE1, Ras Converting CAAX Endopeptidase; REAM, Reduced Expression
Associated with Metastasis (zDHHC2); SNP, Single Nucleotide Polymorphisms;
TMD, Trans-membrane Domain, XLID, X-linked Intellectual Disability
1

1.2

Introduction to Protein Lipidation

Protein lipidation refers to the covalent addition of lipids onto the side chains of a
large and diverse group of eukaryotic proteins. The lipids that are added are also
diverse and include isoprenoids (farnesyl (C15) and geranylgeranyl (C20)), fatty
acids (myristoyl (C14) and palmitoyl (C16)) and cholesterol (Fig. 1.1) [1-4]. The
functional significance of lipidation depends on the protein and the subcellular
location where it occurs. For example, lipidated proteins destined for export from
the cell, such as wnt and sonic hedgehog, undergo palmitoylation in the lumen of
the ER during the export process [4].

The ER-localized enzymes that

palmitoylate secreted proteins belong to a family called the MBOATs
(membrane-bound O-acyltransferases) [5].

This is referred to as O-

palmitoylation and results in an oxyester bond [5]. Cytosolic proteins and integral
membrane proteins can also be palmitoylated. Cytosolic palmitoylation occurs
as either a labile thioester bond on cysteine residues (S-palmitoylation), or as a
stable amide bond on glycine residues (N-palmitoylation). Protein palmitoylation
will refer to S-palmitoylation for the remainder of this dissertation.
Palmitoylation occurs on a broad range of proteins and has a significant role in
the localization and function of proteins.

Some of the cellular processes

palmitoylation regulates are signal transduction, protein trafficking, protein
turnover, vesicle fusion, and cell-cell interactions [6-9].

More than 400

palmitoylated human proteins have been identified including G protein-coupled
receptors, Golgi-localized mannosyltransferases, plasma-membrane-localizedphosphatases, Gα subunits, Src family kinases, Ras proteins, neurotransmitter
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receptors, endothelial nitric oxide synthase (eNOS), soluble N-ethylmaleimidesensitive factor attachment protein receptor (NSF), and amino acid permeases
[10-14].
Palmitoylation is often coupled with other lipidations [15].

An example of a

protein that undergoes dual-lipid modifications is Gα subunits that undergo
myristoylation prior to palmitoylation [16].

Myristoylation is the irreversible

addition of a 14-carbon saturated fatty acid onto an α -amino group of an Nterminal glycine residue via an amide bond [17]. Another example of a dual-lipid
modified protein is the Ras family of proteins that get farnesylated on a Cterminal CAAX motif (a cysteine residue (C), followed by two aliphatic amino
acids (A), and the terminal amino acid (X)) prior to palmitoylation [18].
Farnesylation is the irreversible addition of a 15-carbon isoprenoid by the
cytosolic enzyme farnesyltransferase (FTase) [2].

In the absence of FTase,

some Ras proteins can be prenylated by geranylgeranyl transferase (GGTase)
[19]. Geranylgeranylation is the irreversible addition of a 20-carbon isoprenoid
onto a cysteine residue [20]. Unlike other lipid modifications, palmitoylation is
reversible [21].

1.3

Enzymology of Protein Palmitoylation

For many years, the existence of an enzyme responsible for palmitoylation was a
matter of controversy. Twenty years passed between the identification of the first
palmitoylated protein and the identification of the first enzyme responsible.
Unlike other enzymatic reactions, substrates of palmitoylation lack an identifiable
3

consensus sequences suggesting that the mechanism is non-enzymatic [22].
Peptides derived from palmitoylated proteins, as well as the palmitoylated
proteins rhodopsin and G-protein regulatory subunits, were able to undergo
spontaneous palmitoylation further supporting that palmitoylation occurs nonenzymatically [23-27].
Conversely, mutagenesis studies suggest that the position of the cysteine
residue is influential in palmitoylation outcome, and the palmitoylated proteins,
SNAP-25, GAP-43, and Fyn kinase are not spontaneously palmitoylated in vitro
supporting the enzymatic mechanism of palmitoylation [22, 26]. Thiolase A, a
requirement for fatty acid β-oxidation, was observed to palmitoylate H-Ras in
vitro, but is an unlikely physiological protein acyl transferase (PAT) candidate due
to its in vivo location in peroxisomes [28, 29].

More support came for an

enzymatic mechanism when a candidate PAT was identified for N-palmitoylated
Hedgehog protein [30, 31].

Unfortunately, there was a failure to identify a

physiologically relevant PAT enzyme for S-palmitoylation [22].
The major impediments for identifying an enzyme that catalyzes palmitoylation
are the insolubility of candidate PATs and the instability of the PAT activity.
When PAT activity was identified, it required detergent solubilization to be
purified and the subsequent chromatographic separation resulted in a loss of that
activity [30-32].
The debate ended when Lobo et al. performed genetic screens in S. cerevisiae
demonstrating that palmitoylation was an enzymatic reaction [33].

They

constructed a yeast strain dependent on Ras2 palmitoylation for viability. They
4

knocked down candidate proteins to identify an enzyme critical for Ras2
palmitoylation in their constructed strain. The identified enzyme is an Erf (Effect
on Ras Function) complex, Erf2-Erf4 [33]. Erf4 was previously described as a
partial suppressor of Ras [34, 35]. Palmitoylation of Ras2 in Saccharomyces
cerevisiae did not occur when the enzyme was deactivated by heat shock
treatment [33]. In the same year, another yeast PAT, Akr1, was also identified
through genetic screens. The discovery of Erf2-Erf4 and Akr1 further supported
that palmitoylation is an enzymatically catalyzed reaction [36].
The catalytic core of PATs is a highly conserved ~51 amino acid cysteine-rich
domain (CRD) containing a zinc-binding domain and an Asp-His-His-Cys
(zDHHC) motif [37]. zDHHC PATs are polytopic membrane proteins predicted to
contain at least four trans-membrane-spanning domains (TMDs) with the CRD
domain on the cytosolic face of the membrane [38, 39]. A conserved aspartic
acid, proline, glycine (DPG) motif has been observed next to the second
predicted TMD of zDHHC PATs, and a conserved threonine, threonine, x,
glutamine (TTxE) motif has been observed next to the fourth predicted TMD of
zDHHC PATs (Fig. 1.2) [38]. Both the DPG and TTxE motifs are predicted to be
on the same side of the membrane but lack an identified functional significance
[38]. Some zDHHC PAT enzymes contain SH3 domains, ankyrin repeats, and
PDZ-binding motifs. It is predicted that these additional motifs and domains may
be important for substrate specificity but little research has elucidated this.
Erf2 contains the DHHC catalytic motif, whereas Erf4 lacks any defined motifs or
domains. The half-life of Erf2 in the presence of Erf4 is ~100 minutes, where it is
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reduced to only ~9 minutes in the absence of Erf4 [38]. Thus, it is predicted that
Erf4 acts as an auxiliary protein critical for Erf2 function [33, 40]. The deletion of
either Erf2 or Erf4 resulted in a reduction in Ras2 palmitoylation, suggesting a
role for Erf4 in palmitoylation as well [33].
The zDHHC enzyme family is observed in all eukaryotes examined to date with
at least 22 zDHHC containing proteins identified in mammals and seven in yeast
(Fig. 1.2) [14, 18, 41]. The additional zDHHC containing proteins were screened
to confirm their role in palmitoylation [41]. Most of the zDHHC proteins are
expressed ubiquitously, and they associate with all intracellular membrane
compartments but the majority associate with the ER or the Golgi [41].

1.4

Protein Palmitoylation and Disease

Nearly all of the zDHHC PATs have been associated with human disease (Table
1.1). Most notably, the dysregulation of zDHHC PATs has been implicated in
neurological disorders, infectious disease, and cancer. This section will highlight
the key findings for the dysregulation of palmitoylation in disease with focus on
neurological disorders and cancer.
zDHHC PATs in neurological disorders: Dysregulation of palmitoylation is
implicated in neuronal development, Huntington’s Disease (HD), Alzheimer’s
Disease (AD), X-linked Intellectual Disability (XLID), and schizophrenia.

A

significant role of palmitoylation has been described for axon growth, synaptic
plasticity, and neurotransmitter release [42-45].

Compromised zDHHC PAT

activity is linked to neurodevelopmental and neuropsychiatric disorders,
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suggesting a fundamental role of palmitoylation in proper neuronal function. In
particular, zDHHC2 plays a critical role in synaptogenesis and synaptic plasticity
by inducing specific, stoichiometric palmitoylation and synaptic accumulation of
PSD-95 [46]. zDHHC2 senses changes in synaptic activity and rapidly
translocates from dendrites to postsynaptic membranes. Zhu et al. demonstrated
the critical role of palmitoylation in localizing CDKL5 to synapses and facilitating
the normal development of dendritic spines [47]. These findings suggest that
disruption of the interaction via mutations could be implicated in the pathogenesis
of CDKL5-related disorders [47].
zDHHC17, originally named Huntingtin Interacting Protein 14 (HIP14) for its
interactions with the Huntingtin protein, transfers palmitate to the protein
huntingtin (htt). In the polyglutamine repeat expanded version of the disease
form of HD, the interaction between htt and zDHHC17, as well subsequent
palmitoylation of htt, is markedly decreased [45]. Depalmitoylated htt is less
stable, which causes aggregation of the protein amyloid [45]. zDHHC17-deficient
mice develop features of HD, supporting that zDHHC17 is dysfunctional in HD
[45]. The addition of wild type zDHHC17 to two different HD mouse models was
able to partially reverse the HD disease phenotype [48].
Dysfunction of palmitoylation is also implicated in AD. Amyloid precursor protein
(APP) is palmitoylated by zDHHC12 [49]. β-Secretase (BACE1) is a neuronspecific membrane-associated protease that cleaves APP to generate β-amyloid
protein (Aβ) [50]. BACE1 and Aβ are both palmitoylated proteins. Motoki et al.
discovered that mutant BACE1 lacking the palmitoylation modification was
7

markedly reduced in comparison to wild-type BACE1 in neuroblastoma cells and
rat primary cortical neurons expressing BACE1 via recombinant adenoviruses
[51].
There are two nonsense mutations and two missense mutations of zDHHC9 that
are implicated in XLID [52]. The two nonsense mutations result in a loss of the
catalytic DHHC domain of zDHHC9 either through a truncation or a frame shift
[52].

The two missense mutations (R148W and P150S) are on conserved

residues within the CRD of zDHHC9 [52]. The Deschenes’ lab evaluated the
effect of the missense mutations on zDHHC9 PAT activity and concluded that
both mutations resulted in a reduction of steady-state autopalmitoylation of
zDHHC9 [53]. This reduction was through different mechanisms; the R148W
mutant decreased the stability of the palmitoyl-PAT intermediate, whereas the
P150S mutant reduced the burst autopalmitoylation activity of zDHHC9 [53]. In
both cases, it is predicted that this reduction of steady-state zDHHC9
autopalmitoylation would subsequently reduce the amount of palmitoyl moiety
available for transfer to the protein substrate.
There has been conflicting evidence in regards to the role of zDHHC8 in the
development of schizophrenia. Five single nucleotide polymorphisms (SNPs)
included within the zDHHC8 coding frame in the vicinity of the 22q11 locus [54].
Every tested variation of these five SNPs demonstrated a significant association
with schizophrenia [54]. A case-controlled study in the Han Chinese population
supported these findings in family-based linkage disequilibrium studies [55].
However, a Taiwanese cohort for zDHHC8 SNPs demonstrated an association
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with schizophrenia in the presence of a deficit in sustained attention [56].
zDHHC8 may also influence smooth pursuit eye movement function in
schizophrenia patients from a Korean population [57].

Unfortunately, many

researchers produced negative findings, suggesting that there was no
association between zDHHC8 and schizophrenia in Japanese and European
populations [58-61]. A zDHHC8-knockout mouse lent support to the association
between zDHHC8 and schizophrenia due to decreased exploratory activity and
reduced sensitivity to dizocilpine, an NMDA antagonist used to treat
schizophrenia [62]. Use of the 22q11 microdeletion mouse model demonstrates
that the introduction of enzymatically active zDHHC8 can recapitulate the wildtype phenotype [63]. This mouse also led to the characterization of PSD-95 as a
substrate of zDHHC8 [63]. There still lacks any experimental validation outside
of the mouse model that the loss of zDHHC8 function leads to the progression of
schizophrenia.
zDHHC PATs in Infectious Diseases:

The role of palmitoylation in several

parasitic infections may yield novel therapeutic targets for diseases such as
malaria, Chagas disease, and toxoplasmosis.

The palmitoyl-proteome of the

schizont stage of Plasmodium falciparum suggests a role for palmitoylation in
host cell invasion, protein export, and organelle biogenesis in malaria [64]. Over
400 proteins regulated by palmitoylation in P. falciparum have been identified,
including those involved in adherence, drug resistance, signaling, development,
and invasion [65]. In 2013, Batista et al. identified and showed the subcellular
localization of TcHIP, a presumptive Trypanosoma cruzi (responsible for Chagas
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disease) zDHHC palmitoyl transferase [66]. zDHHC7 has a significant impact on
host-cell invasion by Toxoplasma gondii (considered to be a leading cause of
death related to foodborne illness) [64].
Palmitoylation also plays a role in viral infections. Most notably, the Influenza
virus has at least three palmitoylated viral proteins that are required for plasma
membrane association, assembly and budding [67, 68]. Other studies suggest a
role for palmitoylation in the pathogenesis of hepatitis V infection [69]. Thus,
inhibiting palmitoylation may be a promising strategy for treating infectious
diseases.
zDHHC PATs in Cancer: The extranuclear estrogen receptor α (ERα) [70].
Cysteine residue 451 on ERα is palmitoylated by zDHHC7 and zDHHC21 [71,
72].

It is suggested that ER α requires chaperone proteins to uncover a

conformationally buried cysteine residues for palmitoylation.

Although ERα

exists as a monomer or dimer, only the monomers have been observed to get
palmitoylated [73].

Heat shock protein 27 is predicted to promote the

palmitoylation of ERα by allowing the zDHHC PAT to gain access to the site of
palmitoylation by conformationally opening the monomeric structure of the ERα
[74].

The palmitoylation of the internal cysteine residue of ERα promotes

trafficking of ERα to the plasma membrane [75]. Increased palmitoylation may
cause this localization of ER since its depalmitoylation disrupts membraneinitiated steroid signaling. Conversely, palmitoylation of CD44 in breast cancer
has been shown to regulate cell migration and control metastasis in breast

10

cancer [76]. This suggests that inhibiting palmitoylation may not be beneficial in
some breast cancers.
It was first proposed that the human chromosome 8p21-22 locus harbored a
tumor suppressor gene due to the observed loss of heterozygosity in multiple
cancer samples [77-83]. Oyama et al. established that human REAM (reduced
expression associated with metastasis), now referred to as zDHHC2, is down
regulated in more than 50% of human colorectal cancers. It was subsequently
shown that zDHHC2 is also reduced in approximately two-thirds of the cases with
liver metastasis [84]. In addition, reduced expression of zDHHC2 is observed in
lymph node metastasis and gastric adenocarcinomas [85]. Consistent with the
idea that zDHHC2 is a tumor suppressor, overexpression of zDHHC2 reduced
the proliferation and invasiveness of a hepatocellular carcinoma cell line [86].
Additionally, two substrates of zDHHC2, CKAP4 and CD9, have been shown to
be tumor suppressors [87-89].
Microarray analysis of colorectal tumor and gastric cancer samples show an
upregulation of zDHHC9 protein compared to non-cancerous samples [90].
zDHHC9 palmitoylates human Ras proteins [91]. The dysregulation of zDHHC9
may affect the subcellular localization and signaling of H-/N-Ras, which are also
associated with colorectal cancers [92].

1.5

Ras Biology and Cancer

There are four major Ras proteins in humans; K-Ras(4A), K-Ras(4B), H-Ras, and
N-Ras. The four proteins are >90% identical in their first 168-169 amino acids
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that confer the GTPase activity and effector interaction sites, but differ in their
remaining 20 C-terminal amino acids (Fig. 1.3). The highly divergent, 20 Cterminal residues comprise the hypervariable region (HVR) and are critical for
membrane targeting [93, 94].
Ras proteins are regulatory switch proteins that cycle between inactive (GDPbound) and active (GTP-bound) conformations and are activated by Receptor
Tyrosine Kinases at the cell surface (Fig. 1.4). Guanine Nucleotide Exchange
Factors (GEFs) contain a CDC25 homology region responsible for the catalytic
release of GDP from Ras [95]. GTP is approximately ten times more abundant in
the cytosol than GDP allowing for GTP to bind Ras following the release of GDP.
GTPase Activating Proteins (GAPs) increase the intrinsic GTPase activity of Ras,
increasing the rate of GTP hydrolysis and returning Ras to the inactive GDPbound state [95].
Ras is trafficked between numerous subcellular compartments including the
Golgi and the ER. Although it is capable of signaling from multiple locations, Ras
most frequently signals from the plasma membrane (PM) [96]. Ras proteins play
a critical role in regulating cell growth and survival due to their downstream effect
on transcription factors for actin cytoskeletal integrity, proliferation, differentiation,
cell adhesion, apoptosis and cell migration [97, 98]. The signal from Ras can
extend into intracellular compartments through a vast number of effector protein
interactions (Fig. 1.5) [98-100].

For example, Ras is a key regulator in the

mitogen-activated protein kinase (MAPK) cascade [101].
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Ras genes are the most frequently mutated family of oncogenes in human
cancers [102].

Ras is considered a driver of oncogenesis in several human

cancers either through a conformationally active mutant Ras or through the
increased activity of wild-type Ras resulting from the over stimulated receptor
tyrosine kinases. The overstimulation of Ras signaling often leads to malignant
cell transformation through deregulated proliferation, survival, invasiveness, and
angiogenesis. This can lead to increased metastasis and decreased apoptosis
[100, 103]. Mutations at residues G12, G13 and Q61 cause insensitivity to GAP
(G12 and G13) and increased stability of GTP (Q61) resulting in the constitutive
activity of Ras [104]. This leads to unregulated downstream effects of Ras in the
absence of extracellular signals, and ultimately oncogenesis and cancer [105].
The most frequently found mutated Ras isoforms in human cancer are K-Ras
and N-Ras [105]. Mutated forms of Ras are implicated in 20-25% of all human
tumors [98].

Ras can also be overactive due to the high rate of mutational

activation or overexpression of growth-factor receptors and their ligands, which
accounts for a higher ratio of chronically active Ras to mutant Ras [106].

1.6

Ras Processing

Ras is initially synthesized as a hydrophilic, soluble protein that immediately
undergoes posttranslational modifications (PTMs) at the C-terminal CAAX motif.
(Fig. 1.6) [93, 107]. These modifications are required for targeting Ras to the
cytoplasmic surface of the plasma membrane, where it primarily elicits its
interactions with effector proteins.
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The first PTM of Ras, farnesylation occurs on the cysteine residue of the CAAX
motif [18]. K-Ras and N-Ras, the two Ras proteins most frequently associated
with cancer, may also be prenylated by GGTase in the absence of FTase [19].
Following farnesylation, the terminal three amino acids of the CAAX motif are
proteolytically removed. The proteolytic cleavage of the terminal three amino
acids is catalyzed by Ras Converting CAAX Endopeptidase 1 (RCE1) [108, 109].
A subsequent carboxyl methyl esterification of the newly terminal cysteine is
catalyzed by Isoprenylcysteine Carboxyl Methyltransferase (ICMT) [110].
These PTMs enhance Ras association with endomembranes but are not
sufficient for its binding to the plasma membrane. K-Ras(4B) has a polybasic
sequence in the HVR that enables an electrostatic interaction with negatively
charged plasma membrane phospholipids (Fig. 1.3) [93]. K-Ras(4A), H-Ras, and
N-Ras cycle between palmitoylated and depalmitoylated states [92]. Ras has
been a model for the spatial organization, dynamics, and turnover of protein
palmitoylation [93, 111, 112].

While palmitoylated Ras is found on the

cytoplasmic surface of the plasma membrane, depalmitoylated Ras is found
primarily on internal membranes, primarily the ER and Golgi [113, 114].

K-

Ras(4A) is palmitoylated at cysteine residue 180, H-Ras is dually palmitoylated at
cysteine residues 181 and 184, and N-Ras is palmitoylated at cysteine residue
181 [115].
In yeast, Ras proteins are palmitoylated by Erf2-Erf4.

The gene product of

zDHHC9 was a candidate human homolog zDHHC PAT of Erf2 due to its 70%
sequence identity with the CRD domain and a 31% overall sequence identity with
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Erf2 (Fig. 1.7) [91]. In early studies, the zDHHC9 protein could not recapitulate
Erf2 activity, suggesting that zDHHC9 may similarly require an auxiliary protein to
function. Although there were no obvious candidates, a 16 kDa Golgi Complex
Protein (GCP16) was eventually identified due to its limited sequence similarity to
Erf4 [91]. zDHHC9 is unstable in the absence of GCP16 similar to Erf2 in the
absence of Erf4 [91]. The direct interaction between zDHHC9 and GCP16 is not
investigated as thoroughly as Erf2 and Erf4 but is expected to be similarly
valuable [40].

Although the role of Erf4 and GCP16 subunits is currently

unknown, experiments are underway to determine if these auxiliary subunits play
a role in substrate specificity, enzyme kinetics, and PAT localization [116].

1.7

Therapeutically Targeting Oncogenic Ras

Prior attempts to target Ras therapeutically via its GTPase activity or early PTMs
such as farnesylation, failed to be successful in the treatment of cancer.
Attempts to inhibit GTP-binding and activation of Ras proteins were unsuccessful
due to the high concentrations of GTP within the cell that binds Ras with a
picomolar affinity, and attempts to inhibit specific GEFs was also ineffective [102,
117-119]. Feedback loops and poor therapeutic windows resulted in a lack of
success to target downstream signaling pathways of Ras as a means to inhibit
Ras signaling [102]. Inhibitors of FTase were ineffective due to the ability of
GGTase to restore the activity of K- and N-Ras after FTase inhibitor treatment
[102, 117]. Palmitoylation remains an intriguing processing step to target in an
attempt to block the oncogenic activity of Ras.
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H- and N-Ras rely on

palmitoylation for association with the plasma membrane, whereas K-Ras has
two isoforms; K-Ras(4A) which gets palmitoylated and K-Ras(4B) which relies on
a polybasic sequence in the HVR for its association with the plasma membrane.
Thus, targeting palmitoylation would not inhibit all Ras proteins. K-Ras is the
most frequently mutated Ras protein in cancer, but studies have yet to clearly
distinguish between the palmitoylated and non-palmitoylated isoforms [120, 121].
The reversibility of palmitoylation makes it an appealing target for modulation that
can be regulated by physiological stimuli [122]. Because palmitoylation modifies
proteins involved in cell growth, signaling, and synaptic transmission the
enzymes responsible may become therapeutic targets. Development of a PAT
inhibitor could provide an important tool to explore palmitoylation, and has the
potential to be a therapeutic strategy to target the previously untreatable
oncogenic Ras or other diseases the dysregulation of palmitoylation is implicated
in. Recently, there has been some success in designing specific, small molecule
inhibitors of oncogenic, K-Ras(4B) by targeting either the oncogenic mutation or
specific protein-protein interactions [123, 124]. Due to the lack of success in
targeting Ras function or upstream modifications, there is still a need for an
inhibitor that specifically targets palmitoylated Ras isoforms.

1.8

Central Hypothesis and Closing Remarks

There is an urgent need to identify specific, sensitive modulators of palmitoylation
to further understand the mechanism and influence of palmitoylation in human
disease. A specific, sensitive inhibitor of palmitoylation will allow for a more
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accurate validation of palmitoylation targets, the enzymes involved, and
subsequently the substrate/enzyme pairs. An inhibitor of protein palmitoylation
will have a great impact on understanding the role of palmitoylation in disease
allowing for better therapeutic interventions. The goal of this project is to design a
sensitive HTS for the detection and evaluation of palmitoylation. The HTS will be
implemented in inhibitor screens of Erf2 autopalmitoylation to identify specific
inhibitors of Erf2-Erf4. These inhibitors could lead to use in a clinical setting or
for use as probes of palmitoylation in the research setting.
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Table 1.1. Human zDHHC Genes Implicated in Human Disease.
zDHHC

Disease/Disorder

zDHHC2
zDHHC3
zDHHC5
zDHHC7
zDHHC8
zDHHC9

Gastric Cancer
Cervical Cancer
Schizophrenia
Breast Cancer
Schizophrenia
Colorectal Cancer
Gastric Cancer
X-Linked Intellectual Disability

zDHHC11
zDHHC12
zDHHC13

Non-Small-Cell Lung Cancer
Alzheimer's Disease
Huntington’s Disease

Substrate(s)

Proposed
Mechanism
3
3
1
1 or 2
3
1
1
4

[85]
[125]
[126]
[71, 73, 76]
[126]
[90]
[90]
[52, 53, 127]

1
1
3 or 4

[128]
[49]
[129-131]

Osteoporosis (mouse)

3

[132, 133]

zDHHC14

Acute Myeloid Leukemia
Gastric Cancer
Lymphomas
Testicular Germ Cell Tumors

2
1
1
3

[134]
[135]
[136]
[137]

zDHHC15
zDHHC16
zDHHC17

X-Linked Intellectual Disability
Apoptosis Regulation
Huntington’s Disease

4
1
3 or 4

[127, 138]
[139]
[48, 129, 130,
140-144]

zDHHC21

Breast Cancer

1 or 2

[71, 73, 76]

GRIP1b
AR, ERα,
PR
GRIP1b
H- and N-Ras
H- and N-Ras

APP
Htt, GLT-1,
SNAP-25

c-Abl
Htt, GLT-1,
GAD65
AR, ERα,
PR

Reference

Proposed mechanisms include increase in expression (1), increase in activity (2),
decrease in expression (3), and decrease in activity (4).
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Figure 1.1. Protein Lipidation Classifications. A. Protein Farnesylation is the
C-terminal thioether attachment of a 15-carbon isoprenoid. B. Protein Geranylgeranylation is the C-terminal thioether attachment of a 20-carbon isoprenoid. C.
Myristoylation is the N-terminal amide attachment of a 14-carbon saturated fatty
acid. D. S-Palmitoylation is the thioester attachment of a 16-carbon saturated
fatty acid. E. A cholesterol moiety forms an ester bond with the C-terminal
glycine of proteins.
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Figure 1.2. List and Predicted Conformation of Human and Yeast zDHHC
PAT Enzymes. There are at least 22 zDHHC PATs identified in humans, and
seven in yeast.
They are each predicted to have a minimum of four
transmembrane domains (green), and a cytoplasmic DHHC motif within a
Cysteine-Rich Domain (pink). Ankyrin motifs have been identified in two of the
human zDHHC PATs and two of the yeast zDHHC PATs (red). Adapted from
[41].
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Figure 1.3. Sequence Alignment of Ras Protein Hyper Variable Regions. KRas(4A), K-Ras(4B), H-Ras, and N-Ras differ in their final 20 amino acids, but all
contain the CAAX motif. Adapted from [145].
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Figure 1.4. Ras Isoforms are GTPases. Ras cycles between the GTP-bound
active conformation and the GDP-bound inactive conformation. Natural GTPase
activity of Ras facilitates the removal of one phosphate group to go from GTPbound to GDP-bound Ras. GTPase Activating Proteins can increase the
GTPase activity of Ras. Guanidine Exchange Factors facilitate the removal of
GDP from Ras allowing for GTP to interact with Ras.
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Figure 1.5. Example Signal Transduction Pathways of Human Ras. A
majority of the pathways that Ras signaling is involved in result in cellular growth,
survival and apoptosis. The signaling pathways through RAL-GDS, RAF, PLC,
and NORE1/RASSF1, and PI3K are the best understood, but are only a small
subset of all Ras interactions. Adapted from [146].
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Figure 1.6. Ras CAAX Motif Processing. The four C-terminal amino acids (a
cysteine (C) residue, two aliphatic (A) amino acids, and the terminal (X) amino
acid) comprise the CAAX motif of Ras proteins. Ras proteins undergo
farnesylation of the CAAX motif cysteine residue by farnesyl transferase (FTase),
the -AAX is proteolytically cleaved by Ras Converting CAAX Endopeptidase 1
(RCE1), and the now-terminal cysteine residue gets carboxyl methylated by
Isoprenylcysteine Carboxyl Methyltransferase (ICMT).
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Figure 1.7. Sequence Alignment of Erf2 and zDHHC9. zDHHC9 and Erf2
contain 70% sequence identity within the CRD domain and 31% sequence
identity overall. Adapted from [91].
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CHAPTER 2
A Fluorescent-based Assay to Monitor Autopalmitoylation

2.1

Note to Reader

Portions of this chapter have been previously published in Anal. Biochem. (2014)
1(460), 1-8 and have been reproduced with permission from Analytical
Biochemistry (See Appendix A) [147].

2.2

Overview

During autopalmitoylation, palmitate is transferred from palmitoyl-CoA to the
PAT, creating a palmitoyl:PAT intermediate and releasing reduced CoA. We
have developed an in vitro, single-well, fluorescence-based enzyme assay that
monitors the first step of the PAT reaction by coupling the production of reduced
CoA to the reduction of NAD+ using the α -ketoglutarate dehydrogenase
complex.

This assay is suitable for determining PAT kinetic parameters,

elucidating lipid donor specificity and measuring PAT inhibition by 2bromopalmitate. Finally, it can be used for High Throughput Screening (HTS)
campaigns for modulators of protein palmitoylation.
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2.3

Key Words and Abbreviations

Autopalmitoylation; CoASH; Fluorescence-Based Assay; High Throughput
Screening (HTS); Kinetics
2-BP, 2-Bromopalmitic Acid; α-KDH, α-ketoglutarate dehydrogenase complex;
ABE, Acyl-Biotin Exchange; APT, Acyl Protein Thioesterase; CMC, Critical
Micelle Concentration; CoA, Coenzyme A; CoASH, Reduced Coenzyme A;
FSH1, Family of Serine Hydrolases 1; HTS, High-Throughput Screen; MuDPIT,
Multi-Dimensional

Protein

Identification

Technology;

PAT,

Protein

Acyl

Transferase; PPT, Protein Palmitoyl Thioesterase; RAC, Resin Assisted Capture.

2.4

Introduction

Few assay systems have been developed to examine the acylation reaction
kinetics despite the interest in identifying proteins that are palmitoylated and the
understanding of the mechanism(s) that regulates the palmitoylation. As a result,
a limited number of specific inhibitors of protein palmitoylation have been
developed. There is a need for effective assays that can monitor the protein acyl
transferase reaction.

Not only will a strong assay give insight into the

enzymology of protein palmitoylation, it will provide insights into the biochemical
mechanism(s) of substrate recognition and the kinetics of the reaction, and aid in
the identification of specific inhibitors of protein palmitoylation.
Protein palmitoylation proceeds by a two-step mechanism. In the first step,
autopalmitoylation, the palmitoyl moiety from palmitoyl-CoA is transferred to the
zDHHC cysteine side chain, forming the palmitoyl:enzyme intermediate and
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producing reduced CoA (CoASH) (Fig. 2.1A).

Once the autopalmitoylation

intermediate is formed, one of two reactions can occur: a) in the presence of the
protein substrate, the palmitoyl group of the intermediate can be transferred to a
substrate cysteine or b) in the absence of protein substrate, the palmitoyl group
of the intermediate can by hydrolyzed, yielding the enzyme and palmitate. The
formation of the palmitoyl:enzyme intermediate has been monitored by SDSPAGE and autoradiography using radiolabeled palmitoyl-CoA as the lipid donor
[33, 40, 91, 148-151]. However, there are several limitations to assays that rely
on radiolabeled palmitate. First, this assay measures the steady-state amount of
palmitoyl:PAT intermediate, not the total amount [40, 149]. Secondly, the use of
a radioactive reagent complicates high throughput screening techniques. Finally,
sensitivity is a key issue. At the lower limit of the assay’s sensitivity, the reaction
can accurately detect 5 fmols of transferred palmitate per min, which equates to
a signal to noise ratio of approximately 1.5. The main disadvantages of the
radioactive assay as it pertains to a high throughput format are the cost of the
reagents and the amount of time required to perform each step.

2.5

Mechanism of Palmitoylation

In some circumstances, the zDHHC PAT forms a complex with a heterologous
subunit prior to autopalmitoylation. Therefore, there are five mechanistic phases
of palmitoylation: enzyme complex formation, autopalmitoylation, substrate
acylation, hydrolysis of the enzyme-palmitoyl moiety intermediate, and
depalmitoylation of the substrate by thioesterases.
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Complex formation: Erf2-Erf4 and zDHHC9-GCP16 are examples of zDHHC
PATs that are more active when in complex with an auxiliary subunit [40, 53].
The subunits of the Erf2-Erf4 complex require co-translation to form an active
enzyme, and greater than 4 M urea is required to dissociate the subunits once
the complex is formed. Other complexes may exist for other zDHHC PATs but
have not been detected. Whether that element is provided within the zDHHC
subunits through the folding of variant amino acid domains or an accessory
subunit is not yet determined.
Autopalmitoylation:

Prior to transferring the palmitoyl moiety to Ras2, the

zDHHC PAT enzyme undergoes self-acylation, referred to as autopalmitoylation
[149]. By reducing the formation of the palmitoyl:PAT intermediate one would
inherently be reducing the availability of the palmitoyl moiety for the transferase
reaction.

Autopalmitoylation could be targeted by reducing the affinity of

palmitoyl-CoA for the zDHHC PAT, or by reducing the burst activity of the
formation of the palmitoyl-PAT intermediate.

Specificity is a concern due to

sequence conservation and the use of the same lipid donor in the first step of all
zDHHC reaction mechanisms. Identified inhibitors of autopalmitoylation should
be screened against additional zDHHC PATs to determine if they are specific to
individual PAT enzymes or general inhibitors of all PATs, sometimes referred to
as “pan” inhibitors.
Substrate Acylation: The large number of zDHHC PAT enzymes suggests that
the individual zDHHC PATs may have substrate specificity and be specialized for
certain pathways. Unfortunately, little is known of which enzymes are specific for
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which substrates.

Except for the cysteine residue that gets palmitoylated,

palmitoylation sites lack an identifiable sequence requirement.

However,

palmitoylation often occurs in the context of myristoylation and prenylation
residues or TMDs [14]. This suggests that substrates of palmitoylation must
have a preliminary membrane association that allows for palmitoylation to occur,
and that palmitoylation mediates the stability of the attachment to the membrane
rather than initiate it. A kinetic trap model hypothesizes that myristoylation and
prenylation promote transient interactions between the protein substrates and
cellular membranes allowing for the protein substrates to migrate freely between
internal cellular membranes [15, 92, 152]. The additional lipidation by palmitate
now instills a stronger association with membranes causing the acylated protein
substrates to be stably anchored and migrate by vesicle-mediated transport. It is
suggested that the localization of the specific zDHHC PAT enzymes may dictate
which cellular membranes the protein substrates are then anchored to [15, 92,
152].

Trapping refers to the reduced ability for the protein substrate to

disassociate from the membranes [153].
Hydrolysis: An increase in the hydrolysis rate of the palmitoyl-enzyme
intermediate would decrease the steady-state amount of palmitoyl:PAT
intermediate. This would reduce the available palmitate for transfer to the protein
substrate [53, 149].

Conversely, decreasing the rate of hydrolysis may still

impact the amount of palmitoylated substrate, as it would reduce the
concentration of active enzyme. Similar to autopalmitoylation, there is concern
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over designing a pan-zDHHC PAT modulator of hydrolysis versus targeting
specific zDHHC PATs.
Thioesterase activity: Many factors can contribute to the half-life of palmitate on
palmitoylated proteins. The number of acyl linkages, the activation state of the
protein and the general esterase accessibility are just some examples [154, 155].
Although the half-life of Ras protein is around 24 hours, the half-life of palmitate
on Ras is much faster [156]. H-Ras has a palmitate half-life of 2.4 hours and NRas has an even shorter half-life of palmitate at only 20 minutes [155-157].
When H-Ras is in the GTP-bound (active) conformation, the half-life of palmitate
on it is 2.4x faster than when H-Ras is GDP-bound [156]. Modulating the activity
of depalmitoylation would have just as substantial an impact on disease as
targeting any other step of autopalmitoylation.

The removal of the palmitate

moiety from a protein is depalmitoylation.

The enzymes that catalyze

depalmitoylation are either involved in lysosomal protein degradation (protein
palmitoyl thioesterases (PPTs)) or in the regulation of palmitoylation for protein
function in the cytosol (acyl protein thioesterases (APTs)) [154, 158].
Ppt1 and 2 are two examples of lysosomal PPTs capable of removing palmitate
from H-Ras in vitro [159-162]. The cytosolic APTs, Apt1 and Apt2, have been
described to affect Ras subcellular localization and pathway flux [163, 164]. Apt1
is a 29-kDa cytosolic protein that gets palmitoylated [165, 166]. Palmitoylation of
Apt1 is predicted to allow for its access to the membrane-associated
palmitoylated substrates [10].

Apt1 exhibits lysophospholipase activity towards

palmitoylated glycerol-3-phosphocholine and removes palmitate from Gi, H-Ras
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and eNOS in vitro [167-169]. Biochemical labeling support that both Apt1 and
Apt2 are also substrates for palmitoylation [166]. However, deletion of the Apt1
gene does not affect the half-life of Ras2 palmitoylation, the subcellular
localization of Ras2, or the growth of palmitoylation-dependent Ras2 alleles in
vivo.

Apt1 is the frontrunner for enzymes that catalyze depalmitoylation but

ongoing studies aim to identify other potential thioesterases. Both the identified
PPTs and APTs contain the catalytic triad characteristic of serine hydrolases.
These residues are required for their thioesterase activity. Thus it is predicted
that other serine hydrolases may elicit thioesterase activity. In an in vitro study,
the Deschenes’ lab compared the ability of yeast Apt1 to reduce palmitoylation of
Ras2 to that of another serine hydrolase, Family of Serine Hydrolases 1 (FSH1).
Their unpublished work suggests that Apt1 may be targeting the zDHHC PAT,
Erf2, rather than directly targeting the palmitoylation of the substrate, Ras2.
Conversely, FSH1 had no effect on either the enzyme or substrate. Inhibiting
depalmitoylation would be clinically desirable for many diseases that have
decreased expression and/or activity of zDHHC PATs. Similar to other aspects
of palmitoylation regulation, a balance needs to be struck for depalmitoylation
regulation, and effectiveness comes down to specificity.

2.6

Strategies to Evaluate Palmitoylation

Traditionally palmitoylation was evaluated through the use of [3H]palmitoyl-CoA.
Although effective, [3H]palmitoyl-CoA is hazardous and requires lengthy
exposure times. The samples are run on an SDS-PAGE that is subjected to
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auto-fluorography with a minimum exposure time of one week but sometimes as
long as a month for accurate visualization [170].

[14C]palmitoyl-CoA has

increased sensitivity over [3H]palmitoyl-CoA but it is also more hazardous. Tsai,
et al. describes a method of intensifying detection with [3H]palmitoyl-CoA
resulting in a reduction in experimental time to 1-3 days [171]. The use of nonradioactive chemical labeling with biotin or alternatives has also made recent
progress [172, 173].
In an attempt to identify additional protein palmitoylation substrates many
researchers utilize mass spectrometry [174, 175].

Metabolic labeling and

identification of palmitoylated proteins using acyl-biotin exchange (ABE) or
Resin-Assisted Capture (RAC) followed by mass spectrometry, provides a
comprehensive inventory of potentially palmitoylated substrates.

Large-scale

profiling studies with ABE have identified approximately 50 palmitoylated proteins
in yeast and several hundred in mammalian cells [14, 176-179]. Although this is
less than has been described to date, the numbers are comparable to previous
means of detection [10-12].
Additionally, algorithms for revealing putative palmitoylated protein substrates are
becoming available. These include CSS-Palm, WAP-Palm, and Palm-Pred [180182]. Oku, et al. successfully identified ten new substrates of protein
palmitoylation through in silico screening with CSS-Palm 2.0 [183].

Further

studies with ABE identified Neurochondrin as a substrate for zDHHC 1/11; a PAT
subfamily that had no prior identified substrates [183]. This success at identifying
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substrates highlights the abilities of in silico screening and lends optimism in the
search for more substrate/enzyme pairs.
More recently, work has been focused on designing assays that utilize coppercatalyzed Huisgen 1,3-dipolar cycloaddition click chemistry to elucidate the
palmitoylation story. Groups have used biomimetic acyl azides or omega-alkynyl
palmitate to identify proteins of palmitoylation through the copper-catalyzed
reaction that combines an azide group with an alkyne group to form a triazole
ring structure [184-187]. Others have conjugated Alk-C16-modified proteins to
azide-tagged biotin, fluorescent dye, or for crosslinking with a photo-activatable
diazirine [188]. The technique has also been used with fluorescently labeled
probes for quantitative and compartmentalization studies of palmitoylated
proteins in intact cells. Recently a clickable long alkyl chain analog of cerulenin
was designed for use as a chemical probe to profile zDHHC PATs [189, 190].
Click chemistry was coupled with a proximity ligation assay to visualize
palmitoylated proteins [191].
A relatively new technology, multi-dimensional protein identification technology
(MuDPIT) has led to the identification of much of what is known of palmitoylation
sites [11, 14, 192]. MuDPIT is a high-throughput, tandem mass spectrometrybased proteomic technology [192]. After subjecting cellular membrane extracts
to ABE, and affinity purifying the resulting biotinylated proteins on streptavidin
agarose the resulting substrates can be identified with MuDPIT [11, 14, 192].
MuDPIT and ABE are becoming the standard procedures for confirming the role
of palmitoylation in in vivo systems [11, 14, 192].
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Additionally, a light-inducible targeting system approach for achieving a better
understanding of complex biological systems has been developed. This system
can be applied to visualize where a palmitoylated protein is localized [193]. A
capillary electrophoresis assay may also be used to measure palmitoylation of a
fluorescently labeled peptide in vitro [194].

2.7

High-Throughput Screening Palmitoylation

In most high-throughput screens (HTS) each compound is only tested in singlet
or duplicate.

Thus there is a critical need for accuracy and sensitivity to

accurately identify active compounds (hits) [195]. To validate the accuracy and
sensitivity of a HTS campaign a Z’-factor is calculated which determines optimal
signal window for HTS.

In addition to a Z’-factor, standard deviation and

coefficient of variance are also important factors in the validation of a HTS. To
calculate all of these, it is important to test the assay in triplicate each day for
three days to determine variability in one day, as well as day-to-day variation
[195]. Even with the validation of the assay, it is important to screen the hits by
at least two different modes of activity detection, to remove false positives [195].
In this chapter, we describe and demonstrate the utility of a single well,
fluorescence-based, coupled assay system that monitors the steady-state rate of
autopalmitoylation of PAT in vitro.

This system measures the production of

CoASH, a product of the autopalmitoylation reaction. The CoASH is used in the
conversion of α-ketoglutarate to succinyl-CoA with the corresponding reduction
of NAD+ to the fluorescent NADH, a reaction that is catalyzed by α-ketoglutarate
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dehydrogenase complex ( α -KDH) [196-200].

Here, we use this assay to

demonstrate lipid substrate specificity on the autopalmitoylation activity of the
Erf2-Erf4 complex [40, 149]. In addition, we show that the coupled assay can be
applied to studying inhibition by 2-bromopalmitate (2-BP), a known inhibitor of
protein palmitoylation [201]. Finally, we present evidence that this assay system
can be used in a High Throughput Screening format in an attempt to identify
modulators of PAT enzymes.

2.8

Development of an in vitro Fluorescence-Based Coupled Enzymatic

Assay to Monitor Autopalmitoylation
The first step in the palmitoylation reaction, autopalmitoylation, can be monitored
by the production of CoASH. The amount of CoASH produced in turn can be
coupled to the reduction of NAD+ to NADH by α-KDH (Fig. 2.1A). NADH has
fluorescence excitation and emission maxima at wavelengths of 340 nm and 465
nm, respectively [196]. The α-KDH reaction is essentially irreversible (-ΔGo (pH
7.0) of approximately 10 kcal/mole) and has a KM value for CoASH of less the 0.1
µM [197].

When NAD+ and α -ketoglutarate are present in molar excess

compared to CoASH, the reaction proceeds to completion with approximately
zero-order kinetics.

The source of α-KDH is pig heart, but historically was

purified from ox heart [202]. NADH and succinyl-CoA can inhibit α-KDH to a
slight degree. This inhibition is abolished if the NAD+ concentration is in great
excess relative to the concentration of CoASH being assayed [198].
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As proof of principle, we performed a pilot study measuring yeast Erf2-Erf4
autopalmitoylation

activity.

The

production

of

NADH

was

monitored

fluorometrically in a single cuvette using a PTI Double-Double QuantaMaster 3
Fluorometer (340 nm excitation/ 465 nm emission). The reaction is linear
throughout the 5 min monitoring phase (Fig. 2.1B). Denaturing Erf2-Erf4 by
boiling abolishes the formation of NADH demonstrating that there is no
measurable background hydrolysis of palmitoyl-CoA (Fig. 2.1B). In addition, an
inactive mutant of Erf2, Erf2 C203S, that was purified in parallel with wild type
Erf2-Erf4, does not produce NADH above that of the boiled wild type Erf2,
demonstrating the increase in fluorescence is not due to a contaminating moiety
from the enzyme preparation protocol. These controls demonstrate that even
though there is a small amount of drift of the fluorescence signal, the signal is
specific for active, wild type Erf2-Erf4. Similar results were obtained using the
mammalian ortholog of Erf2-Erf4, zDHHC9-GCP16 as described in [53].

A

standard curve of known amounts of exogenously added CoASH, ranging from
0-3000 pmol CoASH, was used to quantify the amount of steady-state
autopalmitoylation, as the formation of the intermediate and production of CoASH
are in a 1:1 stoichiometry.

2.9

Determination

of

the

Kinetic

Parameters

for

Erf2-Erf4

Autopalmitoylation Using a 96-well Format.
Similar reactions have been performed that couple CoASH production to the
production of NADH through α -KDH that are detected by a change in
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fluorescence in a microtiter plate reader [200]. The coupled fluorescence-based
assay was developed for a 96-well plate format, thus allowing a number of
samples to be run simultaneously. As an initial evaluation of the assay, varying
concentrations of palmitoyl-CoA were used to assess the activity of the enzyme
over a 1 h period (Fig. 2.1C). The palmitoyl-CoA concentrations varied from 0200 µM. Plotting the initial change in fluorescence versus the concentration of
palmitoyl-CoA, we observed a curve that approached saturation until
approximately 100 µM of palmitoyl-CoA, and then showed an apparent decrease
in the activity for the concentrations above 100 µM. The observed decrease
could be a result of inhibition of α-KDH by high concentrations of palmitoyl-CoA
[198], or more likely the result of formation of palmitoyl-CoA micelles reducing the
effective concentration of

palmitoyl-CoA.

The approximate critical micelle

concentration for palmitoyl-CoA is in the range of 80-100 μM. Accordingly, we
limited the palmitoyl-CoA concentrations to below 100 µM and determined the
Vmax, 43 pmols CoASH produced/(min.µg), and KM of the reaction to be 43 µM for
palmitoyl-CoA, which agreed with the values we calculated using a single cuvette
reaction in a PTI Double-Double QuantaMaster 3 Fluorometer. The Vmax was
calculated by fitting the data to the Michaelis-Menten equation using Prism 6
software (GraphPad Software, San Diego, CA). A direct linear plot was used to
calculate the KM, the concentration of substrate that resulted in a reaction velocity
half that of the calculated Vmax.
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2.10

The Effect of Detergents in the Autopalmitoylation Reaction

All zDHHC protein acyl transferases so far identified are integral membrane
proteins with four or more TMDs [14, 41, 42, 203]. Therefore, isolation and
characterization of zDHHC PATS requires detergent solubilization. To determine
the effect of different detergents on the autopalmitoylation reaction, we screened
for changes in autopalmitoylation activity using a 72 detergent collection
(Hampton Research, Aliso Viejo, CA). The detergent was added to the reaction
prior to the Erf2-Erf4 enzyme at a final concentration equal to the critical micelle
concentration (CMC) for the respective detergent. The ratio of autopalmitoylation
in the presence of detergent to the autopalmitoylation in the “no detergent added”
control for each detergent is shown in Table 2.1. Over 50% of the detergents
examined provided at least 70% of the autopalmitoylation activity when
compared to the control. Although there was no measurable difference observed
amongst the non-ionic and zwitterionic detergents effect on autopalmitoylation,
ionic detergents had the most consistently detrimental effect on activity.

2.11

The Effect of Acyl-CoA Chain Length on Auto-acylation Activity

The availability of acyl-CoAs of varying chain lengths and the non-radioactive
nature of the coupled assay allowed us to test directly the specificity of the chain
length of the acyl donor for Erf2-Erf4. We determined the Vmax and KM kinetic
parameters for acyl-CoAs of carbon lengths between 8 and 20 (C8:0 – C20:0), as
well as palmitoleoyl CoA (C16:1 n7), cis-vaccenoyl CoA (C18:1 n7) and oleoyl
CoA (C18:1 n9). The mean KM values ranged between 9 and 90 µM for all the
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hydrocarbon chains examined (Fig. 2.2; inset).

We also observed a similar

phenomenon as for palmitoyl-CoA, where the velocity of the reaction decreased
at higher concentrations of substrate, suggesting that perhaps, at higher
concentrations of the longer chain lengths, the hydrocarbon was not as soluble.
However, by lowering the concentrations of the acyl-CoA substrates, we were
able to overcome the insolubility issues and obtain highly reproducible data to
calculate the parameters.
Given the purified system of this in vitro assay the concentration of substrate is at
a higher concentration than the product, thus it can be assumed that the reaction
is essentially irreversible. Therefore, the catalytic efficiency can be established
as kcat/KM. We used the specificity constant (kcat/KM) to compare the relative
rates of reaction of each of the substrates and plotted these values as a function
of acyl chain length (Fig. 2.2). Acyl chain lengths between 8 and 14 carbons
produced the greatest activity followed by acyl chain lengths of 16 carbons.
Saturated chain lengths of 18 and 20 carbons produced the lowest activities. Desaturating the 18 carbon chain length (cis-vaccenoyl-CoA) increased the activity
between 2- and 3-fold. These data demonstrate that protein acyl transferases
may be able to utilize acyl-CoAs of various chain lengths with varying degrees of
saturation as substrates for acylation and could serve as a possible explanation
for the heterogeneity observed with acyl modifications to proteins [150, 175].
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2.12

2-Bromopalmitate

Covalently

Modifies

and

Inhibits

Autopalmitoylation Activity of Erf2-Erf4
2-Bromopalmitate has been used as a lipid metabolism inhibitor for over 50 years
[204, 205]. Initially, we observed that the Erf2-Erf4 activity inhibition by 2-BP
could not be diluted or removed from the reaction (data not shown) suggesting
the inhibition of palmitoylation was irreversible.

In addition, 2-BP covalently

modifies native Erf2 at a rate of approximately 0.1 pmol/min (Fig. 2.3A; squares)
as measured by incorporation of 3H-2-BP into Erf2-Erf4 complexes (Fig. 2.3A,
lower panel). On a molar ratio basis, 2-BP was in 172-fold excess compared to
the amount of Erf2-Erf4 complexes. A calculation of the amount of Erf2-Erf4
complexes labeled reveals 5 pmols compared to the 5 nmols of 2-BP added to
the reaction. This results in one molecule of 2-BP reacting with an Erf2-Erf4
complex for every 1000 molecules of 2-BP. As bromide at the 2 position is a
good leaving group and is most likely the site of covalent bond formation
between Erf2 and 2-BP, the reaction product is not hydroxylamine labile.
Interestingly, the incorporation of the tritium signal is not detectable if the Erf2Erf4 complex is denatured before addition of 3H-2-BP (Fig. 2.3A; diamonds)
implying the native structure of the Erf2-Erf4 complex is required for labeling by
2-BP.
The effect of 2-BP on autopalmitoylation was examined using the coupled assay.
The initial rate of autopalmitoylation with increasing concentrations of palmitoylCoA was measured under conditions where the Erf2-Erf4 enzyme complex had
been pre-incubated with 2-BP. When no 2-BP was present, a curve of velocity
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versus palmitoyl-CoA concentration was observed similar to previous curves for
the wild type enzyme (Fig. 2.3B). However, when 2-BP is pre-incubated with the
enzyme, the velocities and the Vmax are decreased in a dose dependent manner.
Three concentrations of 2-BP (50 µM, 100 µM and 150 µM) were compared,
resulting in increasing levels of inhibition with an IC50 value of approximately 100
µM. Intriguingly, the amount of inhibition due to 2-BP was never as much as
observed for the catalytically inactive Erf2 (C203S)-Erf4 mutant (approximately
80% of the catalytically dead enzyme control).

Although it was previously

reported that the Ki for 2-BP was 10 µM [148], a concentration of at least 100 µM
is required to reduce the Vmax of Erf2-Erf4 complex by 50% in this assay. The
difference may be due to the effect of 2-BP on other steps required for
palmitoylation in addition to covalent modification of the enzyme [206].

2.13

Discussion

In the past, the method of choice for evaluating palmitoylation was through the
use of radiolabeled palmitate. The drawbacks of using a radiolabeled palmitate
are that the steady-state levels of the palmitoylated species can be monitored,
but the turnover of the enzyme cannot be easily quantified.

Secondly,

visualization can require an inordinate amount of time. Finally, the radiolabel is
cost prohibitive.

The price of 3H-palmitoyl-CoA is approximately $33-50 per

assay. For a library the size of 40,000 compounds, the cost of the 3H-palmitoylCoA from commercial sources is therefore prohibitive (>$1M). The cost can be
reduced by synthesizing 3H-palmitoyl-CoA from 3H-palmitate, CoASH, and acyl
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CoA synthetase; lowering the cost to approximately $0.30 per assay ($12,000 for
a 40,000 compound screen), but detecting the radioactive signal is still
problematic. By comparison, the cost of performing the single well, fluorescencebased coupled assay is approximately $0.07 per assay ($2800 for a 40,000
compound library).

Included in this amount is the cost of expressing and

purifying the PAT enzyme from the galactose-inducible S. cerevisiae overproduction system.
Protein palmitoylation plays a role in a variety of cellular processes involved in
cancer, cardiovascular disease, infectious disease, and neurological disorders
[116] and is required for membrane association and neoplasm promoting activity
of H- and N-Ras [107]. Palmitoylation has also been shown to play an important
role in other cancer targets. For example, estrogen signaling in breast cancer
involves palmitoylation [73].

Despite the central role of palmitoylation in the

subcellular localization and function of numerous signaling proteins involved in
cancer

and

several

neurological

disorders,

no

specific,

high

affinity,

palmitoylation inhibitors exist and a detailed understanding of the relationship
between zDHHC enzyme and substrates is lacking.

Therefore, a potential

application of this technology is to use high throughput screening procedures to
identify inhibitors of protein palmitoylation. A Z’-value is a measure of statistical
effect size, and is commonly used to evaluate whether the response in a HTS is
robust. Z'-prime values range from 0 to 1, and designate the percent difference
between mean positive control of an assay and mean negative control of an
assay that falls between standard deviations of both controls, thus an assay with
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a Z'-value greater than 0.5 is considered a robust assay. The Coefficient of
Variance, also known as relative standard deviation (RSD), of an assay is an
indication of the reproducibility of an assay.

The autopalmitoylation/coupled

assay is reproducible and robust (Table 2.2). For the Erf2-Erf4 complex, the
assay has a Z’-value of 0.87, a Coefficient of Variance of 6.2, and a signal-tonoise ratio of 33. In addition, the enzyme complex can be isolated in relatively
large quantities from yeast and is stable for greater than 24 h at 4˚C. The activity
of the human ortholog of the Erf2-Erf4 complex, zDHHC9-GCP16, is similarly
robust and reproducible with a Z’-value of 0.77, a Coefficient of Variance of 2.6
and a signal-to-noise ratio of 21.
In the present study, we have developed a fluorescence-based assay that can
measure the turnover activity of the protein acyl transferase and to determine
kinetic parameters.

We have demonstrated the usefulness of this assay to

measure the auto-acylation activity of Erf2-Erf4 using several acyl-CoAs of
varying chain lengths. Finally, we have shown that this assay can be used to
examine protein acyl transferase inhibition in a manner that is reproducible and
robust, and therefore applicable to HTS applications.

2.14

Experimental Procedures

Strains, media, and yeast techniques- Yeast and bacteria growth media were
prepared as described previously [207]. Cells were grown in synthetic complete
(SC) medium or YPD (1% yeast extract, 2% peptone, and 2% glucose) medium
[207, 208].

Induction of GAL1, 10 promoters were achieved by adding 4%
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galactose to SC medium.

Yeast transformations were performed using the

lithium acetate procedure [209]. The yeast strains used in this chapter, RJY1842
(MATa/α ade2-1/ade2-1 leu2-3,112/leu2-3,112 ura3-1/ura3-1 trp1-1/trp1-1 his311,15/his3-11,15 can1-100/can1-100 erf4Δ::NATr/erf4Δ::NATr GAL+) [40, 149]
and RJY1330 (MATα leu2-3,112 ura3-52 ade2Δ ade8Δ lys2-801 ras1::HIS3
ras2::Ras2CS-Ext erf2::KANr <YCp52RAS2>) have been previously described
[34, 40, 149].
Plasmid construction- The sequences of the deoxyoligonucleotide primers used
to construct zDHHC9 alleles are available upon request. The DNA sequences of
all constructs were verified by DNA sequencing (GeneWiz, Plainfield, NJ). The
construction of B1302 and B1595 has been described previously [149, 208].
zDHHC9 (accession number: BC006200) and GCP16 (BC001227) were
obtained from the Image consortium (Image numbers: 2964425 (zDHHC9) and
3456384 (GCP16)). The zDHHC9 open reading frame was amplified by PCR
using primers that would encode a C-terminal 6xHIS epitope as well as an inframe C-terminal FLAG epitope flanked by sequences homologous to MCS1 of
B1192 (pESC-Trp (Stratagene, Santa Clara, CA)) to facilitate ligase-independent
cloning (LIC), producing B1500 (pESC-Trp zDHHC9).

B1856 (pESC-Trp

zDHHC9-GCP16) was constructed by inserting the PCR amplified GCP16
possessing the proper flanking sequences into MCS2 of B1500 by LIC.
Protein expression and purification-

Erf2-Erf4 enzyme complexes were

expressed from the pESC-Leu divergent GAL1,10 promoter in strain RJY1842,
which also harbored a second plasmid to enhance galactose induction, pMA210
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[210] ([208]. Cultures were grown in synthetic medium containing 2% glucose
and lacking leucine and histidine. zDHHC9-GCP16 enzyme complexes were
expressed from the pESC-Trp divergent GAL1,10 promoter in strain RJY1842
along with pMA210 and grown overnight at 30˚C with shaking (230 RPM) in
synthetic medium containing 2% glucose and lacking tryptophan and histidine.
Approximately 3x107 cells were inoculated into 50 mls of synthetic medium
containing 2% glucose and lacking the appropriate amino acids and the cultures
were grown at 30˚C with shaking (230 RPM) until the cell density was between
1.6x107 cells/ml (OD600 0.8) and 2.4x107 cells/ml (OD600 1.2). To induce the
expression of the enzyme complexes, approximately 50 OD600 of cells (1x109)
were seeded into 1 L of YEP containing 2% galactose and the culture was
incubated at 30˚C with shaking (230 RPM) for 18 h. The cells were harvested by
centrifugation at 3000xg for 15 min. The resulting pellet was resuspended in
breaking buffer (50 mM Tris-Cl pH 8, 500 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol (DTT), 1x protease inhibitor cocktail (PIC) (1 µM Leupeptin, 2 µM
Pepstatin A, and 16 mM Benzamidine), and the cells were lysed using glass
beads (400-600 mesh, Sigma-Aldrich, St. Louis, MO) for 40 min with 1 min
pulses/1 min cooling (20 cycles) [40, 149, 208]. The resulting extract was spun
at 3000xg for 15 min to remove cellular debris and unbroken cells, to yield a
whole cell extract (WCE).
The enzyme-containing particulate fraction (P19) was isolated from the WCE by
centrifugation at 19,000xg for 30 min at 4˚C. The soluble portion (S19) of the
WCE was decanted and the particulate pellets were solubilized using 0.8% n-
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Dodecyl-β-D-maltoside (DDM) at 4˚C for at least 5 h with gentle agitation [40,
149, 208].

Detergent insoluble particulates were removed from the P19 by

centrifugation at 19,000xg for 30 min at 4˚C. The soluble P19 samples were then
moved to clean tubes. To aid in purification of the 6xHis:Erf2-Erf4 complexes,
urea and imidazole were added to a final concentration of 2 M and 1 mM,
respectively (6xHis:zDHHC9-GCP16 complexes were supplemented with only 1
mM imidazole). The resulting supernatant was incubated with Ni-NTA resin (FivePrime, Gaithersburg, MD) at 4˚C for 1h.

The resin was washed once with

Solution W (50 mM Tris•HCl, pH 8.5, 0.08% DDM, 5 mM β-ME) containing 300
mM NaCl, and then twice with Solution W containing 150 mM NaCl. The protein
was eluted with 50 mM Tris HCl, pH8.5, 150 mM NaCl, 0.08% DDM, 5% glycerol
and 250 mM imidazole. Eluents were desalted and the buffer changed to SPB
(50 mM Sodium Phosphate Buffer, pH6.8, 10% glycerol) using a column of G-25
resin.

Fractions containing 6xHis:Erf2-Erf4 complexes (or 6xHis:zDHHC9-

GCP16 complexes) were pooled to obtain approximately 0.5 mg of purified Ras
PAT per liter of culture. These samples were flash frozen with liquid nitrogen and
stored at -80˚C for up to 3 years [149].
Coupled Protein Acyl transferase (PAT) Assay- The production of NADH was
monitored in 96-well format with a Biotek Mx fluorimeter (Biotek, Winooski, VT)
using an excitation of 340 nm and emission of 465 nm [149, 196-198]. The 200
µl reaction contained 2 mM 2-oxoglutarate (α-ketoglutamic acid isolated from pig
heart), 0.25 mM NAD+, 0.2 mM thiamine pyrophosphate, 2 µg of purified PAT
complex, 1 mM EDTA, 1 mM dithiothreitol, and 32 mU 2-oxoglutarate
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dehydrogenase ( α -KDH, Sigma-Aldrich, St. Louis, MO) in 50 mM sodium
phosphate buffer, pH 6.8. The reaction was initiated by the addition of varying
concentrations of palmitoyl-CoA and monitored for 30 min at 30˚C. The first 10
min of the reaction was analyzed to determine the initial rates of CoASH release.
The PAT specific activity was determined from a standard curve of fluorescence
values

generated

concentrations.

under

reaction

conditions

using

different

CoASH

In these reactions, CoASH was added to the standard PAT

reaction mixture (without PAT complex) and the reaction was allowed to proceed
to equilibrium before fluorescence was measured. To further validate the assay,
two types of controls were performed. For the first control, the PAT enzyme was
boiled to inactivate the autopalmitoylation activity, and therefore the PATdependent formation of NADH, to demonstrate that there is no measurable
background hydrolysis of palmitoyl-CoA in the reaction. Boiled enzyme produced
significantly less fluorescence (<20%) suggesting no significant contribution from
sample heterogeneity or non-specific fluorescence.

Secondly, a catalytically

inactive mutant form of the PAT complex (Erf2 (C203S)-Erf4 or zDHHC9
(C169A)-GCP16) was used to determine the baseline activity of the reaction and
to show no significant contribution of contaminating activities to the assay results.
For reactions that incorporated 2-BP, Erf2-Erf4 complexes were incubated with
different concentrations of the inhibitor, 2-BP (dissolved in DMSO), for 20 min at
room temperature prior to incorporation into the assay.

Assay conditions

permitted as much as 6% DMSO without affecting Erf2-Erf4 autopalmitoylation
activity (Fig. 2.4).
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The rate of the coupled reaction (α-KDH) must have a first-order dependence on
the concentration of CoASH, a product of autopalmitoylation.

However, this

assumes a Vmax rate of the autopalmitoylation reaction (the first reaction) and
therefore the concentration of palmitoyl-CoA would need to be at saturation
conditions. This is not realistic for this reaction given the interference in the
activity observed at higher concentrations of palmitoyl-CoA (Fig. 2.1C). Instead,
for measurements of the rate of the coupled reaction (at sub-Vmax concentrations
of CoASH) to provide accurate information concerning the initial rate of
autopalmitoylation, a steady-state concentration of CoASH must be reached
before the rate of autopalmitoylation diminishes noticeably from its initial value.
Using the method of Storer and Cornish-Bowden [211], we calculated the time
needed to reach a steady-state concentration of CoASH (334pM) as
approximately 2 seconds, where the rate of autopalmitoylation is about 3% of the
limiting rate of the coupled reaction and where the ratio of the CoASH dependent
rate of the coupled reaction to the rate of autopalmitoylation is 0.99. Therefore,
in practice, there is no appreciable time lag while the system reaches equilibrium.
Therefore, the accumulation of NADH adequately represents the rate of
autopalmitoylation.
Radioactivity-based 2-BP labeling assay- Covalent modification of Erf2-Erf4 by
3

H-2-BP was performed by combining 8 µg (approximately 29 pmols of Erf2-Erf4

per time point) of native Erf2-Erf4 complex (or boiled Erf2-Erf4) and 100 μM 2BP (specific activity, 0.4 Ci/mmol) [9,10-3H] 2-BP (American Radiolabeled
Chemicals, St. Louis, MO) in 200 µL of 50 mM sodium phosphate buffer, pH 7.4
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and 0.5 mM dithiothreitol.

The reaction was incubated at 30°C and 50 µL

samples removed to tubes containing 12 µL of 5x reducing protein loading buffer
to stop the reactions at the indicated times.

Samples were boiled for 3 min,

centrifuged for 3 min at 13,000xg to removed insoluble particulates and
separated by SDS-PAGE (10%). To visualize the radioactivity, after separation,
the gel was soaked in En3Hance (Perkin-Elmer, Waltham, MA), as per the
manufacturer’s instructions and dried under a vacuum. Typical film exposure
times ranged from 2-4 days. To determine the number of dpm comprising each
labeled Erf2 band, the bands corresponding to Erf2 were excised from the dried
gel using the exposed film as a template and soaked in 500 µL Soluene S-350
(Perkin-Elmer, Waltham, MA) and 81 µL of a 50% (w/v) solution of hydroxylamine
(1 M; final) (Sigma/Aldrich, St. Louis, MO) for 18 h at 37˚C in scintillation vials to
dissolve the acrylamide and release the radioactivity. Scintillation cocktail (5 ml)
was added directly to the Soluene S-350 dissolved samples in the vials. The
samples were allowed to equilibrate for 2 h and the number of cpm determined
by scintillation counting (Beckman-Coulter, LS6500, Indianapolis, IN). The
counting efficiency of the tritium was determined by adding a known amount of
tritium standard (dpm) (American Radio Chemicals, St. Louis, MO) to the vials
containing samples and the vials recounted. Counting efficiency was calculated
as the difference between the cpm from the combination of standard plus sample
and the sample alone divided by the amount of dpm of the standard
(approximately 90%). To determine the efficiency with which the tritium was
released from the acrylamide, native Erf2-(FLAG)Erf4 bound with anti-FLAG
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conjugated to agarose beads (Sigma-Aldrich, St. Louis, MO) was incubated with
3

H-2-BP for 30 min at 30˚C.

The free

3

H-2-BP label was washed away

extensively (5x 1 ml) with buffer. The Erf2-(FLAG)Erf4 complexes were removed
from the beads with 0.1 M glycine, transferred to a fresh tube and neutralized
with 1 M Tris•Cl, pH 7.5. One fifth of the sample was submitted for scintillation
counting (with 500 µL Soluene S-350 added) and the remainder of the sample
was separated by SDS-PAGE (10%).

The radioactivity was isolated and

released under the same conditions as the time point samples. Comparison of
the dpm obtained directly from the control complexes and those obtained from
the gel slices showed the procedure to be approximately 35% efficient.
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Table 2.1. Effect of Detergents on the Enzymatic Autopalmitoylation
Activity of the Erf2-Erf4 Complex.
Detergent
No detergent
Anapoe 35
n-Octyl-β-d-thioglucoside
IPTG
ZWITTERGENT 3-12
C12E9
DDMAB
LDAO
C12E8
CYMAL-1
CYPFOS-3
MEGA-9
ZWITTERGENT 3-14
n-Tetradecyl-β-d-maltoside
n-Dodecyl-β-d-maltoside
FOS-Choline-12
1-s-Nonyl-β-d-thioglucoside
n-Undecyl-β-d-maltoside
n-Dodecyl-N,N-dimethylglycine
Pluronic F-68
DDAO
Sucrose monolaurate
n-Tridecyl-β-d-maltoside
CYMAL6
n-Nonyl-β-d-maltoside
ZWITTERGENT 3-08
n-Decyl-β-d-maltoside
Triton X100
FOS-Choline-10
FOS-Choline-9
n-Hexadecyl-β-d-maltoside
n-Decyl-β-d-thiomaltoside
n-Nonyl-β-d-maltoside
n-Decanoylsucrose
CYMAL5
n-Dodecyl-β-d-maltotrioside
HEGA-10
n-Nonyl-β-d-glucoside
Big CHAP, Deoxy

Type*
NA
NI
NI
NI
Z
NI
Z
NI
NI
NI
NI
NI
Z
NI
NI
Z
NI
NI
Z
NI
NI
NI
NI
NI
NI
Z
NI
NI
Z
Z
NI
NI
NI
NI
NI
NI
NI
NI
NI
52

% Control
100
96
90
87
87
86
85
85
85
84
83
83
82
82
82
82
81
80
80
79
79
79
78
76
75
75
75
75
75
74
74
74
74
72
72
72
71
66
64

Table 2.1. (Continued).
Detergent
Type* % Control
CYMAL-4
NI
63
n-Octyl-β-d-thiomaltoside
NI
62
n-Octanoylsucrose
NI
62
n-Octyl-β-d-glucoside
NI
61
MEGA 8
NI
60
HECAMEG
NI
60
Anapoe X-405
NI
58
Anapoe X-305
NI
58
CYMAL-2
NI
57
C8E5
NI
57
1-s-Heptyl-β-d-thioglucoside
NI
54
ZWITTERGENT 3-10
Z
52
n-Heptyl-β-d-thioglucopyranoside
NI
51
Anapoe 20
NI
50
Thesit
NI
50
OPOE
NI
47
CHAPS
Z
46
Anapoe 80
NI
44
CYMAL 3
NI
44
CHAPSO
Z
43
C-HEGA-11
NI
39
FOS-Choline-8
Z
39
Anapoe 58
NI
37
n-Hexyl-β-d-glucopyranoside
NI
36
Anapoe X-114
NI
34
Anapoe C10E9
NI
31
Anapoe C13E8
NI
31
Anapoe C10E6
NI
31
HEGA-9
NI
30
HEGA-8
NI
25
C-HEGA 10
NI
24
CTAB
I
23
C-HEGA-9
NI
20
Anapoe C12E10
NI
14
BAM
I
0
No enzyme
NA
0
* NA (not applicable), NI (non-ionic), Z (zwitterionic) and I (ionic).
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Table 2.2. Kinetic and HTS Parameters for zDHHC9-GCP16 and Erf2-Erf4
Complexes.
Parameter
zDHHC9-GCP16
Erf2-Erf4
Autopalmitoylation activity
(pmol/min/µg)
47.0 ± 2.5
43.0 ± 3.0
KM (µM)
45 ± 4
43 ± 8
Yield (mg/L)
1-3
2-4
Z'-value*
0.77
0.87
Coefficient of variance*
2.6
6.2
Signal-to-noise ratio*
21
33
Stability (4 °C)
>24H
>24H
*Values were determined on 3 successive days using the National Center for
Advancing Translational Sciences high-throughput screening criteria.
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Figure 2.1. Validation of an in vitro, Single Well, Fluorescence-based
Coupled Assay that Measures Protein Acyl Transferase Catalyzed
Autopalmitoylation Activity. A. Schematic of the coupled assay reaction. B.
Production of CoASH is dependent on active Erf2-Erf4 complexes. The reaction
was performed as described in the Experimental Procedures using 2 µg wild
type Erf2-Erf4 complexes, catalytically dead Erf2 (C203S)-Erf4 complexes or
boiled Erf2-Erf4 complexes (Blank). Fluorescence was recorded continuously
(ex. 340 nm/ em. 460 nm) for 5 min at 30˚C. C.
Graphic representation of
reaction rates using varying concentrations of palmitoyl-CoA substrate.
Reactions were performed in quadruplicate and repeated three times (n=3) at
30˚C with intermittent shaking. The fluorescence values (ex. 340 nm/ em. 460
nm) were recorded at 1 min intervals for 10 min. The data were analyzed and
fitted to the Michaelis-Menten equation using algorithm of Prism 6 (GraphPad
Software, San Diego, CA). The data were corroborated using the Direct Linear
Plot method [212, 213]. The amount of CoASH produced was based on a
standard curve using known concentrations of CoASH and expressed as
pmols/s +/- SD.
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Figure 2.2. The Effect of Acyl CoA Substrate Specificity on Erf2-Erf4 Autoacylation Activity. Graphical representation of specificity constants (kcat/KM) for
acyl CoAs of varying saturated hydrocarbon chain lengths (C8:0-C20:0; closed
circles), unsaturated lengths (palmitoleoyl CoA (C16:1 n7), cis-vaccenoyl CoA
(C18:1 n7) (open circles) and oleoyl CoA (C18:1 n9) open square) for the Erf2Erf4 steady-state auto-acylation activity. The assays were performed in
triplicate and repeated three times (n=3). (Inset) Graphical representation of the
KM values used to calculate the kcat/KM values (above). The saturated acyl
hydrocarbon chains are denoted by closed circles, palmitoleoyl and cisvaccenoyl chains are denoted by open circles and the oleoyl chain denoted by
an open square.
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Figure 2.3. Covalent Modification and Inhibition of Erf2-Erf4
Autopalmitoylation Activity by 2-Bromopalmitate. A. Native Erf2-Erf4
complexes and boiled Erf2-Erf4 were incubated with 3H-2-BP for the times
shown. The products of the reactions were separated by SDS-PAGE and
subjected to autoradiography (bottom panel). The intensities of the signals
corresponding to palmitoyl-Erf2 were determined by cutting the bands from the
gels, dissolving the gel slices in Soluene S-350 to release the tritium and the
amount of radioactivity determined by scintillation counting [33]. Tritium-based
counts were converted to pmols and plotted versus time (top panel). Wild type
Erf2-Erf4 complexes are denoted by closed squares and boiled Erf2-Erf4
denoted by closed diamonds. B. Reaction rates of Erf2-Erf4 autopalmitoylation
activity with increasing concentrations of palmitoyl-CoA in the presence of 2-BP.
Samples include Erf2-Erf4 (closed circles), Erf2-Erf4 plus 50 µM 2-BP (closed
squares), Erf2-Erf4 plus 100 µM 2-BP (closed triangles), Erf2-Erf4 plus 150 µM
2-BP (open circles) and Erf2 (C203S)-Erf4 (Xs). Reactions were performed in
triplicate (n=3) at 30˚C. The fluorescence values (ex. 340 nm/ em. 460 nm) were
recorded at 1 min intervals for 10 min. The data were analyzed and fitted using
Prism 6 (Michaelis-Menten algorithm) (GraphPad Software, San Diego, CA).
The values for Vmax and KM were corroborated using the Direct Linear Plot [212,
213].
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Figure 2.4. Erf2-Erf4 Autopalmitoylation Activity Tolerates Relatively High
Concentrations of Dimethylsulfoxide (DMSO). Erf2-Erf4 catalyzed
autopalmitoylation reactions containing varying percentages of DMSO were
performed as described in Materials and Methods using 2 µg wild type Erf2-Erf4
complex. The reaction proceeded for 5 min at 30˚C while continuously monitoring
the fluorescence intensity (ex. 340 nm/ em. 460 nm). The reactions were
performed eight times (n=8) and are expressed as the mean +/- SD. The Pvalues are given on the figure. The P-value for 0 and 6 percent DMSO is 0.7.
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CHAPTER 3
Inhibition of Erf2 Autopalmitoylation by Fungal Metabolites
3.1

Overview

The fluorescence-based autopalmitoylation assay was used to screen a library of
fungal metabolite obtained from Dr. Baker (Department of Chemistry and the
Center for Drug Discovery and Innovation, University of South Florida, Tampa,
FL).

We screened 81 extracts for effect on Erf2 autopalmitoylation with the

fluorescent-based coupled assay, and identified two lead fungal metabolite
extracts that exhibited Erf2 autopalmitoylation inhibitory effects similar to that of
2-bromopalmitic acid.

An orthogonal gel-based assay validated that these

extracts were inhibitors of Erf2 autopalmitoylation. Future work with individual
metabolites will be performed to establish the selectivity and efficacy of the leads.

3.2

Key Words and Abbreviations

Autopalmitoylation; Enzyme Inhibitor; Erf2; Fungal Metabolite; High Throughput
Screen (HTS)
α-KDH, α-ketoglutarate dehydrogenase; 2-BP, 2-bromopalmitate; DNMTi, DNA
Methyltransferase Inhibitor; HDI, Histone De-acetylase Inhibitor.
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3.3

Introduction

The reversibility of protein palmitoylation and the implications of its dysregulation
in

cancer,

cardiovascular

disease,

and

neurological

disorders

makes

palmitoylation an ideal target for therapeutic intervention [214, 215]. There are
few inhibitors of palmitoylation described, and the inhibitors available are limited
in their selectivity and specificity. Known inhibitors of palmitoylation lack
sensitivity and specificity, which interferes with their therapeutic potential and
their ability to act as probes to further characterize palmitoylation. Despite their
limitations, the inhibitors 2-bromopalmitate (2-BP), cerulenin, and tunicamycin
have been used to validate palmitoylation.
2-BP: The most commonly used inhibitor of protein palmitoylation is the
halogenated fatty acid 2-bromohexadecanoic acid, more commonly known as 2BP. 2-BP was introduced nearly 50 years ago as a nonselective inhibitor of
metabolism but was later identified as a non-metabolizable analog that may
inhibit palmitoylation by interacting with proteins in the same manner as palmitate
[201, 204, 205]. 2-BP has been shown to act as a covalent inhibitor of Spalmitoylation of H-Ras, Src kinase, Rho family members and PSD-95 [216]. 2BP is thought to inhibit protein palmitoylation by acting as a palmitate mimetic
due to its structural similarity to the 16-carbon saturated fatty acid (Fig. 3.1).
Similar palmitate analogs (e.g., 2-hydroxypalmitate, 16-hydroxypalmitate, and
palmitoleic acid) do not inhibit palmitoylation, suggesting that the bromo- group
may be aiding in the specificity [201]. Upon entering the cell, 2-BP is converted
to 2-bromopalmitoyl-CoA in cells similarly to how palmitate is converted to

60

palmitoyl-CoA but with less efficiency. 2-BP blocks the formation of the PAT-acyl
intermediate in vitro with an IC50 of ~10 μM, and ~15 μM in live cells [148, 217].
For these reasons, along with the simplicity of use and ease of acquisition, 2-BP
has been an attractive modulator of protein palmitoylation.
Unfortunately, 2-BP exerts pleiotropic effects on cellular metabolism and inhibits
carnitine palmitoyl transferase I, fatty acid CoA ligase, glycerol 3-phosphate acyl
transferase, NADPH cytochrome c reductase, and glucose 6-phosphatase [1,
218]. Initially reported as a β-oxidation inhibitor 2-BP also inhibits mono-, di-, triglycerol

transferases,

fatty

acyl-CoA

ligase,

glycerol-3-phosphate

acyl

transferases, non-lipid processing enzymes like NADPH cytochrome C reductase
and glc-6-phosphatase at sub-millimolar concentrations [204, 205]. Recent mass
spectrometry analysis identified >450 targets of 2-BP, including PAT enzymes,
transporters, and many palmitoylated proteins, with no observable preference for
CoA-dependent enzymes [206]. Additionally, reduced activity of the thioesterase
APT1

demonstrates

that

2-BP

could

inhibit

both

palmitoylation

and

depalmitoylation of protein substrates [216]. 2-BP may not be directly inhibiting
the zDHHC PAT but may be acting in a non-specific manner to target reactive
thiols. Two analogs were synthesized to overcome the drawbacks of 2-BP and
serve as activity-based probes of palmitoylation [219].

Unfortunately, the

analogs, 2-bromohexadec-15-ynoic acid and 2-bromooctadec-17-ynoic acid,
similarly lack in specificity. These drawbacks associated with 2-BP reinforce the
need for new sensitive and specific inhibitors of palmitoylation.
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Cerulenin: 2,3-epoxy-4-oxo-7,10 dodecadienoylamide, Cerulenin, is a naturally
derived antibiotic.

Cerulenin inhibits fatty acid synthesis by alkylating β -

ketoacyl-carrier protein synthase. Cerulenin was implicated as an inhibitor of
palmitoylation because it affects insulin uptake in rat adipocytes [220].

A

cerulenin analog blocks palmitoylation of p21 Ras by alkylating the protein
palmitoyl transferase, zDHHC17, without inhibiting fatty acid synthase [221].
Cerulenin and its analogs inhibit palmitoylation at concentrations ranging from 730 μM in a panel of human tumor cell lines but at 1 mM in in vitro studies [222,
223].

Unlike 2-BP, the structure of Cerulenin does not resemble palmitate.

Therefore it is not expected to act as palmitate mimetic (Fig. 3.1). The proposed
mechanism of action for cerulenin and its analogs include the inhibition of
palmitoylation through alkylation effects or chemical modification of sulfhydryl
groups [223]. Cerulenin may be interacting with critical thiols on enzymes or
substrates involved with palmitoylation. However, cerulenin inhibits β-keto-acylACP synthase and HMG-CoA synthetase activity resulting in inhibition of fatty
acid biosynthesis and cholesterol biosynthesis, respectively [224, 225].
Tunicamycin: The nucleoside antibiotic tunicamycin was identified for its ability to
inhibit N-glycosylation but has been demonstrated to also inhibit palmitoylation.
The mechanism of action of tunicamycin is unknown but it may compete with
palmitoyl-CoA for zDHHC PAT association.

Tunicamycin shares structural

similarities with both palmitate and Coenzyme A (Fig. 3.1). Tunicamycin inhibits
the palmitoylation of GAP-43, N-type calcium channels, ER-α variant, and
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myelin proteolipid protein [222, 226-228] in the micromolar concentration range
[222, 229].
Mechanism-based inhibitors: Due to the lack of specific and sensitive
palmitoylation inhibitors, Ducker et al. performed cell-based, high throughput
screens to identify compounds that inhibited palmitoylation-dependent cell growth
[230].

The inhibitors were categorized based on their ability to inhibit

palmitoylation of Type I substrates (proteins like Ras that get farnesylated prior to
palmitoylation) or Type II substrates (proteins like Src that get myristoylated prior
to palmitoylation). Through this process, they identified five chemical classes of
inhibitors. One representative compound (designated Compounds I-V) for each
chemotype was selected and subjected to further characterization. The
representative compounds inhibited the palmitoylation of fluorescently labeled
peptides with IC50 values in the low micromolar range.

Unfortunately, the

compounds failed to inhibit the activity of purified zDHHC2, zDHHC9-GCP16,
Pfa3 and Erf2-Erf4 in in vitro studies at concentrations as high as 100 μM [148].
Compound V inhibited the PAT activity for the purified zDHHCs but lacked the
specificity that Ducker, et al. described [148, 230, 231]. Although this wave of
inhibitor screening produced mixed results, the improvement to assays,
screening techniques, and chemical libraries encourage the ability to identify
new, specific inhibitors and modulators of palmitoylation.
Thioesterase Inhibition: Initial attempts to identify inhibitors of Apt1 resulted in
synthetic benzodiazepinediones with hexadecylsulfonamide that had IC50 values
in the low nanomolar range [232, 233]. Although these compounds worked well
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in vitro, they were never supported by in vivo studies. Using “protein structure
similarity clustering” as a bioinformatics-based strategy to design inhibitors for
Apt1, Waldmann and colleagues have developed a depalmitoylation inhibitor
consisting of palmostatins with β -lactone cores [163]. The palmostatins
competitively inhibited Apt1 through a reversible covalent modification of the
active site serine associated with protein depalmitoylation [163]. The most potent
inhibitor of Apt1 was palmostatin B with an IC50 of 670 nM. Apt1 was validated
as a cellular target of palmostatin B in a Madine-Darby canine kidney cell line by
demonstrating an interaction between palmostatin B and the thioesterase in vivo
[163]. Palmostatin B inhibits depalmitoylation and causes a loss of the precise
steady-state localization of palmitoylated Ras, and induces partial phenotypic
reversion in oncogenic HRasG12V-transformed fibroblasts [163].

Thus,

palmostatin B may be a valuable starting point for the development of modulators
of pathological signaling for Ras proteins [163].

3.4

Fungal Metabolite Extracts

Dr. Baker and colleagues have prepared extracts from entophytic fungi isolated
from coastal Florida mangroves stands. Each fungal isolate was grown in rice
media under three different growth conditions: in the presence of a histone deacetylase inhibitor (HDI), a DNA methyltransferase inhibitor (DNMTi), or vehicle
control.

The cultures were extracted in ethyl acetate, dried, resuspended in

100% DMSO at a concentration of 5mg/mL, and plated for the bioassay
screening.

The provided fungal metabolite library will be applied to the
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fluorescence-based coupled assay described in chapter 2. The different growth
conditions are expected to activate latent pathways and produce novel
metabolites that may not otherwise be detected in normal laboratory growth
conditions [234]. These crude extracts are a mixture of metabolites that may
contain non-polar natural products, lipids, small peptide chains, and possibly
DNA intercalators. This chapter presents the identification of two lead fungal
metabolite extracts that inhibit Erf2 autopalmitoylation greater than 100 μM 2BP.

3.5

Dose Response of 2-BP on Erf2 Autopalmitoylation

The first step in a screening campaign is to establish the controls for the assay in
the same solvent as the provided library. The fungal metabolites are provided as
extracts in 100% DMSO. This assay has previously been optimized for a final
1% DMSO, but for this screen it was optimized for 5% DMSO to allow for a
greater concentration of metabolites.
2-BP was screened on the fluorescence-based coupled assay in triplicate at 25
μM, 50 μM, 100 μM, and 150 μM against vehicle control (5% DMSO) (Fig.
3.2). This was to determine an effective dose of 2-BP that would result in a
~50% reduction of Erf2 autopalmitoylation. The slopes (velocity of the reaction),
indicative of increase in NADH over time, were consistent (Fig. 3.2A), yielding
minimal standard deviation (Fig. 3.2B).

25 μ M 2-BP resulted in a ~30%

decrease in reaction velocity, 50 μM 2-BP resulted in a ~50% decrease in
reaction velocity, 100 μM 2-BP resulted in a ~85% decrease in reaction velocity,
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and 150 μM 2-BP completely inhibited the reaction. Thus 50 μM 2-BP was
selected as the Erf2 autopalmitoylation inhibition control for the fluorescencebased coupled assay.

3.6

The Fungal Metabolite Isolates Inhibit Erf2 Autopalmitoylation

The fungal metabolite library consists of extracts from entophytic fungi isolated
primarily from the Florida mangroves.

Fungal isolates were grown in the

presence of HDAC or DNMT inhibitors, and were provided at approximately
5mg/mL in 100% DMSO.

The fungal metabolites were diluted 1:20 in the

reaction for a final concentration of approximately 2.5 mg/ml in 5% DMSO.
Despite the complexity of the fungal metabolite samples the results obtained
from the screen against Erf2 autopalmitoylation resulted in minimal standard
deviation, similar to that of the 2-BP screen.
The control samples from isolates CQ10-23A-1 (B), EG12-31A-6 (G), EG10-34E1 (H), EG12-16C-3 (K), and all three extracts from EG12-32A-2A (Z) elicited
minimal inhibitory effects on Erf2 autopalmitoylation. The remaining fungal
metabolite samples resulted in a decrease in Erf2 autopalmitoylation equal to or
greater than 50 μM 2-BP (Fig. 3.3).

Extracts from all growth conditions of

EG10-47C-1 resulted in decrease in NADH detection, suggesting that they were
somehow quenching fluorescence of the assay. EG10-47C-1 samples were
omitted from the remainder of this study.
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3.7

Dose Response of CoASH on Fluorescence-based Coupled Assay

Control Reaction
To calibrate the results from the fluorescence-based coupled assay and
determine a linear range of concentrations, the assay was performed in the
absence of Erf2-Erf4, utilizing CoASH as a reaction catalyst, rather than
palmitoyl-CoA.

A dose response for CoASH was performed to determine a

working concentration of CoASH in the presence of 5% DMSO. CoASH was
screened in the control reaction at 0.5 μM, 1 μM, 2.5 μM, 5 μM, 7.5 μM, 10
μM, 15 μM, 20 μM, 40 μM, and 80 μM.
Due to the rapid conversion of NAD+ to NADH via α -ketoglutarate
dehydrogenase (α-KDH) it is difficult to accurately capture the start of the
reaction. Thus, the detected rates of the reaction are inconsistent even from well
to well. When the reaction is not coupled to the production of CoASH from
autopalmitoylation it reaches Vmax prior to the first point of data collection (< 5 s).
The control reaction is evaluated as relative end-point fluorescence after a 10
min. reaction.

Reducing the concentration of CoASH resulted in a linear

reduction in the end-point fluorescence for 7.5 μM CoASH and higher. There is
minimal difference in end-point fluorescence between baseline (0 μM CoASH)
and 7.5 μM CoASH (Fig. 3.4). This demonstrates that 20 uM CoASH falls within
the linear range of the concentrations screened, which is consistent with prior
studies [147]. Based on these findings 20 μM CoASH was selected for the
control reaction as it falls below the KM of the control reaction (~40 μM) [147].
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3.8

The Fungal Metabolite Isolates have Minimal Background Effects on

the

Fluorescence-based

Coupled

Assay

Independent

of

Erf2

Autopalmitoylation
To determine if the extracts have intrinsic fluorescence interfering with the assay,
the background fluorescence of the fungal metabolite isolates was measured.
The total end-point fluorescence after a 10 min. reaction was also measured.
The initial relative fluorescence was subtracted from the total end-point
fluorescence resulting in the normalized effect of the extracts on α-KDH.
All of the fungal metabolite samples demonstrated a degree of background
fluorescence (Fig. 3.5), which could be due to an artifact of the extraction
technique, or a common metabolite present in all the samples. Despite this, very
few of the fungal metabolite samples demonstrated an effect on α-KDH activity.
Isolates from the control treatment for isolate EG12-3C-2 (AA) resulted in a ~80%
reduction in α-KDH activity. All three treatments from EG12-24A-3A (F) and
EG11-21B-1 (R), and DNMTi treatment for isolate EG12-18A-13 (W) resulted in a
~10-25% reduction in α-KDH activity. All three treatments from EG10-60E-1 (I)
resulted in ~60% increase in α-KDH activity. All three treatments from EG1047C-4 (D) resulted in a 40-fold increase in background fluorescence (Fig. 3.5).
The background effects may be driving their effects in the fluorescence-based
coupled assay. The remaining isolate samples did not elicit a background effect.
The results from the Erf2 autopalmitoylation screen were then normalized for
effect on the α -KDH reaction (total end-point relative fluorescence minus
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background fluorescence) to establish specific effect of the fungal metabolite
samples on Erf2 autopalmitoylation (Fig. 3.6). The lead isolates were selected
for Erf2 steady-state autopalmitoylation screens. These isolates are the HDItreated CQ10-23A-1 (B), control treated EG10-52E-2 (Q), DNMTi-treated EG1224A-3A (F), DNMTi-treated EG10-47C-4 (D), DNMTi-treated EG10-52E-2 (Q),
HDI-treated EG12-24A-5 (X), HDI-treated EG12-18A-13 (W), and control treated
EG12-31A-9 (Y) isolates. Two of these isolates resulted in a reduction in α-KDH
activity (DNMTi treated EG12-24A-3A and HDI-treated EG12-18A-13).

3.9

Evaluating Erf2 Steady-State Autopalmitoylation

The fluorescent-based coupled assay is an indirect means of evaluating
autopalmitoylation through the production of NADH.

It is possible that the

extracts could be eliciting this effect through targeting hydrolysis of the enzymepalmitoyl moiety complex rather than targeting the autopalmitoylation reaction.
Steady-state autopalmitoylation was evaluated on the gel-based assay that
exploits BODIPY®-C12-CoA as a fluorescent mimic of palmitoyl-CoA [40] (Fig.
3.7).

The reactions were separated by SDS-PAGE and steady-state

autopalmitoylation was determined by co-migration of the BODIPY® fluorophore
with Erf2. This demonstrates that Erf2 was acylated by BODIPY®-C12 [40]. A
reduction in the co-migrating BODIPY® fluorescence with Erf2 would be
indicative of a reduction in Erf2 steady-state auto-acylation.

The fungal

metabolite isolates were applied to the gel-based assay to determine the effect
on Erf2 autopalmitoylation. At ~2.5 mg/ml in 5% DMSO the HDI-treated CQ1069

23A-1 (B), and control and DNMTi treated-EG10-52E-2 (Q) isolates resulted in
an ~85% reduction in Erf2 steady-state autopalmitoylation (Fig. 3.8).

The

remaining isolates; DNMTi treated EG10-47C-4 (D), HDI-treated EG12-24A-5
(X), HDI-treated EG12-18A-13 (W), and control treated EG12-31A-9 (Y) resulted
in a ~60% reduction in Erf2 steady-state autopalmitoylation. The DNMTi-treated
EG12-24A-3A

(F)

isolate

had

the

least

effect

on

Erf2

steady-state

autopalmitoylation (a ~25% reduction). This isolate was discarded as it inhibited
α-KDH activity. 100 μM 2-BP was an inhibition control of Erf2 steady-state
autopalmitoylation as it resulted in a >50% reduction in co-migrated BODIPY®
fluorescence with Erf2 on the gel-based assay.
To compare the different treatments of the lead isolates on Erf2 steady-state
autopalmitoylation, the three isolates that resulted in the greatest reduction in
Erf2 steady-state autopalmitoylation were evaluated. The HDI treated CQ1023A-1 (B), and control and DNMTi-treated EG10-52E-2 (Q) isolates were
screened by the gel-based assay against the remaining treatment samples from
their respective isolate groups; control and DNMTi-treated CQ10-23A-1 (B), and
HDI-treated EG10-52E-2 (Q). Similar to the fluorescence-based coupled assay,
the HDI-treated CQ10-23A-1 (B) isolate resulted in a greater degree of steadystate Erf2 autopalmitoylation inhibition compared to control and DNMTi-treated
CQ10-23A-1 (B) isolates. Conversely, there was no discernable difference
between growth treatments for isolate EG10-52E-2 (Q). They each inhibited Erf2
steady-state autopalmitoylation to a similar degree as 100 μM 2-BP, ~95% (Fig.
3.9).
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3.10

Discussion

The current inhibitors of palmitoylation interact with a variety of cellular pathways
in addition to palmitoylation [1, 206, 218, 222, 224-228].

As the field of

palmitoylation expands, the need for specific and sensitive inhibitors to validate
the involvement of palmitoylation, and probe for new substrates becomes urgent.
Unfortunately, the lack of specificity of currently available inhibitors is not ideal for
either purpose. The involvement of protein palmitoylation in signaling pathways
and disease states is often validated by 2-BP, but 2-BP also inhibits carnitine
palmitoyl transferase I, fatty acid CoA ligase, glycerol 3-phosphate acyl
transferase, NADPH cytochrome C reductase, and glucose 6-phosphatase in
addition to >450 interactions identified by mass spec [1, 206, 218].

More

recently, analogs of another protein palmitoylation inhibitor, cerulenin, have been
used as probes for substrates of palmitoylation, but cerulenin lacks specificity,
and inhibits fatty acid and cholesterol biosynthesis [190, 224, 225]. This further
justifies the need for a more specific inhibitor of protein palmitoylation.
The Florida mangroves have a diverse inventory of fungal organisms that
researchers are only now just starting to investigate. Furthermore, the novel
concept of modifying the fungal growth conditions to introduce a greater variety
of fungal metabolites increases the odds of detecting a metabolite of interest.
In that context, the CQ10-23A-1 (B) isolate extracts are of great interest as
modifying the growth conditions resulted in a range of inhibitory effects on Erf2
autopalmitoylation. This suggests that under different growth conditions isolate
CQ10-23A-1 (B) produces different metabolites or expresses existing metabolites
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more efficiently. Thus, there is a great opportunity for one of those metabolites to
be an effective inhibitor in either this screen or even a completely different
screen.
Conversely, for our purposes of identifying a novel inhibitor of protein
palmitoylation, samples from both isolates, CQ10-23A-1 (B), and EG10-52E-2
(Q), are of interest. Both isolates were able to produce metabolites that resulted
in a 75% reduction of Erf2 autopalmitoylation, and a 95% reduction in steadystate autopalmitoylation; suggesting that they are producing metabolites that
inhibit the formation of the Erf2-palmitoyl moiety intermediate.
This is especially encouraging as the fungal metabolite samples are not
individual purified individual metabolites, but complex mixtures of not-yetcharacterized non-polar extracts. Once the metabolites have been fractionated
and can be screened individually, it will be interesting to observe if they have a
greater or weaker effect individually. There is the potential that the metabolites
within a sample are acting in an additive manner to elicit the inhibitory effects on
Erf2 autopalmitoylation, and that when they are fractionated to individual
metabolites, they will have lost efficacy from synergistic effects. It is also feasible
that individual metabolites are causing the inhibition, and by fractionating to
remove inactive constituents will result in more potent inhibition.
The metabolite samples from the lead isolates are currently being fractionated so
that individual metabolites may be screened. Following the identification of lead
individual metabolites, they will be further optimized for structure-activity
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relationship, and screened against additional zDHHC PATs to evaluate their
specificity.
Screening the fungal metabolite library has highlighted the screening capabilities
of the fluorescence-based coupled assay. 81 fungal metabolite samples were
evaluated on a 96-well plate format for specific effects on Erf2 autopalmitoylation,
which lead to the identification of lead samples for additional screens.
Previously established inhibitors of protein palmitoylation were first characterized
for their inhibitory effects on other cellular mechanisms, but these potential
inhibitors were identified by virtue of their ability to inhibit purified zDHHC protein
autopalmitoylation [204, 205, 224-226]. These findings could ultimately lead to
the identification and characterization of first in class zDHHC inhibitors, creating
an opportunity to explore the therapeutic potential of specific PAT inhibitors.

3.11

Experimental Procedures

Coupled PAT Assay- As discussed in chapter two, the production of NADH was
monitored with a Biotek Mx fluorimeter (Biotek, Winooski, VT) using 340 nm
excitation/ 465 nm emission. The 50 µl reaction contained 2 mM 2-Oxoglutarate
(α-ketoglutamic acid), 0.25 mM NAD+, 0.2mM Thiamine Pyrophosphate, 0.5 µg
of purified 6xHIS-Erf2/FLAG-Erf4, 1 mM EDTA, 1 mM dithiothreitol, 32 mU 2oxogluarate dehydrogenase (α-ketoglutarate dehydrogenase), 50 mM sodium
phosphate, pH 6.8, and 0 - 100 µM inhibitor in 5% DMF. The addition of 40 μM
palmitoyl-CoA initiated the reaction, which was monitored for 30 min. at 30˚C.
The first 10mins of the reaction was analyzed to determine the initial rates of
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CoASH release. The PAT specific activity was determined from a standard curve
of NADH production with different CoASH amounts. In these reactions, CoASH
was added to the standard PAT reaction mixture (without Erf2/Erf4 complex or
palmitoyl-CoA) and the reaction was allowed to proceed to equilibrium (~10 min.)
before fluorescence was measured. The assay can be assembled as a kit for
consistency between experiments. Each 96-well plate experiment uses ~1.5 ml
of a 4x reaction buffer, ~3 ml of a 2x Palmitoyl-CoA stock, and 50 μl of purified
Erf2-Erf4 (~0.5 μg per reaction). The volume of Erf2-Erf4 is based off of a ~1 μ
g/μl preparation. To avoid cycles of freezing and thawing the 4x reaction buffer
and palmitoyl-CoA can be produced in bulk and stored at -20oC in appropriate
aliquot volumes for one 96-well plate experiment. We maintain 50 μl aliquots of
Erf2-Erf4 at -80oC. Because all the elements of the assay are prepared in bulk,
and stored in workable aliquots, there is an increased reproducibility and
reliability from the fluorescent-based coupled assay. This has allowed for the
reliable

evaluation

of

compound

libraries

for

their

effects

on

Erf2

autopalmitoylation.
Coupled Assay Control Screen- The 50 µl reaction contained 2 mM 2Oxoglutarate ( α -ketoglutamic acid), 0.25 mM NAD+, 0.2mM Thiamine
Pyrophosphate, 1 mM EDTA, 1 mM dithiothreitol, 32 mU 2-oxogluarate
dehydrogenase (α-ketoglutarate dehydrogenase), 50 mM sodium phosphate,
pH 6.8, and 0 - 100 µM inhibitor in 5% DMF. The addition of 20 μM CoASH
initiated the reaction, which was monitored for 30 min. at 30˚C. The value of the
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first reading was subtracted from the value of the last reading at the end of the
reaction to determine the effect of the inhibitors on α-ketoglutamic acid activity.
BODIPY®-C12:0 Autopalmitoylation Assay- BODIPY®-C12:0-CoA (40 µM final,
unless specified otherwise) was added to a 50 µl reaction containing
approximately 0.5 µg enzyme (6xHis-Erf2/FLAG-Erf4) and 2.5 mg/ml inhibitors in
5% DMSO in 50mM sodium phosphate buffer, pH 6.8.

The reactions were

incubated 10 min with inhibitor, and then the reaction was initiated by the addition
of BODIPY®-C12:0-CoA, and incubated 15 min. at 30˚C.

The reaction was

terminated by the addition of 5x non-reducing protein loading buffer.

Each

reaction was then subjected to SDS-PAGE (12%). The gel was washed three
times in ddH2O and visualized on the Typhoon 9410 Variable Mode Imager (GE
Healthcare, Piscataway, NJ) for BODIPY® fluorescence (ex. 488 nm / em. 532
nm) to visualize co-migration of the BODIPY® signal with 6xHIS-Erf2/FLAG-Erf4.
The amount of 6xHIS-Erf2/FLAG-Erf4 was determined empirically using SDSPAGE/western blot analysis under reducing conditions against a standard curve
of bovine serum albumin.
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Figure 3.1. Current Inhibitors of Palmitoylation Compared to Palmitate and
Coenzyme A. 2-Bromopalmitate is structurally the same as palmitate with the
exception of the 2-bromo group. Half of tunicamycin is reminiscent of palmitate,
where the other half of tunicamycin is reminiscent of coenzyme A. Cerulenin is
similar in hydrophobicity and chemical space to palmitate.
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Figure 3.2. Dose Response of 2-BP on Erf2 Autopalmitoylation. A. The
fluorescence-based coupled assay is performed in the presence of varying
concentrations of 2-BP in 5% DMSO. The resulting fluorescent units are graphed
against time (seconds) in triplicate, where the slope is equal to the velocity of the
reaction. B. The average velocity of Erf2 autopalmitoylation is presented as a
fraction of vehicle control (5% DMSO) +/- standard deviation. The velocity of
Erf2 autopalmitoylation was detected as an increase in fluorescence over time.
A reaction lacking Erf2 ( - ) was a control for the baseline activity of the assay.
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Figure 3.3. Fungal Metabolite Screen for Erf2 Autopalmitoylation Inhibition.
The fungal metabolites were screened at ~2.5 mg/ml, and the average relative
velocity of Erf2 autopalmitoylation of three reactions is presented as a fraction of
vehicle control (5% DMSO) +/- standard deviation. The velocity of Erf2
autopalmitoylation was detected as an increase in fluorescence over time. The
fungal isolate samples are CQ10-15C-1 (A), CQ10-23A-1 (B), EG10-42B-2 (C),
EG10-47C-4 (D), EG11-13B-1 (E), EG12-24A-3A (F), EG12-31A-6 (G), EG1034E-1 (H), EG10-60E-1 (I), EG11-15C-3 (J), EG12-16C-3 (K), EG12-31A-3B (L),
EG12-49E-5 (M), EG12-8A-3 (N), CC10-10B-1 (O), CQ10-17B-1 (P), EG10-52E2 (Q), EG11-21B-1 (R), EG12-33D-3 (S), KML12-2MG-C1 (T), CQ10-28A-4 (U),
EG11-15C-3 (V), EG12-18A-13 (W), EG12-24A-5 (X), EG12-31A-9 (Y), EG1232A-2A (Z), and EG12-3C-2 (AA). For a visual aid, results from every other
isolate group is shaded by a gray box behind the graph. 50 μM 2-BP is a control
for inhibition of Erf2 autopalmitoylation, and a reaction lacking Erf2 ( - ) was a
control for baseline activity in the assay.

78

Figure 3.3. (Continued).
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Figure 3.4. Dose Response of CoASH on Control Experiment of
Fluorescence-based Coupled Assay. The fluorescence-based coupled assay
was performed in the absence of Erf2-Erf4 using CoASH as substrate rather than
palmitoyl-CoA. Varying concentrations of CoASH were applied to the reaction in
the presence of vehicle control (5% DMSO). The average relative end point
fluorescence of three 10 min. reactions is represented as the total relative
fluorescent units +/- standard deviation.
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Figure 3.5. Fungal Metabolites on Background Fluorescence and α-KDH
Activity. The fluorescence-based coupled assay was performed in the absence
of Erf2-Erf4 using CoASH as substrate rather than Palmitoyl-CoA. The fungal
metabolites were screened at ~2.5 mg/ml, and the average relative end point
fluorescence (dark grey), background fluorescence (light grey), or α-KDH
Activity (end point fluorescence – background fluorescence; white) of three 10
min. reactions is presented as total relative fluorescent units +/- standard
deviation. The fungal isolate samples are CQ10-15C-1 (A), CQ10-23A-1 (B),
EG10-42B-2 (C), EG10-47C-4 (D), EG11-13B-1 (E), EG12-24A-3A (F), EG1231A-6 (G), EG10-34E-1 (H), EG10-60E-1 (I), EG11-15C-3 (J), EG12-16C-3 (K),
EG12-31A-3B (L), EG12-49E-5 (M), EG12-8A-3 (N), CC10-10B-1 (O), CQ1017B-1 (P), EG10-52E-2 (Q), EG11-21B-1 (R), EG12-33D-3 (S), KML12-2MG-C1
(T), CQ10-28A-4 (U), EG11-15C-3 (V), EG12-18A-13 (W), EG12-24A-5 (X),
EG12-31A-9 (Y), EG12-32A-2A (Z), and EG12-3C-2 (AA). 50 μM 2-BP is a
control for inhibition of Erf2 autopalmitoylation, and a reaction lacking Erf2 ( - )
was a control for baseline activity in the assay.
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Figure 3.5. (Continued).

82

Figure 3.5. (Continued).
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Figure 3.6.
Fungal Metabolite Screen Normalized to Background
Fluorescence and α-KDH Activity. The fungal metabolites were screened at
~2.5 mg/ml, and the average relative velocity of Erf2 autopalmitoylation of three
reactions normalized to background effects on the reaction is presented as a
fraction of vehicle control (5% DMSO). The velocity of Erf2 autopalmitoylation
was detected as an increase in fluorescence over time. The fungal isolates were
treated with either vehicle control (dark grey), DNMT (light grey), or HDAC
(white), and are samples CQ10-15C-1 (A), CQ10-23A-1 (B), EG10-42B-2 (C),
EG10-47C-4 (D), EG11-13B-1 (E), EG12-24A-3A (F), EG12-31A-6 (G), EG1034E-1 (H), EG10-60E-1 (I), EG11-15C-3 (J), EG12-16C-3 (K), EG12-31A-3B (L),
EG12-49E-5 (M), EG12-8A-3 (N), CC10-10B-1 (O), CQ10-17B-1 (P), EG10-52E2 (Q), EG11-21B-1 (R), EG12-33D-3 (S), KML12-2MG-C1 (T), CQ10-28A-4 (U),
EG11-15C-3 (V), EG12-18A-13 (W), EG12-24A-5 (X), EG12-31A-9 (Y), EG1232A-2A (Z), and EG12-3C-2 (AA). 50 μM 2-BP is a control for inhibition of Erf2
autopalmitoylation, and a reaction lacking Erf2 ( - ) was a control for baseline
activity in the assay.
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Figure 3.7. Schematic of Orthogonal Gel-based Screen of Steady-state
Autopalmitoylation.
In the orthogonal screen a BODIPY®-C12-CoA is
combined in reaction with a zDHHC PAT. If auto-acylation occurs then
BODIPY®-C12 will label the zDHHC PAT, and CoASH will be released. The
reaction can be separated by SDS-PAGE and viewed on a fluorescent flatbed
scanner to detect BODIPY® fluorescence (ex. 485 nm / em. 528 nm) that comigrated with zDHHC PAT, indicative of autopalmitoylation. An inhibitor of
autopalmitoylation is expected to reduce the amount of steady-state zDHHC PAT
acylated by BODIPY®-C12, and thus will be detected as a decrease in
fluorescence in the SDS-PAGE at the apparent molecular weight of the zDHHC
PAT.
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Figure 3.8. Fungal Metabolite Screen Hits on Gel-Based Assay. An
orthogonal screen of steady-state Erf2 autopalmitoylation with ~2.5 mg/ml of
each of the lead fungal metabolite isolate samples; CQ10-23A-1 (B), EG10-52E2 (Q), EG12-18A-13 (W), EG10-47C-4 (D), EG12-24A-3A (F), EG12-24A-5 (X),
EG12-31A-9 (Y). The relative BODIPY® fluorescence that co-migrated with Erf2
is presented as a fraction of vehicle control (5% DMSO). A reaction lacking Erf2
( - ) represents baseline activity in the assay. 100 μM 2-BP is a control for
inhibition of Erf2 steady-state autopalmitoylation.
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Figure 3.9. Complete Isolate Sets for the Fungal Metabolite Screen Hits on
the Gel-based Assay.
An orthogonal screen of steady-state Erf2
autopalmitoylation with ~2.5 mg/ml of each of the complete isolate sets for the
lead fungal metabolite isolate samples; CQ10-23A-1 (B) and EG10-52E-2 (Q).
The average relative BODIPY® fluorescence from three reactions that comigrated with Erf2 is presented as a fraction of vehicle control (5% DMSO) +/standard deviation. A reaction lacking Erf2 ( - ) represents baseline activity in the
assay.
100 μ M 2-BP is a control for inhibition of Erf2 steady-state
autopalmitoylation.

87

CHAPTER 4
Identification of Protein Palmitoylation Inhibitors from a Scaffold Ranking
Library

4.1

Note to Reader

Portions of this chapter have been submitted for publication to J. Biol. Chem.
(2015) and the manuscript is under revision.

4.2

Overview

This chapter describes a mixture based screening approach to identify inhibitors
of Erf2 activity, the Saccharomyces cerevisiae PAT responsible for catalyzing the
palmitoylation of Ras2, an ortholog of the human Ras oncogene proteins. A
chemical library developed by the Torrey Pines Institute for Molecular Studies
consists of more than 30 million compounds designed around 68 molecular
scaffolds that are systematically arranged into positional scanning and scaffold
ranking formats.

We have used this approach to identify and characterize

several scaffold backbones and R-groups that reduce or eliminate the activity of
Erf2 in vitro. Here, we present the analysis of one of the scaffold backbones, biscyclic piperazine. We identified compounds that inhibited Erf2 autopalmitoylation
activity using a fluorescence-based, coupled assay in a high throughput
screening (HTS) format and validated the hits utilizing an orthogonal gel-based
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assay. Finally, we examined the effects of the compounds on cell growth in a
yeast cell-based assay. Based on our results, we have identified specific, highaffinity palmitoyl transferase inhibitors that will serve as a foundation for future
compound design.

4.3

Key Words and Abbreviations

Acyl transferase; Enzyme Inhibitor; High Throughput Screening (HTS);
Palmitoylation; zDHHC
2-BP, 2-bromopalmitic acid; APT, acyl protein thioesterase; CoA, Coenzyme A;
DCM, dichloromethane; DIC, diisopropylcarbodiide; DIEA, diisopropylethylamine;
DMF, dimethylformamide; HOBt, 1-hydroxybenzotriazole hydrate; HTS, high
throughput screen; MEOH, methanol; MBHA, p-methylbenzyhydrylamine; PAT,
protein acyl transferase; SAR, Structure and Activity Relationship; TFA,
trifluoroacetic acid; THF, tetrahydrofuran.

4.4

Introduction

Dysregulation of the enzymes which catalyzed the palmitoyl addition and/or the
substrates of these enzymes have been linked to cancer, cardiovascular, and
neurological disorders, implying these enzymes and substrates are valid targets
for pharmaceutical intervention. However, current chemical modulators of
zDHHC PAT enzymes lack specificity and affinity, underscoring the need for
screening campaigns to identify new specific, high affinity modulators.
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Alterations in palmitoylation have been implicated in the etiology of cancer,
cardiovascular disease, and neurological disorders [214, 215]. However, there
are currently no drugs that target palmitoylation and the limited numbers of
inhibitors that do exist exhibit low affinity and lack specificity. 2-BP continues to
be the primary experimental inhibitor of palmitoylation due to the lack of a more
suitable alternative, despite a recent mass spectrometry study where its
preference for palmitoylated substrates or PAT enzymes was not detectable
[206]. Furthermore, 2-BP also inhibits the depalmitoylating thioesterase, APT
[216]. Thus, the need to identify specific, high affinity inhibitors of protein
palmitoylation is critical for the progression of palmitoylation research, and for the
regulation of palmitoylation for therapeutic intervention.
We will be applying the described high-throughput screening technique for
quantifying autopalmitoylation in a screening campaign for inhibitors of
palmitoylation from a unique compound scaffolding chemical library.

This

approach allows us to interrogate millions of compounds with only hundreds of
reactions through positional scanning synthetic combinatorial libraries [147, 235237]. This is a unique and highly efficient means of rapidly acquiring data where
the accuracy for predicting hits and prioritization of compounds is increased due
to the conditional probalistic analysis [236, 237]. Using combinatorial chemistry
to synthesize compound libraries allows for the rapid production, and the
application of “isokinetic mixtures” allows for the production of equimolar mixtures
[235, 238].
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In the present study, we describe the use of this assay for the identification of a
unique class of compounds, based on a bis-cyclic piperazine scaffold, that inhibit
the autopalmitoylation activity of the yeast Ras PAT, Erf2.

4.5

Inhibition of Erf2 Autopalmitoylation using a Fluorescence-based

Coupled Assay
The identification of palmitoylation inhibitors has been hampered by the lack of
assays amenable to high throughout screening applications.

Previously, we

validated an assay that monitors the rate of autopalmitoylation by measuring the
production of CoASH generated from the reduction of palmitoyl-CoA [147]. The
intention of this assay is to couple the amount of CoASH formed (and hence,
enzyme:palmitoyl intermediate formed) to the production of NADH, which is
fluorescent. This assay can be used to monitor autopalmitoylation in real time or
as an end point assay, thus providing flexibility when screening small molecule
compounds.

Compounds with internal fluorescence or that affect the assay

components are easily identified and excluded, allowing for the rapid
identification of the compounds that inhibit or activate PAT autopalmitoylation
activity.
As an initial step in our screening campaign, we interrogated a scaffold ranking
library developed by the Torrey Pines Institute for Molecular Studies [147, 235,
236]. This strategy allows for the evaluation of >30 million synthetic compounds
while screening exponentially fewer reactions (Fig. 4.1A-E). This is achieved by
organizing a large number of chemically diverse compounds into 68 core
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scaffolds. Each scaffold contains between 2,000 to 700,000 unique compounds
at approximately equivalent molar concentrations (Fig. 4.1A). It is predicted that
structural similarities will dictate additive effects increasing the chance that
individual modulators will be detected despite being between nanomolar to subnanomolar concentrations [236, 239]. The vast number of compounds in each
library increases the probability of identifying a compound with useful chemical
characteristics and properties [240] (Fig. 4.1B).

Figure 4.1 highlights a flow

diagram of the stages involved in the identification and optimization of the
compounds. As a first step, we screened compounds representing 68 scaffolds
to determine the optimal scaffold structure. Once we identified a scaffold or
scaffolds, positional scanning libraries, which are organized by R-groups at each
position around a given scaffold, are utilized. This allows for the prediction of
optimal R-groups for each position on the core scaffold (Fig. 4.1C). Based on the
optimized scaffold and knowledge of the active R-groups, individual compounds
can be designed and synthesized to determine the positional effects of the Rgroups on activity (Fig. 4.1D).

Finally, based on the level of inhibition, we

selected a subset of lead compounds for further analysis (Fig. 4.1E). This
approach allows us to expedite the screening process of millions of compounds
and to generate structure-activity relationship (SAR) information early in the
screening process.

A description of the library construction and use can be

found in recent reviews [235, 240-243].
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4.6

Scaffold Ranking of the Erf2 Autopalmitoylation Inhibitors

We screened 68 scaffold ranking samples, each at a concentration of 100 μ
g/ml/scaffold (Fig. 4.2).

Each scaffold sample was pre-incubated with Erf2

enzyme for 10 min at 30˚C before initiating the reaction with the addition of
palmitoyl-CoA. We monitored the production of CoASH for 30 min to ensure a
linear response over time and determined the rate of the reaction for each
scaffold sample. Incubation of the enzyme with several of the scaffold samples
resulted in a reduction in the production of CoASH. As an initial criterion, we
defined inhibition as a reduction in activity greater than three standard deviations
from the mean activity value. We identified eight of the scaffold libraries that fit
this definition. Scaffolds 2103, 2236, 2165, 2220, 1509, 2160, 2228, and 2221
caused at least a 50% reduction in Erf2 autopalmitoylation activity. This is similar
to the level of inhibition (60%) caused by 2-BP at a comparable compound
concentration (100 µM). With the exception of scaffold sample 1509, none of the
samples had an effect on the reaction in the absence of Erf2-Erf4, when 20 μM
CoASH replaced 40 μM Palmitoyl-CoA as substrate (Fig. 4.3). Thus, scaffold
sample 1509 was excluded from further analysis.

The data from two of the

scaffolds, 2165 and 2228, were inconsistent and not reproducible. Therefore,
these scaffolds were also excluded. Finally, we established a baseline of
inhibition using boiled and catalytically inactive enzyme.
We next screened the remaining 5 scaffolds for dose responsiveness at 200 μ
g/ml, 100 μg/ml, and 50 μg/ml (Fig. 4.4A). Similar to the dosage response
observed for 2-BP, three of the five scaffold libraries (2160, 2220 and 2236)
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demonstrated some degree of dosage response at these concentrations.
Interestingly, these three scaffold libraries included a piperazine-analog feature.
Scaffold 2220 is a piperazine, scaffold 2221 is a pyrolidine piperazine, and
scaffold 2160 is a bis-cyclic piperazine (Fig. 4.4B).
Additionally, we want to consider Lipinski’s Rule of 5 [244]. Our lab is not
equipped to calculate the octanol-water partition coefficient, but we can establish
that the scaffolds have less than 5 hydrogen bond donors, 10 hydrogen bond
acceptors, and a molecular mass less than or equal to 500 g/mol. Scaffold 2103,
a dithiazole, only has one hydrogen bond donor and four hydrogen bond
acceptors with a molecular weight of ~252 g/mol. Scaffold 2236, a bis-cyclic
lipopeptide, has 13 hydrogen bond donors and 21 hydrogen bond acceptors, with
a molecular weight of ~1621 g/mol. Scaffold 2220 only has one hydrogen bond
donor and two hydrogen bond acceptors with a molecular weight of ~86 g/mol.
Scaffold 2160 only has one hydrogen bond donor and four hydrogen bond
acceptors with a molecular weight of ~250 g/mol. Scaffold 2221 only has one
hydrogen bond donor and three hydrogen bond acceptors with a molecular
weight of ~181 g/mol. Therefore, scaffold 2236 would not be an ideal candidate
for therapeutic intervention as it is unlikely to be absorbed, distributed,
metabolized, or excreted efficiently according to Lipinski’s Rule of 5 [244].
Conversely, the other four lead scaffolds, without consideration of their side
groups, fall well within the limits of the Rule of 5.
Of these, scaffold 2160 reproducibly decreased PAT activity in a dose dependent
fashion to the greatest extent. Structurally, scaffold 2160 has a core bis-cyclic
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piperazine with three R-groups, and a total diversity of 45864 compounds (Fig.
4.1C).
The 45864 compounds in scaffold 2160 were synthesized into 110 mixture
samples organized by R-group to optimize activity (Fig. 4.1C). At position R1
and R3 there were 42 carboxylic acids (samples 2160.001-2160.042 and
2160.069-2160.110, respectively), and 26 amino acids at the R2 position
(samples 2160.043-2160.068). Thus, samples organized by R1 or R3 positions
contain 1092 (42 x 26) compounds per sample, and samples organized by the
R2 position contain 1764 (42 x 42) compounds per sample.
The 110 samples were screened for inhibitory effects on Erf2 autopalmitoylation
in the fluorescence-coupled assay at 100 μg/ml. Most had mild to no effect on
Erf2 autopalmitoylation as represented by a yellowish-orange color designation in
Tables 4.1, 4.2, and 4.3. Others resulted in a greater percent reduction of Erf2
autopalmitoylation as represented by darker shades of green in Tables 4.1, 4.2,
and 4.3. A cutoff for hits was set at 25% reduction in Erf2 autopalmitoylation.
There were six functional groups at position R1 that resulted in a greater than
25% reduction of Erf2 autopalmitoylation (Table 4.1). Of those, the functionalities
from samples 2160.001, 2160.014, 2160.016, and 2160.038 were selected for
design of individual compounds. There were three consistent functional groups
at the R2 position that reduced Erf2 autopalmitoylation by at least 25%;
2160.051, 2160.065, and 2160.066 (Table 4.2).

The functionality for sample

2160.060 was also included for design of individual compounds despite only
resulting in a 24% decrease in Erf2 autopalmitoylation.
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Three functionalities

were selected that resulted in a greater than 25% decrease in Erf2
autopalmitoylation at the R3 position; 2160.082, 2160.084, and 2160.108 (Table
4.3). Thus, the four functionalities at position R1, four functionalities at position
R2, and three functionalities at position R3 were combined for a total diversity of
48 individual compounds.

4.7

Individual

Compounds

Screened

for

Inhibition

of

Erf2

Autopalmitoylation
The 48 compounds were screened with five of the positional scanning samples
(2160.066, 2160.082, 2160.001, 2160.065, and 2160.108) and the complete
2160-scaffold sample (Fig. 4.5). Scaffold 2160 and positional scanning samples
inhibited Erf2 autopalmitoylation consistent with prior screens and demonstrated
that as the complexity decreased from 45864 compounds (scaffold 2160), to
1000-2000
compounds,

compounds
there

was

(positional
a

scanning),

concomitant

and

increase

finally,

to

in

inhibition

the

individual
of

autopalmitoylation (Fig. 4.5). As an additional control, we included non-optimized
compounds (compounds 49-54), which were designed with side groups that did
not pass the original cutoff in the positional scanning screen. These compounds,
as anticipated, demonstrated poor inhibition of Erf2 autopalmitoylation in
comparison to the compounds whose design was based on the positional
scanning results. From this screen the top ten compounds were selected for
further examination; 13, 14, 19, 22, 25, 27, 28, 30, 34, 43.

The top ten

compounds were purified, and then screened for dose responsiveness on the
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fluorescence-based coupled assay (Fig. 4.6).

All ten purified compounds

demonstrated a dose-responsiveness effect on Erf2 autopalmitoylation, and
inhibited to a similar degree or better than 2-BP at the same doses.

We

determined the inhibition constant (Ki) for the ten compounds by determining the
rate of autopalmitoylation activity for varying amounts of inhibitor compound. The
autopalmitoylation inhibition constants ranged from ~63-142 µM for the ten
compounds identified in this study, and 59 μM for 2-BP (Fig. 4.7, right panel).
There did not appear to be a preference within the top 40 compounds for the R2
position amongst the four possibilities; hydroxybenzyl, phenyl, and (L or D)
naphthymethyl groups (Fig. 4.7). There were three possibilities at the R3
position, and it was at this position that the greatest preference was observed. 2(4-isobutyl-phenyl)-propyl was the optimal group at this position and is present in
seven of the top ten hits.

2-(3,5-bis-trifluoromethyl-phenyl)-ethyl is the most

prevalent in the next 15, and the completely aliphatic functional group,
adamantan-1-yl-methyl, is in this position for a majority of the remaining top 40
individual compounds. The R1 position also showed similar specificity for the
functional groups utilized in the individual compounds. At the R1 position, nearly
all of the top 30 compounds have either 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl or
2-(4-isobutyl-phenyl)-propyl, the same top two groups for the R3 position. A
>50% reduction in Erf2 autopalmitoylation was observed for most of the
optimized individual compounds, but only the top ten were selected for additional
analysis.
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To determine if the ten compounds identified in this study were inhibiting
autopalmitoylation, and not targeting hydrolysis of the enzyme, steady-state
autopalmitoylation was evaluated at 100 μM of each compound compared to
100 μM 2-BP and DMF (vehicle) alone. This was performed in a gel-based
reaction using BODIPY®-C12-CoA [40]. The reactions were separated by SDSPAGE and steady-state autopalmitoylation was determined by the relative
BODIPY® fluorophore that co-migrated with Erf2, demonstrating that Erf2 was
acylated by BODIPY®-C12 [40]. At 100 μM, the ten compounds each resulted
in a 50% or greater decrease in steady-state Erf2 autopalmitoylation compared to
vehicle alone. All of the compounds inhibited autopalmitoylation to either an
equal or greater extent compared to 2-BP (Fig. 4.8). Dose response curves of
steady-state autopalmitoylation activity were examined to determine the Ki for
each compound (Fig. 4.9).

The steady-state autopalmitoylation inhibition

constants ranged from ~34-72 µM for the ten compounds identified in this study,
and 79 μM for 2-BP (Fig. 4.7, right panel).

4.8

The Mode of Erf2 Autopalmitoylation Inhibition by Compounds 13

and 25 is Different than 2-BP
We selected compounds 13 and 25 for further analysis, based on our screening
results and criteria for inhibition.

To elucidate if these compounds are

mechanistically different from 2-BP, we approached the analysis of the reaction
using Michaelis-Menten kinetics by varying the amount of compound 13 (or
compound

25)

and

palmitoyl-CoA.

Unfortunately,
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the

critical

micelle

concentration is between 40 µM and 80 µM for palmitoyl-CoA limiting the ability
to screen concentrations of palmitoyl-CoA higher than 80 µM due to poor
solubility [245-247]. For both compounds 13 and 25, we observed that addition
of increasing concentrations of inhibitor compound increased the KM (palmitoylCoA) of the reaction while having little effect on the Vmax, thus suggesting that
compounds 13 and 25 act through predominantly a competitive inhibition
mechanism (Fig. 4.10). The KM and Vmax values calculated are summarized in
Table 4.4.

The limitation to the concentration of palmitoyl-CoA limited the

reaction in that it is possible that the activity could increase more at higher
substrate concentrations. Thus, the calculated KM and Vmax values may not be
completely accurate, and the mode of inhibition cannot be accurately determined.
The mode of inhibition was also explored for effects on steady-state
autopalmitoylation using the gel-based orthogonal assay. Compound 13 exhibits
a greater dosage response for Erf2 autopalmitoylation inhibition at lower
BODIPY®-C12-CoA concentrations rather than at higher BODIPY®-C12-CoA
concentrations, further supporting that compound 13 is acting competitively with
BODIPY®-C12-CoA (Fig. 4.11). Conversely, 2-BP has been previously
demonstrated as an uncompetitive or mixed inhibitor of Erf2 autopalmitoylation
[147], demonstrating that compounds 13 and 25 utilize a different inhibitory
mechanism compared to 2-BP.

Thus, we have identified a new class of

palmitoylation inhibitors that are structurally distinct and utilize a mode of action
different from the most used palmitoylation inhibitor, 2-BP.
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4.9

Inhibition of Ras2-dependent Growth in a Palmitoylation-sensitive

Saccharomyces cerevisiae Strain
To examine the inhibition of Ras palmitoylation in vivo, we utilized a strain of S.
cerevisiae we developed that requires Ras2 palmitoylation for viability [34]. The
RJY1942 (palmitoylation sensitive strain) was grown in the presence (or
absence) of our inhibitor candidates and the growth monitored every 30 min for
24 hrs compared to an isogenic wild type control strain (RJY1941) (Fig. 4.12A).
EC50 values were calculated using Prism 6 (GraphPad Software, San Diego, CA)
to extrapolate the effective concentration of each inhibitor that caused a 50%
reduction in growth. The ten compounds identified in this study have EC50 values
ranging from 2 μM to an EC50 value of 7.5 μM in the sensitive strain, compared
to 12.5 μM for 2-BP in the sensitive strain (Fig. 4.12B). These data demonstrate
that a) these compounds are able to permeate the yeast cell wall to exert their
effects and b) these compounds inhibit at a lower concentration than that of 2BP. Compounds 13, 25, and 2-BP show a modest selectivity for the sensitive
strain, RJY1942, over the control strain, RJY1941, resulting in a 2-fold greater
EC50 value in the control strain as compared to the sensitive strain (Fig. 4.12B,
values listed in Fig. 4.7, right panel).
We next compared the ability of Compounds 13, 14, 25 to inhibit growth of the
Ras-dependent palmitoylation strain compared to an isogenic wild type strain.
Serial dilutions of RJY1941 (control) and RJY1942 (sensitized) were spotted on
agar plates following incubation for 24 hrs with varying inhibitor concentrations.
Compounds 13, 25, and 14 completely inhibited growth of RJY1941 (control) at
100

20 µM, but had no detectable effect at lower concentrations.

Conversely,

compound 13 inhibited (100%) the growth of the sensitized strain at 5 µM.
Compound 25 also inhibited at 5 μM, albeit at approximately 90% of that
observed for compound 13 for the sensitized strain. Compound 14 demonstrated
partial inhibition (approximately 10%) at 5 µM, however, total inhibition could be
observed for the sensitized strain at higher inhibitor concentrations. 2-BP did not
inhibit at the dose range screened, most likely due to poor permeability of 2-BP in
yeast (Fig. 4.13).

The remaining compounds were similarly selective to

compounds 13, 14, and 25, with the exception of compound 19. Compound 19
partially inhibited (approximately 25%) the growth of RJY1941 (control) at 20 μ
M, but also only partially inhibited (approximately 10%) the growth of RJY1942
(sensitized) at 20 μM, suggesting a mild selection for sensitized over control, but
not to the same degree as the other compounds. Interestingly, Compounds 13,
14, and 25 have the same functional group at the R2 position, but differ at their
R1 and R3 positions. Compound 13 has 2-(4-Isobutyl-phenyl)-propyl on both the
R1 and R3 positions. Compound 14 has the same functional group on position
R1,

but

has

2-(3,5-bis-trifluoromethyl-phenyl)-ethyl

on

the

R3

position.

Compound 25 has the same functional groups as Compound 14, but has 2-(3,5bis-trifluoromethyl-phenyl)-ethyl on the R1 position, and 2-(4-Isobutyl-phenyl)propyl on the R3 position (Fig. 4.7). Further SAR studies and compound design
will be necessary to increase the sensitivity and selectivity of these compounds.
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4.10

Discussion

Protein palmitoylation is a posttranslational modification that regulates the
subcellular localization and activity of a diverse set of signaling and structural
proteins. Dysregulation of protein palmitoylation has been linked to a number of
diseases. Examples include up-regulation of zDHHC9 in colorectal cancer [90]
and down-regulation of zDHHC9 in leukemogenesis [248]; zDHHC3/GODZ is
linked to cervical cancer [125]; and zDHHC2 mutations have been found in
several colorectal cancers [84]. The importance of palmitoylation in physiology
and pathophysiology suggests that modulators of catalyzed palmitoyl transfer
may play a role in disease treatment. The availability of protein acyl transferase
(PAT) inhibitors is very limited.

2-Bromo-palmitate (2-BP), cerulenin, and

tunicamycin have been reported to inhibit palmitoylation [201, 203, 223, 249], but
2-BP is now known to be highly promiscuous, with no preference for CoAdependent enzymes, including zDHHC PATs [206].

Similarly, cerulenin and

tunicamycin inhibit palmitoylation within cells but also inhibit other cellular
process including fatty acid synthesis [250] and N-glycosylation [251],
respectively.

In addition, there are few assays available that can measure

palmitoylation [147, 149] in a high throughput platform. There is therefore an
urgent need to establish methods to identify small molecule PAT inhibitors for
use in vitro and in vivo.
The current failure to find the desired high affinity, specific inhibitors is due to
difficulties purifying biochemical quantities of PATs, limited information on the
enzymatic mechanism, and the lack of a 3D crystal structure.
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We have

developed methods to purify stable, active zDHHC PATs, along with a validated
HTS method to identify inhibitors. We have approached the search for chemical
modulators of PAT enzymes by developing several innovative protocols. First,
we have developed a system for the expression and purification of the zDHHC
proteins. Secondly, we have developed and validated a simple, coupled
fluorescence assay that allows us to screen for inhibitors of enzyme
autopalmitoylation in an HTS platform.

Thirdly, we have developed counter

screens, orthogonal and cell-based assays, to characterize and analyze
candidate inhibitors. With these tools in hand we are able to identify compounds
that regulate Erf2 and establish a methodology to identify modulators of other
zDHHC PATs as well.
Through the use of a scaffold ranking approach to screen for novel inhibitors of
Erf2 autopalmitoylation, we have identified a group of inhibitors based on the biscyclic piperazine backbone. This is the first time piperazines have been shown to
modulate palmitoylation, but their analogues have already been demonstrated to
be effective drug-like compounds. Piperazine analogs are currently being used
as pharmaceutical modulators of GPCR activity and piperazine-like compounds
and analogs are currently being used as pharmaceuticals to treat cancer,
behavioral disorders, and insomnia (e.g.,imatinib, quetiapine, and eszopiclone)
[252-254]. It has not yet been determined if the compounds identified in this
study inhibit Erf2 specifically. They could be pan-palmitoylation inhibitors that
alter the activity of other zDHHC PATs, but they could also lack in specificity like
2-BP. As they were identified in a purified system and lack sequence similarity to
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palmitoyl-CoA, it is predicted that they will not suffer the same degree of a lack in
specificity as 2-BP, but it has yet to be established if they modulate other zDHHC
PATs. To further explore their specificity for use as modulators of palmitoylation,
there is ongoing work to address any inhibitor:enzyme specificity issues by
establishing if the inhibitors identified in this study act specifically on Erf2dependent palmitoylation, or if they act on one or more of the other PAT
enzymes.

Further screens in the fluorescent-based couple assay with other

zDHHC PATs will be needed to validate these compounds as pan inhibitors of
palmitoylation, which could still be used as probes to further understand the field
of palmitoylation and would be beneficial over 2-BP due to the extent of nonspecific inhibition that occurs with the use of 2-BP.

If it is found that these

compounds are specific inhibitors of Erf2 and its human homolog, zDHHC9, then
they could lead to anti-cancer drug therapy interventions. Understanding how
the different functional groups lend to their activity and specificity is key to further
optimize these compounds. The compounds best align with the Ki and EC50
values from the respective screens when they were organized by the R3 position
with consideration of the R1 and R2 positions (Fig. 4.7). Of the functionalities
used at the R1 and R3 positions both 2-(4-Isobutyl-phenyl)-propyl and 2-(3,5-bistrifluoromethyl-phenyl)-ethyl seemed to be the most preferential for both
positions. This, along with the apparent symmetry of bis-piperazine, suggests
that perhaps these compounds can act as symmetrical entities. The lack of
preference, other than for an aromatic group, in the R2 position supports this
notion. Overall, we have identified a novel class of bis-cyclic piperazines that
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inhibit Erf2 autopalmitoylation to a greater extent than 2-BP in our fluorescencebased coupled assay, orthogonal gel-based assay and cell growth assay by
selectively inhibit palmitoylation in vitro at low μM concentrations and reducing
the Ras2 palmitoylation-dependent growth rate of S. cerevisiae in vivo.

4.11

Experimental Procedures

Synthesis of Library 2160 and Individual Compounds and Construction of
Scaffold Ranking Plate- General Synthesis of bis-cyclic piperazine (Fig. 4.14):
Library 2160 as well as the individual compounds reported herein (Compounds
1-54) were synthesized following the same synthetic scheme (Fig. 4.14) [255,
256].

Utilizing

the

“tea-bag”

methodology

[257],

100

mg

of

p-

methylbenzhydrylamine (MBHA) resin (1.1 mmol/g, 100-200 mesh) was sealed in
a mesh “tea-bag”, neutralized with 5% diisopropylethylamine (DIEA) in
dichloromethane (DCM) and subsequently swelled with additional DCM washes.
Fmoc-L-Lys(Boc)-OH was coupled in Dimethylformamide (0.1M DMF) for 120
mins in the presence of Diisopropylcarbodiimide (DIC, 6 equiv.) and 1Hydroxybenzotriazole hydrate (HOBt, 6 equiv.) (Fig. 4.14, Step 1). The Fmoc
protecting group was removed with 20% piperidine in DMF for 20 mins and the
R1 carboxylic acids was coupled (10 equiv.) in the presence of DIC (10 equiv.)
and HOBt (10 equiv.) in DMF (0.1 M) for 120 mins (Fig. 4.14, Step 2). The Boc
protecting group was then removed with Trifluoroacetic Acid (TFA) in DCM for 30
mins and subsequently neutralized with 5% DIEA/DCM (3x). Boc-Amino Acids
(R2) were coupled utilizing standard coupling procedures (6 equiv.) with DIC (6
105

equiv.) and HOBt (6 equiv.) in DMF (0.1 M) for 120 mins. The Boc group was
removed with 55% TFA/DCM for 30 mins and subsequently neutralized with 5%
DIEA/DCM (3x).

Carboxylic acids (R3) were coupled using (10 equiv.) in the

presence of DIC (10 equiv.) and HOBt (10 equiv.) in DMF (0.1 M) for 120 mins
(Fig. 4.14, Step 3). All coupling reactions were monitored for completion using
Ninhydrin. The reduction was performed in a 4000 mL Wilmad LabGlass vessel
under nitrogen. 1.0 M Tetrahydrofuran (THF) borane complex solution was used
in 40-fold excess for each amide bond. The vessel was heated to 65°C and
maintained at this temperature for 96 hrs. The solution was then removed and
the bags were washed with THF and methanol (MeOH). Once completely dry,
the bags were treated overnight with piperidine at 65°C and washed several
times with DMF, DCM and methanol (Fig. 4.14, Step 4). As previously reported
by our group and others, the reduction of polyamides with borane is free of
racemization [258-260].

Before proceeding, completion of reduction was

monitored by LCMS analysis of a control compound (Fig. 4.14, Step 4) that was
cleaved from the solid support (HF, anisole, 0°C 7 hr).

Cyclization was

performed with a 5-fold excess (for each cyclization) of oxalyldiimidazole in a 0.1
M anhydrous DMF solution overnight. Following the cyclization, the bags were
rinsed with DMF and DCM and the resulting diketopiperarzines were reduced
down to their corresponding piperazines (Fig. 4.14, Step 5) using the same
borane reduction procedure as above. The resin was cleaved with HF in the
presence of anisole in an ice bath at 0°C for 7 hours (Fig. 4.14, Step 6). After
removal of the HF by gaseous N2, the products were then extracted from the
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vessels with 95% acetic acid in water, transferred to scintillation vials, frozen and
lyophilized.

The compounds were then reconstituted in 50% acetonitrile and

water, frozen and lyophilized three more times. For initial screening (Fig. 4.4) the
individual compounds were tested as crude material in case the activity is driven
by some side reaction that was also present in the original positional scanning
library. After this initial screening, compounds, 13, 14, 19, 22, 25, 27, 28, 30, 34,
and 43 were selected for purification and NMR characterization; all data reported
in Figures 4.6-4.9 are from the purified stock of these compounds.
LCMS analysis- The purity and identity of all compounds was verified using a
Shimadzu 2010 LCMS system, consisting of a LC-20AD binary solvent pump, a
DGU-20A degasser unit, a CTO-20A column oven, and a SIL-20A HT
autosampler. A Shimadzu SPD-M20A diode array detector was used for
detection. A full spectra range of 190-600 nm was obtained during analysis.
Chromatographic separations were obtained using a Phenomenex Luna C18
analytical column (5 µm, 50 x 4.6 mm i.d.) preceded by a Phenomenex C18
column guard (5 µm, 4 x 3.0 mm i.d.). All equipment was controlled and
integrated by Shimadzu LCMS solutions software version 3. Mobile phases for
LCMS analysis were HPLC grade or LCMS grade obtained from Sigma Aldrich
and Fisher Scientific. The mobile phases consisted of a mixture LCMS grade
Acetonitrile /water (both with 0.1% formic acid for a pH of 2.7). The initial setting
for analysis was set at 5% Acetonitrile (v/v), then was linearly increased to 95%
Acetonitrile over 6 mins. The gradient was then held at 95% Acetonitrile for 2
mins, linearly decreased to 5% over 0.10 mins and held for an additional 1.90
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mins. The total run time was equal to 12 mins. The total flow rate was set to 0.5
mL/minute. The column oven and flow cell temperature for the diode array
detector was set at 30°C. The autosampler temperature was held at 15°C. 5 μl
of compound was injected for analysis.
HPLC Purification (Compounds 13, 14, 19, 22, 25, 27, 28, 30, 34, and 43)- All
purifications were performed on a Shimadzu Prominence preparative HPLC
system, consisting of LC-8A binary solvent pump, a SCL-10A system controller,
a SIL-10AP autosampler, and a FRC-10A fraction collector. A Shimadzu SPD20A UV detector was used for detection. The wavelength was set at 214 nm
during

analysis.

Chromatographic

separations

were

obtained

using

a

Phenomenex Luna C18 preparative column (5 µm, 150 x 21.5 mm i.d.) preceded
by a Phenomenex C18 column guard (5 µm, 15 x 21.2 mm i.d.). Prominence
prep software was used to set all detection and collection parameters. The
mobile phases for HPLC purification were HPLC grade obtained from Sigma
Aldrich and Fisher Scientific. The mobile phase consisted of a mixture of
Acetonitrile/water (both with 0.1% formic acid). The initial setting for separation
was set at 2% (v/v) Acetonitrile, which was held for 2 mins and the gradient was
linearly increased to 20% (v/v) Acetonitrile over 4 mins. The gradient was then
linearly increased to 55% (v/v) Acetonitrile over 36 mins. The HPLC system was
set to automatically flush and re-equilibrate the column after each run for a total
of 4 column volumes. The total flow rate was set to 12 mL/min and the total
injection volume was set to 3900 μl. The fraction collector was set to collect from
6 to 40 mins. The corresponding fractions were then combined and lyophilized.
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NMR analysis of purified compounds- The 1H spectra were obtained utilizing the
Bruker 400 Ascend (400 MHz). NMR chemical shifts were reported in δ (ppm)
using the δ 7.26 signal of CDCl3 (1H NMR).
4-(((2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol
(Compound 13)- Using the synthetic approach described in Figure 4.14 for the
synthesis of compound 13 was synthesized using the following reagents: 4Isobutyl-alpha-methylphenylacetic acid (R1), Boc-L-Tyrosine(BrZ) (R2), 4Isobutyl-alpha-methylphenylacetic acid (R3). Final crude product was purified by
HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.28
(br. s., 1 H) 7.08 - 7.16 (m, 4 H) 7.05 (br. s., 4 H) 6.92 (br. s., 2 H) 6.80 (br. s., 3
H) 2.98 (br. s., 8 H) 2.64 - 2.84 (m, 5 H) 2.58 (br. s., 4 H) 2.45 (t, J=8.01 Hz, 6 H)
2.32 (d, J=16.26 Hz, 2 H) 2.01 (br. s., 1 H) 1.86 (d, J=6.60 Hz, 2 H) 1.52 (br. s., 1
H) 1.42 (br. s., 1 H) 1.36 (br. s., 1 H) 1.30 (br. s., 3 H) 1.12 - 1.26 (m, 4 H) 1.01
(br. s., 1 H) 0.91 (br. s., 12 H). LCMS (ESI+) Calcd for C45H68N4O: 681.54,
found [M+H]+:681.25.
4-(((2S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((2S)-1-(2-(4isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol
(Compound 14)- Using the synthetic approach described in Figure 4.14 for the
synthesis of compound 14 was synthesized using the following reagents: 4Isobutyl-alpha-methylphenylacetic acid (R1), Boc-L-Tyrosine(BrZ) (R2), 3,5Bis(Trifluoromethyl)-Phenylacetic Acid (R3). Final crude product was purified by
HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.75
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(br. s., 1 H) 7.65 (br. s., 3 H) 7.28 (s, 1 H) 7.00 - 7.08 (m, 4 H) 6.95 (br. s., 2 H)
6.81 (br. s., 3 H) 3.07 (br. s., 5 H) 2.93 (br. s., 5 H) 2.76 (br. s., 4 H) 2.65 (br. s., 4
H) 2.43 (d, J=6.36 Hz, 4 H) 2.36 (br. s., 2 H) 2.19 (br. s., 1 H) 2.01 (br. s., 1 H)
1.84 (br. s., 1 H) 1.47 (br. s., 2 H) 1.39 (br. s., 1 H) 1.27 (br. s., 1 H) 1.22 (br. s., 3
H) 1.05 (br. s., 1 H) 0.90 (d, J=5.50 Hz, 6 H). LCMS (ESI+) Calcd for
C42H56F6N4O: 747.44, found [M+H]+:747.20.
(2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine
(Compound 19)- Using the synthetic approach described in Figure 4.14 for the
synthesis of compound 19 was synthesized using the following reagents: 4Isobutyl-alpha-methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2),
4-Isobutyl-alpha-methylphenylacetic acid (R3). Final crude product was purified
by HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm
7.78 (d, J=9.05 Hz, 3 H) 7.61 (br. s., 1 H) 7.44 (br. s., 2 H) 7.29 (br. s., 1 H) 6.99 7.20 (m, 7 H) 4.16 (br. s., 1 H) 3.09 - 3.34 (m, 1 H) 3.00 (d, J=12.59 Hz, 3 H) 2.91
(br. s., 2 H) 2.84 (br. s., 2 H) 2.78 (br.s., 2 H) 2.58 (d, J=12.84 Hz, 2 H) 2.45 (dd,
J=15.89, 6.72 Hz, 7 H) 2.28 (br. s., 3 H) 2.20 (br. s., 2 H) 1.97 (br. s., 1 H) 1.86
(dd, J=13.08, 6.85Hz, 2 H) 1.60 (br. s., 1 H) 1.18 - 1.46 (m, 9 H) 1.15 (br. s., 2 H)
0.70 - 0.95 (m, 12 H). LCMS (ESI+) Calcd for C49H70N4: 715.56, found
[M+H]+:715.30.
(2R)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine
(Compound 22)- Using the synthetic approach described in Figure 4.14 for the
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synthesis of compound 22 was synthesized using the following reagents: 4Isobutyl-alpha-methylphenylacetic acid (R1), Boc-L-Tyrosine(BrZ) (R2), 4Isobutyl-alpha-methylphenylacetic acid (R3). Final crude product was purified by
HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.71
- 7.85 (m, 3 H) 7.60 (br. s., 1 H) 7.44 (br. s., 2 H) 7.28 - 7.35 (m, 1 H) 7.01 - 7.26
(m, 8 H) 3.19 (d, J=10.15 Hz, 1 H) 2.94 - 3.07 (m, 3 H) 2.89 (d, J=9.66 Hz, 3 H)
2.82 (br. s., 3 H) 2.60 - 2.74 (m, 2 H) 2.55 (br. s., 1 H) 2.24 - 2.50 (m, 10 H) 2.19
(br. s., 2 H) 1.97 (br. s., 1 H) 1.74 - 1.92 (m, 2 H) 1.34 (d, J=8.68 Hz, 7 H) 1.22
(br. s., 3 H) 1.13 (br. s., 2 H) 0.91 (br. s., 13 H). LCMS (ESI+) Calcd for
C49H70N4: 715.56, found [M+H]+:715.20.
4-(((2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2(4-isobutylphenyl)propyl)piperazin-2-yl)methyl)phenol (Compound 25)- Using the
synthetic approach described in Figure 4.14 for the synthesis of compound 25
was

synthesized

Phenylacetic

Acid

using

the

(R1),

methylphenylacetic acid (R3).

following

reagents:

Boc-L-Tyrosine(BrZ)

3,5-Bis(Trifluoromethyl)(R2),

4-Isobutyl-alpha-

Final crude product was purified by HPLC as

described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.74 (br. s., 2
H) 7.62 (br. s.,1 H) 7.29 (s, 2 H) 7.07 - 7.26 (m, 4 H) 6.93 (s, 1 H) 6.96 (s, 1 H)
6.82 (d, J=6.97 Hz, 2 H) 3.19 (br. s., 2 H) 3.10 (br. s., 2 H) 3.00 (br. s., 5 H) 2.84
(br. s., 5 H) 2.70 (br. s., 4 H) 2.62 (br. s., 3 H) 2.46 (d, J=6.60 Hz, 3 H) 2.19 (br.
s., 1 H) 2.02 (br. s., 1 H) 1.86 (br. s., 1 H) 1.56 (br. s., 1 H) 1.43 (br. s., 2H) 1.30
(br. s., 3 H) 1.17 (d, J=6.24 Hz, 1 H) 1.10 (br. s., 2 H) 0.91 (d, J=6.11 Hz, 6 H).
LCMS (ESI+) Calcd for C42H56F6N4O: 747.44, found [M+H]+:747.10.
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4-(((S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol
(Compound 27)- Using the synthetic approach described in Figure 4.14 for the
synthesis of compound 27 was synthesized using the following reagents: 3,5Bis(Trifluoromethyl)-Phenylacetic Acid (R1), Boc-L-Tyrosine(BrZ) (R2), 1Adamantanecarboxylic Acid (R3). Final crude product was purified by HPLC as
described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 8.44 (br. s.,
1H) 8.05 (br. s., 1 H) 7.96 (br. s., 1 H) 7.83 (br. s., 1 H) 7.73 (br. s., 1 H) 7.63 (br.
s., 2 H) 7.28 (s, 1 H) 7.00 (br. s., 2 H) 6.83 (d,J=6.48 Hz, 2 H) 3.17 (br. s., 1 H)
2.91 - 3.13 (m, 5 H) 2.84 (br. s., 5 H) 2.54 - 2.77 (m, 7 H) 2.40 (br. s., 2 H) 2.10
(br. s., 1 H) 1.99 (d, J=6.36 Hz, 4 H) 1.69 - 1.85 (m, 3 H) 1.64 (d, J=11.37 Hz, 4
H) 1.50 (br. s., 8 H) 1.28 (br. s., 1 H) 1.13 (br. s., 2 H). LCMS (ESI+) Calcd for
C40H54F6N4O: 721.42, found [M+H]+:721.15.
(2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4isobutylphenyl)propyl)-2-phenylpiperazine (Compound 28)- Using the synthetic
approach described in Figure 4.14 for the synthesis of

compound 28 was

synthesized using the following reagents: 3,5-Bis(Trifluoromethyl)-Phenylacetic
Acid (R1), Boc-L-Phenylglycine (R2), 4-Isobutyl-alpha-methylphenylacetic acid
(R3). Final crude product was purified by HPLC as described above. 1H NMR
(400 MHz, CHLOROFORM-d): δ ppm 7.74 (br. s., 1 H) 7.65 (br. s., 2 H) 7.28 7.40 (m, 2 H) 7.12 - 7.26 (m, 2 H) 6.85 - 7.07 (m, 5 H) 3.43 - 3.66 (m, 1 H) 3.36
(br. s., 1 H) 3.30 (d, J=7.58 Hz, 1 H) 3.22 (d, J=11.37 Hz, 1 H) 3.15 (br. s., 1 H)
3.02 (br. s., 2 H) 2.83 - 2.96 (m, 6 H) 2.78 (d, J=11.37 Hz, 1 H) 2.53 - 2.72 (m, 2
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H) 2.36 - 2.52 (m, 4 H) 2.26 - 2.36 (m, 3 H) 2.21 (br. s., 1 H) 1.98 - 2.16 (m, 2 H)
1.76 - 1.96 (m, 2 H) 1.48 (br. s., 3 H) 1.36 (br. s., 1 H) 1.27 (br. s., 1 H) 1.20 (d,
J=6.24 Hz, 2 H) 1.08 (d, J=6.24 Hz, 2 H) 0.96 (d, J=5.99 Hz, 3 H) 0.88 (d, J=6.11
Hz, 3 H). LCMS (ESI+) Calcd for C41H54F6N4: 717.43, found [M+H]+:17.15.
(S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound
30)- Using the synthetic approach described in Figure 4.14 for the synthesis of
compound

30

was

synthesized

using

the

following

reagents:

3,5-

Bis(Trifluoromethyl)-Phenylacetic Acid (R1), Boc-L-Phenylglycine (R2), 1Adamantanecarboxylic Acid (R3). Final crude product was purified by HPLC as
described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.74 (br. s., 1
H) 7.66 (br. s., 2 H) 7.35 (br. s., 2 H) 7.28 - 7.32 (m, 2 H) 3.49 - 3.76 (m, 3 H)
3.34 - 3.49 (m, 1 H) 3.15 - 3.33 (m, 2 H) 3.03 (d, J=10.64 Hz, 2 H) 2.78 - 2.96 (m,
6 H) 2.59 - 2.73 (m, 2 H) 2.48 - 2.58 (m, 1 H) 2.45 (br. s., 1 H) 2.28 - 2.43 (m, 4
H) 2.20 (t, J=9.90 Hz, 1 H) 2.10 (d, J=13.57 Hz, 1 H) 2.01 (br. s., 1 H) 1.87 (br.
s., 3 H) 1.71 (br. s., 1 H) 1.64 (d, J=11.98 Hz, 3 H) 1.55 (d, J=12.10 Hz, 4 H) 1.35
- 1.51 (m, 6 H) 1.25 (s, 3 H) 1.23 (s, 2 H). LCMS (ESI+) Calcd for C39H52F6N4:
691.41, found [M+H]+:691.10.
(2R)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine

(Compound

34)-

Using the synthetic approach described in Figure 4.14 for the synthesis of
compound

34

was

synthesized

using

the

following

reagents:

3,5-

Bis(Trifluoromethyl)-Phenylacetic Acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2),
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4-Isobutyl-alpha-methylphenylacetic acid (R3). Final crude product was purified
by HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm
7.71 - 7.82 (m, 4 H) 7.59 (s, 1 H) 7.63 (s, 2 H) 7.43 (br. s., 2 H) 7.28 (br. s., 1 H)
7.07 - 7.20 (m, 4 H) 3.54 (br. s., 2 H) 3.33 (br. s., 1 H) 3.19 (d, J=10.64 Hz, 1 H)
3.01 (br. s., 3 H) 2.89 (br. s., 4 H) 2.83 (br. s., 4 H) 2.61 (br. s., 2 H) 2.56 (br. s., 2
H) 2.40 - 2.52 (m, 5 H) 2.36 (br. s., 1 H) 2.26 (br. s., 1 H) 2.19 (br. s., 2 H) 1.88
(d, J=5.99 Hz, 1 H) 1.39 (br. s., 3 H) 1.27 - 1.37 (m, 4 H) 1.23 (br. s., 1 H) 1.16
(br. s., 1 H) 0.92 (br. s., 6 H). LCMS (ESI+) Calcd for C46H58F6N4: 781.46,
found [M+H]+:781.15.
(2S)-4-(4-((S)-1-((4-(tert-butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-1-(2-(4isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine

(Compound

43)-

Using the synthetic approach described in Figure 4.14 for the synthesis of
compound 43 was synthesized using the following reagents: 4-tert-ButylCyclohexanecarboxylic Acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 4-Isobutylalpha-methylphenylacetic acid (R3). Final crude product was purified by HPLC
as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.71 - 7.84
(m, 3 H) 7.60 (br. s., 1 H) 7.45 (br. s., 2 H) 7.29 (br. s., 1 H) 7.02 - 7.26 (m, 4 H)
3.18 (d, J=9.54 Hz, 1 H) 3.04 (br. s., 2 H) 2.97 (br. s., 2 H) 2.91 (br. s., 3 H) 2.83
(br. s., 1 H) 2.73 (d, J=9.54 Hz, 2 H) 2.52 - 2.67 (m, 2 H) 2.48 (br. s., 3 H) 2.41
(br. s., 2 H) 2.31 (br. s., 2 H) 2.22 (br. s., 2 H) 1.91 - 2.09 (m, 2 H) 1.88 (d, J=7.34
Hz, 1 H) 1.75 (d, J=13.94 Hz, 2 H) 1.60 (d, J=13.20 Hz, 1 H) 1.50 (br. s., 3 H)
1.43 (br. s., 3 H) 1.26 - 1.38 (m, 5 H) 1.21 (br. s., 2 H) 0.89 - 1.06 (m, 9 H) 0.65 -
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0.89 (m, 10 H). LCMS (ESI+) Calcd for C47H72N4: 694.58, found
[M+H]+:694.40.
Strains, media, and yeast techniques- Yeast growth media were prepared as
described previously [207]. Cells were grown in synthetic complete (SC) medium
or YPD (1% yeast extract, 2% peptone, and 2% glucose) medium [207].
Induction of GAL1, 10 promoters were achieved by adding 4% galactose to SC
medium.

Yeast transformations were performed using the lithium acetate

procedure [209]. Three yeast strains were used for this study: RJY1941 (S288C)
MAT α leu2-3,112 ura3-52 ade2 ade8 lys2 ras1::HIS3 Ras2(CS-ext) erf2 Δ
::KANr erg6Δ::TRP1 [YCp52-RAS2], RJY1942 (S288C) MATα leu2-3,112 ura352 ade2 ade8 lys2 ras1::HIS3 Ras2(CS-ext) erf2Δ::KANr erg6Δ::TRP1 [YCp52]
and RJY1842 (MATa/α ade2-1/ade2-1 leu2-3,112/leu2-3,112 ura3-52/ura3-52
trp1-1/trp1-1 his3-11,15/his3-11,15 can1-100/can1-100 GAL+/GAL+ psi+/psi+ erf4

Δ::NATr/erf4Δ::NATr [34].
Protein purification- Strain RJY1842 was transformed with pESC(-Leu)-6xHISErf2-(Flag)-Erf4 and grown in SC(-Leu) medium containing 2% (v/v) ethanol/ 2%
(v/v) glycerol at 30˚C with shaking and grown to 2 x 107 cells/ml. 50 mls (1x109
cells) were added to 1 liter of YEP medium supplemented with 4% galactose for
induction. Cells were induced with shaking (230 RPM) for 18h (30˚C) and then
harvested by centrifugation at 3000xg for 15 mins. The resulting pellet was
resuspended in breaking buffer (50mM Tris-Cl pH 8, 500ml NaCl, 1mM EDTA,
1mM DTT, 1xPIC, 8µl/ml saturated PMSF/isopropyl alcohol), and the cells were
lysed using glass beads (400-600 mesh, Sigma) for 40 mins with 1 min pulses (1
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minute cooling). The resulting extract was spun at 3000xg for 15 mins to remove
cellular debris and unbroken cells, followed by a crude membrane fraction (P13)
by centrifugation (13,000xg) for 0.5 hours at 4˚C.

The supernatant was

discarded and the pellet was resuspended in Tris buffered saline, pH 8, with the
aid of a Dounce homogenizer. The resulting extract was adjusted to a final
concentration of 1% Triton-X100. To solubilize the membranes, the extract was
incubated at 4˚C (1.5h). Insoluble material was then removed by centrifugation
(13,000xg) for 0.5 hours at 4˚C. The supernatant was incubated with Ni-NTA
resin at 4˚C for 1h. The resin was washed 3x with Solution W (50mM Tris-HCl,
pH 8, 150mM NaCl and 1% Triton-X100). The protein was eluted with 50mM
Tris-HCl, pH8, 150mM NaCl, 1% Triton-X100, 5% glycerol and 250mM
imidazole. Eluates were desalted and concentrated using (50mM Tris-Cl, pH 8,
150mM NaCl, 1% Triton-X100 and 5% glycerol.

Fractions containing 6xHis-

Erf2/FLAG-Erf4 were pooled to obtain approximately 0.2 mg of purified Ras PAT
per liter of culture as determined by SDS-PAGE against a standard curve of
bovine serum albumin.

The complexes were divided into 50µL aliquots and

frozen at -80˚C until use.
Coupled PAT Assay- The HTS of protein palmitoylation was recently described
[147], but was adjusted for this study. The production of NADH was monitored
with a Biotek Mx fluorimeter (Biotek, Winooski, VT) using 340 nm excitation/ 465
nm emission.

The 50 µl reaction contained 2 mM 2-Oxoglutarate ( α -

ketoglutamic acid), 0.25 mM NAD+, 0.2mM Thiamine Pyrophosphate, 0.5 µg of
purified 6xHIS-Erf2/FLAG-Erf4, 1 mM EDTA, 1 mM dithiothreitol, 32 mU 2116

oxogluarate dehydrogenase (α-ketoglutarate dehydrogenase), 50 mM sodium
phosphate, pH 6.8, and 0 - 100 µM inhibitor in 5% DMF. The reaction was
initiated by the addition of 40 μM palmitoyl-CoA and monitored for 30 mins at
30˚C. The first 10mins of the reaction was analyzed to determine the initial rates
of CoASH release. The PAT specific activity was determined from a standard
curve of NADH production with different CoASH amounts. In these reactions,
CoASH was added to the standard PAT reaction mixture (without Erf2-Erf4
complex or palmitoyl-CoA) and the reaction was allowed to proceed to
equilibrium before fluorescence was measured.
Scaffold Ranking Library- The scaffold ranking library contains one sample for
each of the 68 positional scanning libraries tested.

Each of these samples

contains an approximate equal molar amount of each compound in that library.
So, for example, the sample 2160 in the scaffold ranking library contains 45,864
compounds in approximately equal molar amounts.

These samples can be

prepared by mixing the cleaved products of the complete positional scanning
library, as was the case for sample 2160, or they can be synthesized directly as a
single mixture [236, 261].
Positional Scanning Library 2160-

Positional scanning library 2160 was

synthesized using the general Figure 4.14.

The positional scanning library

incorporates both individual and mixtures of amino acids (R2) and carboxylic acid
(R1 and R3). The synthetic technique facilitates the generation of information
regarding the likely activity of individual compounds from the screening of the
library [235, 262, 263].

Equimolar isokinetic ratios have been previously
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determined and calculated for each of the amino and carboxylic acids utilized for
the respective mixtures [261, 264]. The bis-piperazine library 2160 has a total
diversity of 45,864 compounds (42x26x42=45,864). The R1 and R3 positions as
shown in Figure 4.1 each consist of 42 carboxylic acids and the R2 contains 26
amino acids.
BODIPY®-C12:0 Autopalmitoylation Assay- BODIPY®-C12:0-CoA (40 µM final,
unless specified otherwise) was added to a 50 µl reaction containing
approximately 0.5 µg enzyme (6xHIS-Erf2/FLAG-Erf4) and 100 µM inhibitors in
5% DMF in 50mM sodium phosphate buffer, pH 6.8.

The reactions were

incubated 10 min with inhibitor, and then the reaction was initiated with the
addition of BODIPY®-C12:0-CoA, and incubated 15 mins at 30˚C. The reaction
was terminated by the addition of 5x non-reducing protein loading buffer. Each
reaction was heated at 65˚C for three min and then subjected to SDS-PAGE
(12%).

The gel was washed three times in ddH2O and visualized on the

Typhoon 9410 Variable Mode Imager (GE Healthcare, Piscataway, NJ) for
BODIPY® fluorescence (ex. 488 nm / em. 532 nm) to visualize co-migration of
the BODIPY® signal with 6xHIS-Erf2/FLAG-Erf4.

The amount of 6xHIS-

Erf2/FLAG-Erf4 was determined empirically using SDS-PAGE/western blot
analysis under reducing conditions against a standard curve of bovine serum
albumin.
Growth Inhibition Assay-

The in vivo effect of the inhibitors on Ras2

palmitoylation was investigated by comparing the growth of S. cerevisiae strains
previously described for our complementation assay [34].
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Briefly, the cells

contain a defective allele of RAS2 that is balanced by an episomal copy of RAS2
linked to URA3. Under these conditions, the yeast strain cannot grow unless the
episomal copy of RAS2 is palmitoylated. Varying concentrations of the inhibitors
were added to 200 µl volumes of the yeast cells at an OD600 between 0.8 and 1.2
in a 96-well plate format. The OD600 was observed every 30 mins for 24 hours
and EC50 values were determined by graphing rate of growth against
concentration of inhibitor for each inhibitor.
Yeast cell spot assay- Following 24 hour incubation with varying concentrations
of the inhibitors in 1% DMF, S. cerevisiae strains RJY1941 and RJY1942 were
then diluted 1/100, and spotted onto SC-URA plates with 2% glucose.
Cytotoxicity data was obtained by detecting the colony growth, following 48 hours
incubation at 30˚C, with white light detection on the Bio-Rad Molecular Imager®
ChemiDocTM XRS+ (Hercules, CA) and performing densitometry with Bio-Rad
ImageLabTM software (Hercules, CA).

Triplicate reactions were plated in

triplicate. Values were normalized to vehicle control (1% DMF) for each plate,
and then the averages of each reaction were compared for statistical analysis.
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Table 4.1. Percent inhibition of Erf2 autopalmitoylation for R1 positional
scanning library.
#
2160.001
2160.002
2160.003
2160.004
2160.005
2160.006
2160.007
2160.008
2160.009
2160.010
2160.011
2160.012
2160.013
2160.014
2160.015
2160.016
2160.017
2160.018
2160.019
2160.020
2160.021
2160.022
2160.023
2160.024
2160.025
2160.026
2160.027
2160.028
2160.029
2160.030
2160.031
2160.032
2160.033
2160.034
2160.035
2160.036
2160.037
2160.038
2160.039
2160.040
2160.041
2160.042

R1
(1-phenyl-cyclopropyl)-methyl
2-phenylbutyl
3-phenylbutyl
m-tolylethyl
2-(3-fluoro-phenyl)-ethyl
2-(3-bromo-phenyl)-ethyl
2-(3-trifluoromethyl-phenyl)-ethyl
p-tolylethyl
2-(4-fluoro-phenyl)-ethyl
2-(3-methoxy-phenyl)-ethyl
2-(4-bromo-phenyl)-ethyl
2-(4-methoxy-phenyl)-ethyl
2-(4-ethoxy-phenyl)-ethyl
2-(4-Isobutyl-phenyl)-propyl
3,4-dichlorophenethyl
2-(3,5-bis-trifluoromethyl-phenyl)-ethyl
3-(3,4-dimethoxy-phenyl)-propyl
phenethyl
3,4,5-trimethoxy-benzyl
butyl
heptyl
isobutyl
2-methylbutyl
3-methylbutyl
3-methylpentyl
4-methylpentyl
4-methyl-benzyl
cyclopently-methyl
cyclohexyl-methyl
cyclohexyl-ethyl
cyclohexyl-butyl
cycloheptyl-methyl
2-methylcyclopropyl-methyl
cyclobutyl-methyl
3-cyclopentyl-propyl
cyclohexyl-propyl
4-methyl-1-cyclohexyl-methyl
4-tert-butyl-cyclohexyl-methyl
2-Biphenyl-4-yl-ethyl
adamantan-1-yl-methyl
adamantan-1-yl-ethyl
2-Bicyclo[2.2.1]hept-2-yl-ethyl

100 μ g/ml
16%
-2%
7%
3%
2%
12%
14%
1%
-3%
0%
16%
8%
4%
26%
8%
12%
-2%
5%
3%
-8%
-2%
-1%
-5%
-6%
-3%
-2%
10%
-5%
-1%
1%
9%
1%
-4%
-10%
9%
3%
0%
18%
21%
8%
5%
-1%

21%
-1%
8%
8%
6%
14%
16%
4%
2%
8%
18%
8%
12%
32%
15%
23%
10%
12%
10%
-6%
8%
2%
0%
1%
2%
5%
14%
6%
1%
6%
15%
5%
8%
6%
11%
11%
6%
23%
27%
16%
15%
8%

27%
5%
18%
9%
7%
15%
17%
6%
4%
13%
23%
10%
16%
37%
19%
26%
15%
13%
11%
11%
11%
6%
3%
2%
3%
6%
17%
10%
6%
10%
17%
9%
25%
20%
17%
12%
13%
24%
30%
18%
18%
17%

*

*
*

*

* Functionalities fixed for each of the R groups in the 48 individual compounds
synthesized and tested (1-48).
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Table 4.2. Percent inhibition of Erf2 autopalmitoylation for R2 positional
scanning library.
#

R2

2160.043
2160.044
2160.045
2160.046
2160.047
2160.048
2160.049
2160.050
2160.051
2160.052
2160.053
2160.054
2160.055
2160.056
2160.057
2160.058
2160.059
2160.060
2160.061
2160.062
2160.063
2160.064
2160.065
2160.066
2160.067
2160.068

S-methyl
S-benzyl
hydrogen
S-2-butyl
S-isobutyl
R-hydroxymethyl
(R,R)-1-hydroxyethyl
S-isopropyl
S-4-hydroxybenzyl
R-methyl
R-benzyl
R-2-butyl
R-isobutyl
S-hydroxymethyl
(S,S)-1-hydroxyethyl
R-isopropyl
R-4-hydroxybenzyl
S-phenyl
S-propyl
R-propyl
S-butyl
R-butyl
S-2-naphthylmethyl
R-2-naphthylmethyl
S-cyclohexyl
R-cyclohexyl

100 μ g/ml
0%
15%
-5%
2%
-1%
-9%
1%
3%
24%
0%
13%
-4%
0%
3%
-11%
-7%
13%
13%
-3%
-12%
-1%
-7%
31%
32%
15%
10%

3%
22%
3%
11%
10%
1%
2%
8%
25%
1%
16%
5%
4%
8%
2%
1%
18%
21%
9%
-2%
7%
2%
32%
37%
16%
13%

10%
23%
9%
12%
12%
5%
14%
13%
27%
4%
24%
6%
8%
11%
7%
5%
19%
24%
10%
0%
13%
3%
39%
40%
21%
16%

*

*

*
*

* Functionalities fixed for each of the R groups in the 48 individual compounds
synthesized and tested (1-48).

121

Table 4.3. Percent inhibition of Erf2 autopalmitoylation for R3 positional
scanning library.
100 μ g/ml

#

R3

2160.069
2160.070
2160.071
2160.072
2160.073
2160.074
2160.075
2160.076
2160.077
2160.078
2160.079
2160.080
2160.081
2160.082
2160.083
2160.084
2160.085
2160.086
2160.087
2160.088
2160.089
2160.090
2160.091
2160.092
2160.093
2160.094
2160.095
2160.096
2160.097
2160.098
2160.099
2160.100
2160.101
2160.102
2160.103
2160.104
2160.105
2160.106
2160.107
2160.108
2160.109
2160.110

(1-phenyl-cyclopropyl)-methyl
2-phenylbutyl
3-phenylbutyl
m-tolylethyl
2-(3-fluoro-phenyl)-ethyl
2-(3-bromo-phenyl)-ethyl
2-(3-trifluoromethyl-phenyl)-ethyl
p-tolylethyl
2-(4-fluoro-phenyl)-ethyl
2-(3-methoxy-phenyl)-ethyl
2-(4-bromo-phenyl)-ethyl
2-(4-methoxy-phenyl)-ethyl
2-(4-ethoxy-phenyl)-ethyl
2-(4-Isobutyl-phenyl)-propyl
3,4-dichlorophenethyl
2-(3,5-bis-trifluoromethyl-phenyl)-ethyl
3-(3,4-dimethoxy-phenyl)-propyl
phenethyl
3,4,5-trimethoxy-benzyl
butyl
heptyl
isobutyl
2-methylbutyl
3-methylbutyl
3-methylpentyl
4-methylpentyl
4-methyl-benzyl
cyclopently-methyl
cyclohexyl-methyl
cyclohexyl-ethyl
cyclohexyl-butyl
cycloheptyl-methyl
2-methylcyclopropyl-methyl
cyclobutyl-methyl
3-cyclopentyl-propyl
cyclohexyl-propyl
4-methyl-1-cyclohexyl-methyl
4-tert-butyl-cyclohexyl-methyl
2-Biphenyl-4-yl-ethyl
adamantan-1-yl-methyl
adamantan-1-yl-ethyl
2-Bicyclo[2.2.1]hept-2-yl-ethyl

-2%
5%
-1%
-5%
0%
10%
16%
2%
0%
2%
1%
-4%
-2%
19%
8%
13%
-5%
3%
0%
0%
0%
-6%
-5%
-6%
-6%
-2%
4%
0%
0%
1%
11%
7%
-3%
-5%
2%
3%
3%
8%
18%
19%
11%
2%

2%
9%
8%
7%
2%
12%
20%
3%
4%
5%
8%
1%
3%
26%
8%
24%
0%
6%
1%
1%
0%
-6%
-3%
-1%
-1%
0%
6%
1%
3%
5%
11%
7%
0%
5%
11%
7%
4%
12%
24%
25%
13%
3%

9%
12%
8%
12%
7%
20%
21%
5%
10%
13%
9%
3%
8%
28% *
10%
29% *
12%
7%
3%
1%
2%
-3%
-1%
0%
3%
4%
13%
5%
5%
8%
14%
10%
8%
7%
16%
14%
7%
15%
31%
26% *
21%
10%

* Functionalities fixed for each of the R groups in the 48 individual compounds
synthesized and tested (1-48).
122

Table 4.4. The effect of varying the concentration of compounds 13 and 25,
and 2-BP on the KM and Vmax for the Palm-CoA substrate.
Compound
13
(μM)
0
25
50
100

KM

Vmax

R2

(μM)
3 +/- 1
11 +/- 3
38 +/- 6
145 +/- 30

(μM)
210 +/- 11
243 +/- 20
354 +/- 26
631 +/- 94

0.9
0.87
0.97
0.98

Compound
25
(μM)
0
25
50
100

KM

Vmax

R2

(μM)
3 +/- 1
11 +/-3
23 +/- 6
79 +/- 15

(μM)
296 +/- 17
307 +/- 30
344 +/- 34
542 +/- 60

0.88
0.83
0.91
0.98

2-BP
(μM)
0
25
50
100

KM
(μM)
4 +/- 1
2 +/-1
10 +/-6
14 +/- 7

Vmax
(μM)
222 +/-7
160 +/-5
126 +/- 23
51 +/-8
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R2
0.96
0.95
0.53
0.71

Figure 4.1. Schematic Representation of the Chemical Library Screen. A.
The Torrey Pines Institute for Molecular Studies scaffold library approach starts
with >30 million compounds that are organized by 68 core scaffolds with 2,000 –
700,000 different compounds per scaffold. B. A lead scaffold is selected for the
positional scanning screen. C. All of the compounds in the positional scanning
screen contain the same core scaffold structure and are organized by the Rgroups at each position. Each of the plates contains the same compounds
organized by the different R-group position to determine if a particular functional
group is optimal at one of the positions. The positional scanning library screened
in this study contained 110 positional scanning samples that each comprise of
1,000 – 2,000 individual compounds for a total diversity of 45864 individual
compounds. D. The selectivity for the different R-groups is predicted for each
position based on the positional scanning results. In this study, 48 individual
compounds were synthesized. E. Of the 48 individual compounds synthesized
ten were selected for further analysis in additional assays. In total 226 samples
were tested; 68 Scaffolds, 110 positional scanning scaffolds, 48 individual
compounds.
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Figure 4.2. Result of the Screen for Inhibition of Erf2 Autopalmitoylation.
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Figure 4.2. (Continued). The scaffold ranking library screen of 68 scaffolds
was screened at 100 μg/ml, and the average velocity of Erf2 autopalmitoylation
of three reactions is presented as a fraction of vehicle control (1% DMF). The
velocity of Erf2 autopalmitoylation was detected as an increase in fluorescence
over time. No effect on Erf2 autopalmitoylation would fall at 1 arbitrary unit (solid
line). Scaffolds that resulted in a reduction in Erf2 autopalmitoylation 3 standard
deviations (dashed line) or greater were considered hits of this assay. A heat
inactivated Erf2 (Boiled) and a catalytically inactive mutant of Erf2 (C203S)
represent baseline activity in this assay. 100 μM 2-BP is a control for inhibition
of Erf2 autopalmitoylation.
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Figure 4.3. Background Effects of the Lead Scaffold Ranking Library
Samples on the α -KDH Reaction. Scaffold ranking library samples that
resulted in a reduction in Erf2 autopalmitoylation of 3 standard deviations or
greater were screened against α-KDH activity on the same assay lacking Erf2Erf4, with 20 μM CoASH as substrate rather than 40 μM palmitoyl-CoA.
Samples were screened at 100 μg/ml and the relative fluorescence detected
after a 30 minute reaction is presented as a fraction of vehicle control (1% DMF).
Samples that resulted in any increase in fluorescence 1.5 times greater or more
relative to vehicle control were omitted from further analysis. 50 μM 2-BP was
included as a reference.
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Figure 4.4.
Inhibition of Erf2 Autopalmitoylation by Varying the
Concentration of the Library Samples.
A. The velocity of Erf2
autopalmitoylation on the coupled assay with the lead scaffold ranking library
samples (2160, 2220, 2236, 2221, 2103). The velocity of Erf2 autopalmitoylation
was detected as an increase in fluorescence over time. Average values of three
reactions are presented as a fraction of vehicle control (1% DMF) +/- standard
deviation. Samples were screened at 50 μg/ml (dark grey bars), 100 μg/ml
(light grey bars), and 200 μg/ml (white bars) compared to 2-BP at 50 μM (dark
grey bars), 100 μM (light grey bars), and 200 μM (white bars). A reaction
lacking Erf2 ( - ) represents baseline activity in the assay. B. Structures of lead
scaffolds and 2-bromopalmitic acid. Positions for varying functional groups are
denoted by R1-R4. Scaffold 2160 contains three R-group positions, scaffolds
2220, 2221, and 2103 each contain two R-group positions, and scaffold 2236
contains four R-group positions.
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Figure 4.5. Inhibition of Erf2 Autopalmitoylation by Individual Compounds
Derived from the 2160 Scaffold.
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Figure 4.5. (Continued). Relative velocity of Erf2 autopalmitoylation with 100
μ g/ml of optimized individual compounds (1-48), non-specific individual
compounds (49-54), positional scanning samples (2160.066, 2160.082,
2160.001, 2160.065, and 2160.108), and lead scaffold ranking library sample
(2160). The velocity of Erf2 autopalmitoylation was detected as an increase in
fluorescence over time. Average values of three reactions presented as a fraction
of vehicle control (1% DMF) +/- standard deviation. A reaction lacking Erf2 ( - )
represents baseline activity in the assay. 50 μM 2-BP is a control for inhibition
of Erf2 autopalmitoylation.
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Figure 4.6.
Inhibition of Erf2 Autopalmitoylation by Varying the
Concentration of Individual Compounds Derived from the 2160 Scaffold.
Relative velocity of Erf2 autopalmitoylation with purified lead individual
compounds. The velocity of Erf2 autopalmitoylation was detected as an increase
in fluorescence over time. Average values of three reactions are presented as a
fraction of vehicle control (1% DMF) +/- standard deviation. Compounds were
screened at 25 μM (dark grey bars), 50 μM (light grey bars), and 100 μM
(white bars) compared to 2-BP. A reaction lacking Erf2 ( - ) represents baseline
activity in the assay.
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Figure 4.7. Structure of the Scaffold 2160 Derived Compounds. The
structure for scaffold 2160, bis-cyclic piperazine has three R-group positions
designated R1, R2, and R3. The lead functional groups are 2-(4-Isobutyl-phenyl)propyl (i), 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl (ii), 4-tert-butyl-cyclohexylmethyl (iii), S-4-hydroxybenzyl (iv), S-phenyl (v), S-2-naphthylmethyl (vI), and
adamantan-1-yl-methyl (vii). The curved lines on the functional group structures
designate where they will share a bond with the core scaffold. Positions for each
functional group are described in the right panel. Ki values for the fluorescencebased coupled assay of the rate of Erf2 autopalmitoylation (FCA) and the
orthogonal gel-based assay of steady-state Erf2 autopalmitoylation (GBA) are
listed for each compound (14, 13, 25, 28, 34, 19, 22, 43, 27, and 30) as well as
EC50 values obtained from the growth curve experiments in S. cerevisiae
RJY1942 (Sens.) and RJY1941 (cont.). All values are represented in μM
concentrations. The increased detection sensitivity of the FCA allowed for the
determination of standard deviation.
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Figure 4.8. Inhibition of Erf2 Autopalmitoylation Measured by a Gel-based
Assay. An orthogonal screen of steady-state Erf2 autopalmitoylation with 100 μ
M of each of the ten individual compounds (43, 27, 19, 13, 22, 34, 14, 25, 30,
and 28) was separated by SDS-PAGE. The average relative BODIPY®
fluorescence from three reactions that co-migrated with Erf2 is presented as a
fraction of vehicle control (V; 5% DMF) +/- standard deviation. A reaction lacking
Erf2 ( - ) represents baseline activity in the assay. 100 μM 2-BP is a control for
inhibition of Erf2 steady-state autopalmitoylation.
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Figure 4.9. Inhibition of Erf2 Autopalmitoylation Dose Responsiveness on
Gel-based Assay. An orthogonal screen of steady-state Erf2 autopalmitoylation
of each of the ten individual compounds (43, 27, 19, 13, 22, 34, 14, 25, 30, and
28) was separated by SDS-PAGE. The average relative BODIPY® fluorescence
from three reactions that co-migrated with Erf2 is presented as a fraction of
vehicle control (V; 5% DMF) +/- standard deviation. A reaction lacking Erf2 ( - )
represents baseline activity in the assay. 100 μM 2-BP is a control for inhibition
of Erf2 steady-state autopalmitoylation. Compounds were screened at 25 μM
(dark grey bars), 50 μM (light grey bars), and 100 μM (white bars) compared to
2-BP. A reaction lacking Erf2 ( - ) represents baseline activity in the assay.
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Figure 4.10. Michaelis-Menten Plots for Compounds 13 and 25, and 2-BP.
The velocity of Erf2 autopalmitoylation as altered by the addition of the inhibitors
at 100 μM (filled circles), 50 μM (empty triangles), 25 μM (filled squares), and
vehicle control (1% DMF; empty diamonds) for compounds 13 and 25, and 2-BP.
The velocity of Erf2 autopalmitoylation was detected as an increase in
fluorescence over time. Vmax is the maximum velocity of the reaction, and KM is
the substrate concentration that allows the reaction to reach a velocity that is
50% of the Vmax. On the Michaelis-Menten Plot, a competitive inhibitor would
increase KM without altering Vmax, whereas an uncompetitive inhibitor would
result in a decrease of Vmax without altering the KM of the reaction.
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Figure 4.11.
Inhibition of Palmitoyl-CoA Concentration Dependent
Palmitoylation of Erf2 by Compound 13. Orthogonal screen of steady-state
Erf2 autopalmitoylation with compound 13 at 25 μM, 50 μM and 100 μM was
separated by SDS-PAGE. The average relative BODIPY® fluorescence from
three reactions that co-migrated with Erf2 is presented as a fraction of vehicle
control (VC; 5% DMF) for each concentration of BODIPY®-C12-CoA +/- standard
deviation. A reaction lacking Erf2 ( - ) represents baseline activity in the assay.
Prior experiments in this study used 100 μM Compound 13 with 40 μM
BODIPY®-C12-CoA.
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Figure 4.12. Inhibition of Ras Palmitoylation-sensitized Yeast Growth.
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Figure 4.12. (Continued). A. A Representation of the yeast strains RJY1942
(Sensitized Strain) and RJY1941 (Control Strain). RJY1942 lacks a ras1 gene,
and has a ras2 mutation resulting in a yeast strain dependent on Ras2
palmitoylation for viability as previously described [33, 34, 149]. RJY1941
similarly lacks ras1 and has the ras2 mutation, but has Ras2 re-introduced to
overcome the dependence on Ras2 palmitoylation. B. The EC50 for each of the
individual compounds was established by graphing the logarithmic growth of S.
cerevisiae strain, RJY1941 (solid lines and solid circles) and RJY1942 (hashed
lines and open circles), versus the concentration of each compound. The curves
were used to extrapolate the EC50 values are presented for 2-BP and the ten
compounds identified in this study. Values were normalized to visually compare
relative log of the growth rate of each compound and 2-BP.
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Figure 4.13. Purified Compounds Inhibit Palmitoylated Ras-dependent
Growth in Yeast. A representative (n=3) spot assay of cytotoxic effects in wild
type (RJY1941) S. cerevisiae is compared to that of the palmitoylation-dependent
(RJY1942) strain. Liquid cultures containing the shown inhibitors were spotted
onto selective media and incubated at 30˚C for 3 days. The concentrations used
in the liquid cultures were 2.5 μM, 5 μM, 10 μM, and 20 μM in 1% DMF
(Vehicle).

139

Figure 4.14.
Synthetic Scheme of Bis-cyclic Piperazines.
A, 5%
DIEA/DCM; B, Fmoc-Lys(Boc)-OH, DIC, HOBt, DMF; C, 20% Piperidine/DMF;
D, R1COOH, DIC, HOBt, DMF; E, 55% TFA/DCM; F, Boc-AA(R2), DIC, HOBt,
DMF; G, R3COOH, DIC, HOBt, DMF; H, BH3-THF, 65˚C, 96 hours; I,
Piperidine, 65˚C, 24 hours; J, Oxalyldiimidazole, DMF; K, HF, anisole, 0˚C.
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CHAPTER 5
Discussion of the Fluorescent-based Coupled Assay and Inhibitor Screens
5.1

Key Words and Abbreviations

Enzyme Inhibitor, High-throughput Screen, Palmitoylation, zDHHC; 2-BP, 2Bromopalmitate; AD, Alzheimer’s Disease; ER, Estrogen Receptor; HD,
Huntington’s Disease; HTS, High-throughput Screen; PAT, Protein Acyl
Transferase; PM, Plasma Membrane; PTM, Post-translational Modification; SAR,
Structure-Activity Relationship; XLID, X-linked Intellectual Disability

5.2

The Challenge of Ras as a Therapeutic Target

Despite considerable effort and investment of resources a therapeutic strategy
that targets the most frequently mutated oncogenes in cancer, the three Ras
genes, has eluded investigators [102, 117, 265]. When targeting the activation of
Ras, researchers attempted to design a GTP-mimetic to target the GTPase
activity of Ras similar to ATP-mimetics that inhibit kinases. Unfortunately, GTP is
present at high concentrations within the cell and binds with a picomolar affinity
making it virtually impossible to compete with [102, 117]. Attempts to inhibit
specific GEFs and block the removal of GDP from the active site following the
intrinsic GTPase activity was also ineffective [118, 119]. It is unclear if oncogenic
Ras depends on GEFs in the same manner that wild-type Ras does [118, 119].
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Following the failure to target the activation of Ras, many researchers looked to
target the downstream signaling pathways of Ras.

Curiously, early work to

identify agents that blocked Raf kinase in Ras-transformed cells resulted in the
activation of the pathway [266, 267]. Alternatively, inhibitors designed against
MAP kinase and phosphatidyl inositol 3-kinase had no significant clinical activity.
Feedback loops and poor therapeutic windows account for the failure to target
those pathways [102].

In the context of inhibiting the Raf pathway, it was

observed that unprocessed Ras was capable of binding to Raf, but not of
activating it [266]. This garnered interest for targeting the PTMs of Ras.
Inhibitors of FTase were encouraging in the mouse model but were ineffective in
the clinical setting due to the ability of GGTase to restore the activity of K- and NRas after FTase inhibitor treatment [102, 117]. Curiously, attempts at inhibiting
either RCE1 or ICMT resulted in an increase in Ras-mediated tumorigenesis
[102, 117]. Thus, the final step in Ras processing, palmitoylation, has become
an intriguing target candidate to block the oncogenic activity of Ras.

5.3

Discussion

of

a

Fluorescent-based

Coupled

Assay

for

Erf2

Autopalmitoylation
To fully understand palmitoylation and screen for inhibitors of palmitoylation there
is a need for a reliable HTS. A coupled assay developed by Dr. David Mitchell
was subsequently adapted and optimized for its use in a high-throughput screen
(HTS) format (see Chapter and [147]). The adapted assay has allowed us to
effectively determine the kinetic parameters of PATs, elucidate the lipid donor
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specificity of the reaction, and determine the mode of action of 2-bromopalmitate
(2-BP) [147]. Now that it has been established and validated, the assay can be
used to characterize any zDHHC PAT.
In this project, the assay was used to screen for inhibitors of Erf2
autopalmitoylation. The availability of a HTS format for zDHHC PAT kinetics
increases the chance of detecting a specific inhibitor of protein palmitoylation.
One drawback of this assay is its specificity to the autopalmitoylation reaction,
and not the transfer of the palmitoyl moiety to the protein substrate.
Currently, there are no HTS techniques developed to evaluate the transfer step
of palmitoylation.

The lack of sequence consensus for palmitoylation sites

makes it difficult to design a HTS capable of evaluating different palmitoylation
substrates. The release of CoASH during autopalmitoylation is critical for the
ability to couple the α-KDH reaction to autopalmitoylation. Unfortunately, no
metabolite is released during the transfer step of palmitoylation that could be
exploited for a HTS.
An inhibitor of autopalmitoylation would reduce the palmitoyl moiety available for
transfer to a protein substrate, and is a viable means of inhibiting overall protein
palmitoylation. Given the difficulty in designing a HTS for the transfer step of
palmitoylation, having an autopalmitoylation assay amenable to a HTS format is
a convenient means to evaluate overall protein palmitoylation.
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5.4

Optimizing Inhibition

When designing or screening for PAT inhibitors, one must consider two
properties; specificity and effectiveness. There are certain points to consider
during the screening process to eliminate compounds that lack in either. This
section describes pan assay interference compounds (PAINS), and guidelines for
determining which compounds will be more easily absorbed and processed,
allowing for more efficient inhibition [268, 269].
In a typical academic screening library, 5-12% of compounds are PAINS [270,
271]. PAINS encompass 400 structural classes [270, 271]. Most PAINS function
as chemicals rather than discriminating drugs, and frequently have more than
one interference mechanism [268]. Often PAINS will interfere with many other
proteins [268].

False positives result from interactions with toxic or reactive

metals used to synthesize the screening library, interactions with the assay
reagents, coating a protein, sequestering metal ions, or due to non-specific
chemical reactions [268, 270-273]. To avoid PAINS, one should be mindful of
similar structures or substructures the literature to see if it interacts with unrelated
proteins. There are some disreputable structures that Baell et al. highlight as the
most frequent PAINS: toxoflavin, isothiazolones, curcumin, hydroxyphenyl
hydrazones, ene-rhodanine, phenol-sulphonamides, enones, quinones and
catechols [268, 270-273]. Finally, assays should be assessed and results should
be obtained via at least two different assays that establish results by different
means [268].
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Lipinski’s Rule of Five is based on the observation that most orally administered
drugs are relatively small, and moderately lipophilic [244]. This has no relevance
to pharmacological activity, but rather an increased chance that the drug will
have better absorption, distribution, metabolism, and excretion. The Rule of Five
suggests that an effective inhibitor should have no more than 5 hydrogen bond
donors (-OH or –NH), no more than 10 hydrogen bond acceptors (total O or N), a
molecular mass ≤500 g/mol, and an octanol-water partition coefficient logP≤5
[244]. Small peptide molecules are gaining favor in drug design but often are
limited by poor pharmacokinetic profiled due to poor membrane permeability
[274]. The introduction of hydrogen bond acceptor-donor pairs in small peptide
molecules can improve membrane permeability without diminishing drug-like
properties [274].

Drug Affinity Responsive Target Stability relies on the

protection against proteolysis to identify potential protein targets for small
molecules [275].
In summary, the lead compound may be a false positive acting independently of
the target. Some characteristics tend to make compounds more easily absorbed
and processed, thus allowing for greater efficacy. Baell, et al., and Lipinski have
described precautions and methods for the optimization of drug design [244, 268,
270-273].
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5.5

Discussion

of

Erf2

Autopalmitoylation

Inhibition

by

Fungal

Metabolites
Dr. Baker and collaborators at the Department of Chemistry and the Center for
Drug Discovery and Innovation at the University of South Florida have provided
Florida mangrove fungal extract metabolite library. The metabolites extracted
from fungal isolates by ethyl acetate may contain non-polar natural products,
lipids, small peptide chains, and possibly DNA intercalators. The fungal extracts
are a subset of a larger project and were previously screened for toxicity in a
parasite bioassay. The samples provided exhibited cytotoxicity towards J774
macrophage cells and were not eligible for further investigation for anti-parasitic
leads but were of interest in target-based anti-cancer bioassays. The extract
samples resulted in at least a 20% reduction of Erf2 autopalmitoylation on the
fluorescent-based coupled assay, with a majority exceeding a 50% reduction in
Erf2 autopalmitoylation. The control experiment lacking Erf2 demonstrated that
all of the extracts had minimal background fluorescence, but only three samples
had a 40-fold higher background fluorescence compared to vehicle control (5%
DMSO).

Only 11/81 samples screened had an effect on α -KDH activity,

suggesting that the remaining samples were eliciting their effects on the
fluorescent-based coupled assay through inhibition of Erf2 autopalmitoylation,
and not the other elements of the assay. This was validated for the lead eight
extracts

via

the

orthogonal

gel-based

autopalmitoylation.
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assay

of

Erf2

steady-state

Overall, the fungal metabolite screen on the fluorescent-based coupled assay
validated the use of the assay to accurately identify inhibitors of Erf2
autopalmitoylation in a HTS format. This was the first time we demonstrated
inhibition of Erf2 steady-state autopalmitoylation on the gel-based assay. The
results are encouraging for the future optimization of these samples, but also for
the exploitation of natural products as modulators of protein palmitoylation.
The next phase for the fungal metabolite samples is to fractionate the lead
extracts metabolites. First, the samples will be crudely separated on natural
product medium pressure liquid chromatography (NP MPLC). Then, the samples
will be fractionated by reverse phase HPLC. Metabolites identified in this study
will be optimized for structure-activity relationship (SAR). The lead individual
metabolites will then be screened against other zDHHC PATs to reveal if they
are specific to Erf2 or are pan inhibitors of zDHHC PATs.

5.6

Discussion of Erf2 Autopalmitoylation Inhibition by a Scaffold

Ranking Library
A unique scaffold ranking library from the Torrey Pines Institute for Molecular
Studies was applied to the fluorescent-based coupled assay. In a typical HTS
approach to detect enzymatic inhibitors, millions of samples would be screened
to identify a lead compound. Only after lead compounds are identified would
SAR be applied to further enhance the effectiveness of the inhibitor. Due to the
organization of millions of compounds by core scaffold features, one can screen
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millions of compounds and perform SAR early on in the screening process, while
only examining hundreds of samples, effectively reversing the typical process.
A group of ten bis-cyclic piperazines from the scaffold ranking library were
identified in the fluorescent-based coupled assay. These bis-cyclic piperazines
inhibited Erf2 autopalmitoylation to an equal or greater extent than 2-BP, and
through a different mode of action. Piperazine analogs have previously been
demonstrated as effective drug-like compounds [252-254].

The bis-cyclic

piperazine compounds identified in this study inhibit Erf2 autopalmitoylation in the
μM range but ideally we would like to improve them through SAR so that they
inhibit Erf2 autopalmitoylation in the nM range.
The major considerations for SAR optimization are varying functional groups (to
improve bonds and interactions with the binding pocket), simplifying the
structure, and adding rigidity to the structure through the addition of rigid
functional groups, ring structures, or steric interactions.

As mentioned prior,

some level of SAR was performed in earlier screens due to the design of the
scaffold ranking library. The scaffold ranking library allowed for the optimization
of the functional groups during preliminary screens but there is still a need to fine
tune the lead compounds.
One consideration for optimizing the compounds would be to manipulate the
symmetry of the compounds. Without the R-groups, bis-cyclic piperazine has a
symmetric structure. The R1 and R3 groups are on opposing ends, and share
the same lead functional groups increasing the structural symmetry. Compounds
13, 14, and 25 all have the same functional group at the R2 position but differ at
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their R1 and R3 positions. Compound 13 has the same functional group at R1
and R3 positions. Compound 14 has the same functional group on position R1
as compound 13 but a different functional group on the R3 position. Compound
25 has the same functional groups as Compound 14 but on the opposing
positions. When comparing these three compounds, compound 13 has a mild
inhibitory advantage over the two non-symmetrical compounds. Thus, it would
be of interest to adjust the other non-symmetrical compounds to be more
symmetrical and observe any effects on their ability to inhibitor Erf2
autopalmitoylation.
Another consideration for optimizing the bis-cyclic piperazine compounds would
be to modify the functional group at the R2 position.

Of the three variable

positions, R2 seems to have the lowest effect on overall efficacy. One way the
R2 position could be modified would be to remove it altogether. Another would
be to put a functional group reminiscent of palmitate or coenzyme A at the R2
position. There is no structural information for where the bis-cyclic piperazines
are interacting with Erf2. If the inhibitors are binding at a different active site than
palmitoyl-CoA, then modifying the R2 position to mimic palmitate or coenzyme A
could sequester the inhibitor away from its active site. Conversely, the modified
inhibitor may inhibit preferentially to this new position but it may be acting
mechanistically similar to the current protein palmitoylation inhibitors, which
presumably act through substrate recognition [201, 204, 205].
Although the bis-cyclic piperazines were identified in this study due to their
inhibitory effects on Erf2 autopalmitoylation, it is not yet known if they act
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specifically on Erf2, on zDHHC PATs, on CoA-dependent enzymes, or if they are
as non-specific as 2-BP. The next step for the bis-cyclic piperazines will be to
evaluate the specificity of these compounds for Erf2 versus other zDHHC PATs
on the fluorescent-based coupled assay. A possible mode to detect their
interactions could be to modify them for use as probes. Analogs of 2-BP and
cerulenin analog have been used as a probes for protein palmitoylation in cells
[190, 206]. The 2-BP analog probe detected zDHHC PAT enzymes, transporters
and many validated palmitoylated proteins [206]. The cerulenin analog probe
detected zDHHC PATs and over 200 palmitoylated proteins [190]. Unfortunately,
the probes were not very specific.

The 2-BP analog had no observable

preference for enzymes dependent on CoA, and the cerulenin analog was not
specific to active zDHHC PATs and detected those with mutations to the catalytic
cysteines [190]. The inhibitors described in this study could be similarly modified
to their detect interactions, and for use as a probe of palmitoylation in future
studies. With the similarity between the bis-cyclic piperazine compounds, there
is the potential to fine tune inhibition per zDHHC PAT where similar compounds
may target similar binding locations but with preference for one zDHHC PAT over
the others.

5.7

Implications

of

Palmitoylation

Modulation

for

Therapeutic

Intervention of Disease
While research to clarify the role of palmitoylation is ongoing, the complexity of its
involvement is clear.

Some diseases involve the dysregulation of specific
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zDHHC PATs whereas the zDHHC PAT is unknown for other diseases, but
proteins critical to the disease are modified by palmitoylation. In the context of
oncogenesis there are incidences of an increase in expression (zDHHC9,
zDHHC11, and zDHHC16), incidences of a decrease in expression (zDHHC2,
and zDHHC3), incidences of an increase of either expression or activity
(zDHHC7 and zDHHC21), and even incidences of an increase in expression in
one tumor type and a decrease in expression in another tumor type (zDHHC14)
(Table 1.1).

Due to the variable means that palmitoylation is implicated in

disease, the design of a therapeutic intervention needs to be specific and
precise. Ideally, there would be a set of modulators for palmitoylation rather than
just one. Thus within the set, some modulators could increase the palmitoylation
activity and others would decrease the palmitoylation activity. This will require a
level of specificity not yet established.
Encouragingly, a reliable method to purify stable, active zDHHC PATs has been
developed, along with a validated HTS method to identify inhibitors. Counter
screens, orthogonal assays, and cell-based assays are established to
characterize and analyze candidate inhibitors.

These techniques will help

overcome the current failure to find a desired high affinity, specific inhibitors, and
aid to fill in the gaps of knowledge for protein palmitoylation. At least 22 zDHHC
PATs have been identified in humans but relatively little more is known about
them [41]. The fluorescent-based coupled assay described in Chapter 2 was
implemented to characterize the kinetic effects of zDHHC9 mutations that have
been implicated in X-Linked Intellectual Disability (XLID) [53]. Mutations in other

151

zDHHC9 PATs have been implicated in a variety of diseases and disorders; all of
which can be kinetically characterized with this assay. The assay can also be
applied to validating zDHHC PAT complex formations, validating predicted
inhibitors, and screening countless more chemical libraries for new and improved
inhibitors.
Furthermore, the studies described in Chapters 3 and 4 led to the identification of
fungal metabolites and a family of bis-cyclic piperazines that inhibit Erf2
autopalmitoylation. The inhibitors identified in this study represent a necessary
first step toward the development of a novel drug therapy against oncogenic Ras
for the treatment of colon cancer.

They could also be the next probes of

palmitoylation for use in the research setting.
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